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Preface 
 Beckwith-Wiedemann syndrome (BWS) is a congenital overgrowth condition 
with increased likelihood to develop childhood tumors. Children conceived with the use 
of assisted reproductive technologies (ART) have an increased frequency to have BWS 
compared to naturally conceived individuals.  In ruminants, the use of ART can induce a 
similar overgrowth condition that phenotypically recapitulates BWS, which is referred to 
as large offspring syndrome (LOS).  Previously we have shown that LOS is both 
phenotypically and epigenetically similar to BWS.  The overall goal of our research is to 
use bovine LOS as an animal model to understand the molecular etiology of congenital 
overgrowth syndromes.  As a step to achieve the overall goal, the current project is to 
comprehensively characterize the bovine LOS at the molecular level.  
In this dissertation, chapter 1 reviews the mechanisms of genomic imprinting and 
describes the current progress in understanding the etiology of the loss-of-imprinting 
conditions including BWS and LOS.  In chapter 2, we determined the allelic expression 
of imprinted genes previously identified in human and/mouse in bovine control and LOS 
fetuses.  We demonstrated that LOS is a multi-locus-loss-imprinting syndrome, which is 
similar to what has been reported for a subset of BWS individuals.  This study was 
published in Proceedings of the National Academy of Sciences (PMID: 25825726).  In 
chapter 3, we showed global misregulation of non-imprinted genes in LOS, indicating 
that loss-of-imprinting is not the only molecular lesion of LOS.  Further, most 
differentially expressed genes in LOS cannot be directly associated with the aberrant 
DNA methylation, which highlights that caution should be exercised when interpreting 
time-point-specific DNA methylation data.  The manuscript of this study is currently 
	   xi 
under peer review.  In chapter 4, for the purpose of de novo identification of novel 
imprinted genes, we determined global allele-specific gene expression in bovine 
conceptuses.  We identified eight novel imprinted genes in bovine and demonstrated that 
monoallelic gene expression can be the result of cis-eQTL effect.  Further, we expanded 
the potential adenosine-to-inosine RNA editing sites from ~20 to 671 in bovine.  This 
chapter was published in the Landes Bioscience Journal: Epigenetics (PMID: 27245094).   
Lastly, chapter 5 discusses the key questions that remain to be addressed in the field and 
concludes the dissertation.  
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Chapter 1 Literature review 
1.1 General overview of genomic imprinting 
 Genomic imprinting is a series of precisely regulated epigenetic processes that 
lead to parental-allele-specific expression of a subset of genes in mammals (reviewed in 
Bartolomei and Ferguson-Smith, 2011).  Since the discovery of the first three imprinted 
genes, namely, Igf2, Igf2r, and H19 in 1991 (Barlow et al., 1991; Bartolomei et al., 1991; 
DeChiara et al., 1991), more than 100 genes have been identified to be imprinted in mice 
and humans (http://www.mousebook.org/mousebook-catalogs/imprinting-resource; 
http://www.geneimprint.com/).  Most of the identified imprinted genes are located in 
clusters with two or more imprinted genes that spread over 20kb to 3.7Mb of DNA 
(reviewed in Edwards and Ferguson-Smith, 2007).  Within each cluster, a discrete region 
of DNA, termed as imprinting control region (ICR), regulates the proper allele-specific 
expression of imprinted genes (reviewed in Bartolomei and Ferguson-Smith, 2011).  
ICRs are marked with parental-allele-specific DNA methylation, which distinguishes the 
parental alleles in the same nucleus (reviewed in Bartolomei and Ferguson-Smith, 2011).  
The allele-specific DNA methylation at ICRs is established in a sex-specific manner in 
the germline.  In mice, male germ line methylated ICRs are established before birth, 
while acquisition of the maternal-specific DNA methylation occurs postnatally during 
oocyte growth.  After fertilization, the gametic DNA methylation imprints escape the 
wave of global DNA demethylation and are maintained in somatic cells throughout 
development.  Further, DNA methylation is erased in primordial germ cells in order to re-
establish the imprints appropriately for next generation (reviewed in Bartolomei and 
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Ferguson-Smith, 2011).  Over the past ~26 years, much work has been done to elucidate 
how DNA methylation is erased and acquired in the germ line and how allele-specific 
DNA methylation at ICRs are retained when global DNA demethylation occurs post-
fertilization.  Currently, it is recognized that highly coordinated epigenetic processes 
govern DNA methylation at ICRs to ensure parental-specific expression of imprinted 
genes.    
 The importance of genomic imprinting in mammalian development was first 
demonstrated by the pronuclear transplantation experiments, in which androgenetic and 
gynogenetic mouse embryos resulted in embryonic lethality (Barton et al., 1984; 
McGrath and Solter, 1984).  Androgenetic conceptuses (derived from two paternal 
pronuclei) had a severely retarded fetus but a well-developed placenta while gynogenetic 
fetuses (derived from two maternal pronuclei) were smaller than the bi-parental fetuses 
and had an undeveloped placenta (Barton et al., 1984; McGrath and Solter, 1984).  Later 
it was confirmed that genomic imprinting is the only barrier for viability of the 
gynogenetic embryos (Kono et al., 2004).  In these experiments, alteration of maternal 
imprinting by oocyte reconstruction using non-grown oocytes that had a deletion of the 
H19 region (including the ICR and the H19 transcription unit) allowed gynogenetic 
embryos to develop to term (Kono et al., 2004).   Investigations of imprinted gene 
function also demonstrated the significance of genomic imprinting in mammalian 
development.  For example, mice with maternal transmission of the non-functional allele 
of Igf2, a paternally expressed gene, showed normal growth, but paternal transmission of 
this mutant allele had deficient growth that was similar to Igf2 mull mice (DeChiara et 
al., 1991).  In addition to mouse models, the critical roles of imprinted genes in 
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development are also evident in human, cow, and sheep.  For instance, Beckwith-
Wiedemann syndrome (BWS) in humans and large offspring syndrome (LOS) in 
ruminants (i.e., cattle and sheep), two overgrowth conditions that share many phenotypic 
features, are partially associated with the loss of DNA methylation at the maternal ICR of 
the imprinted KCNQ1 locus (Chen et al., 2013; reviewed in Weksberg et al., 2010).  
Although less effort has been focused on determining the function of imprinted gene 
products when compared to the imprinting mechanisms, these genes emerge as important 
players in numerous biological processes including fetal growth, placental development, 
neural development, and behavior (reviewed in Plasschaert and Bartolomei, 2014).   
In this chapter, the epigenetic properties of imprinted genes are reviewed with 
major focus on the dynamic regulation of DNA methylation imprints from germ cells to 
pre-implantation embryos in mice.  Further, the functional roles of imprinted genes in 
mammalian development are reviewed with detailed description of two loss-of-
imprinting disorders: BWS in humans and LOS in cattle.   
 
1.2  Epigenetic properties of imprinted genes 
1.2.1 Mechanism of imprinted gene regulation 
 Imprinted genes are usually found in clusters containing 2 to 12 genes (reviewed 
in Edwards and Ferguson-Smith, 2007).  These clusters can span 20kb to 3.7Mb of DNA.  
Although not as common, examples of solitary imprinted genes do exist.  A typical 
imprinting cluster contains maternally and paternally expressed protein-coding genes as 
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well as non-coding RNAs (ncRNAs).  Within each cluster, the proper allele-specific 
expression of imprinted genes is regulated by the core cis-element ICR, which exhibits 
parental-specific epigenetic modifications such as DNA methylation and histone 
modifications (reviewed in Bartolomei and Ferguson-Smith, 2011).  Deletion of the ICRs 
can lead to loss-of-imprinting of multiple imprinted genes within a cluster, demonstrating 
the critical role of ICRs in the regulation of imprinted gene expression (Fitzpatrick et al., 
2002; Lin et al., 2003; Thorvaldsen et al., 1998; Williamson et al., 2006; Wutz et al., 
1997; Yang et al., 1998).  There are several mechanisms by which ICRs initiate and 
maintain the monoallelic expression of the imprinted genes within each cluster.  The best-
defined two mechanisms are the insulator model and the ncRNA model (reviewed in Lee 
and Bartolomei, 2013).   
 The insulator model is best exemplified by the H19/Igf2 imprinted domain in 
mice.  In this cluster, Igf2 is a paternally expressed protein-coding gene, while H19 is a 
maternally expressed ncRNA (Bartolomei et al., 1991; DeChiara et al., 1991).   The ICR 
is located approximately 2kb upstream of the H19 transcription start site and is paternally 
methylated while maternally unmethylated (Thorvaldsen et al., 1998; Tremblay et al., 
1995).  On the maternal allele, the insulator protein CTCF binds to the unmethylated ICR 
and prevents the Igf2 promoter from accessing the downstream enhancers (Bell and 
Felsenfeld, 2000; Hark et al., 2000; Leighton et al., 1995b).  Thus, the permissive 
chromatin conformation allows the maternal H19 to access the enhancers and gets 
transcribed.  On the paternal allele, however, DNA methylation of the ICR prevents 
binding by CTCF.  Absence of the insulator leads to a chromatin conformation in which 
the Igf2 promoter engages with the downstream enhancers (Bell and Felsenfeld, 2000; 
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Hark et al., 2000; Leighton et al., 1995b).  Therefore, Igf2 is activated on the paternal 
allele by the downstream enhancers while H19 is repressed.  As illustrated by this 
example, the DNA methylation status of the ICR directs the allelic regulation of 
imprinted genes. 
 The other major imprinting mechanism is the ncRNA model, which can be 
applied to the Kcnq1/Kcnq1ot1 and Igf2r/Airn imprinted clusters. The promoter of the 
long ncRNA can serve as the ICR for the imprinted cluster (Fitzpatrick et al., 2002; 
Mancini-DiNardo et al., 2003; Smilinich et al., 1999; Stoger et al., 1993; Wutz et al., 
1997).   For the Kcnq1/Kcnq1ot1 imprinted domain the unmethylated promoter/ICR on 
the paternal allele allows the transcription of the long ncRNA Kcnq1ot1, which can 
recruit and expand repressive histone modifications to silence the flanking paternally 
imprinted genes (Pandey et al., 2008; Terranova et al., 2008).  However, on the maternal 
allele, the ICR is methylated and the Kcnq1ot1 is not activated, allowing the transcription 
of the proximal maternal genes.  For the Igf2r/Airn imprinted cluster, the unmethylated 
ICR activates the long ncRNA Airn on the paternal allele, which transcribes antisense 
through the Ig2r transcription start site and interferes with the interaction between the 
Igf2r promoter and the RNA polymerase II (Latos et al., 2012; Sleutels et al., 2002).  In 
contrast, the ICR is methylated on the maternal allele and Airn is silenced by DNA 
methylation, and this allows the transcription of Igf2r (Latos et al., 2012; Sleutels et al., 
2002). Notably, the allelic regulation process initiated by ICRs, also known as “primary 
imprints”, can set up additional epigenetic differences in the imprinting clusters, such as 
“secondary DMRs” and allele-specific histone modifications (reviewed in Sanli and Feil, 
2015).  These additional epigenetic differences stably propagate during cell divisions and 
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could act as a candidate mechanism for tissue-specific imprinting.  For example, the 
allele-specific histone modifications established by the long ncRNA Kcnq1ot1 at the 
maternally expressed genes (e.g., Ascl2 and Osbpl5) are lost in embryonic lineages while 
maintained in extra-embryonic lineages (Lewis et al., 2004; Umlauf et al., 2004), 
resulting in the placental-specific imprinting of these genes.  
1.2.2 Dynamic regulation of genomic imprints  
 Erasure of imprints in primordial germ cells 
 In mice, specification of primordial germ cells (PGCs) from the epiblast begins on 
embryonic day 6.5-7.5 (E6.5-7.5) (Ginsburg et al., 1990; Saitou et al., 2002; Sato et al., 
2002).  Following specification, PGCs then proliferate and migrate along the hindgut to 
the genial ridge where they colonize by E11.5 (Molyneaux et al., 2001; Tam and Snow, 
1981).  Before migration, PGCs exhibit similar global DNA methylation profiles to their 
somatic cell origins (Guibert et al., 2012; Seisenberger et al., 2012).  For instance, the 
germline-specific genes (e.g., Mvh and Dazl) and the pluripotent genes (e.g., Nanog) are 
repressed by DNA methylation (Maatouk et al., 2006; Seisenberger et al., 2012).  
However, by E12.5-13.5, the global DNA methylation is very low and the pluripotent 
genes and germline-specific genes are activated (Maatouk et al., 2006; Seisenberger et 
al., 2012).  Further, parental imprints are erased and the silenced X chromosome is 
reactivated in the process of PGC reprogramming (Hajkova et al., 2002; Monk and 
McLaren, 1981; Tam et al., 1994).   
 In mice, it is clear that both passive and active DNA demethylation are involved 
in this process.  Currently, it is recognized that the epigenetic reprogramming in PGCs 
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begins with a passive DNA demethylation during E8.0-10.5 and is then followed by a 
wave of active DNA demethylation from E10.5 to 13.5 (Guibert et al., 2012; 
Seisenberger et al., 2012; Yamaguchi et al., 2013a).  For the passive DNA demethylation, 
the 5-methylcytosines (5mC) are diluted by the rapid proliferation of PGCs (~12h per cell 
cycle) when the DNA methylation machinery is repressed (Kagiwada et al., 2013).  
Specifically, the de novo DNA methyltransferases (Dnmt3a/3b) and their cofactor 
Dnmt3l are silenced in PGCs (Hajkova et al., 2002; Kagiwada et al., 2013; Seki et al., 
2005).  Further, although the maintenance DNA methyltransferase Dnmt1 is abundant in 
PGCs, its essential cofactor Uhrf1 (also known as Np95) is excluded from the nucleus 
(Kagiwada et al., 2013).  In addition, in support of the replication-dependent DNA 
demethylation, hairpin bisulfite sequencing can detect increased incidence of hemi-
methylated DNA strands in PGCs in E9.5-10.5 (Arand et al., 2012).    
 Following passive dilution of 5mC, active DNA demethylation occurs in PGCs 
involving the ten-eleven translocation family of dioxygenases Tet1/Tet2 (Ito et al., 2010; 
Tahiliani et al., 2009) and the thymine-DNA glycosylase Tdg (He et al., 2011; Shen et 
al., 2013).  In the wave of active demethylation, Tet1/Tet2 sequentially oxidize 5mC to 5-
hydroxymethylcytosine (5hmC), 5-formylcytosine (5faC), or 5-carboxycytosine (5caC) 
(Ito et al., 2011).  In support of these mechanisms, the level of 5hmC has a temporal 
increase during E9.5-10.5 accompanied by decreasing 5mC levels, which is then 
followed by a reduction of 5hmC levels at E11.5-12.5 (Hackett et al., 2013).  The 5mC 
derivatives (i.e., 5faC and 5caC) can be either diluted through cell proliferation or 
targeted by Tdg-mediated base excision repair (He et al., 2011; Shen et al., 2013).  This is 
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exemplified in Tdg mutant E11.5 PGCs where the secondary imprints at Igf2 DMR2 
exhibit hypermethylation (Cortellino et al., 2011). 
 Two-phase DNA demethylation process in PGCs suggests that distinct DNA 
demethylation mechanisms (i.e., passive and active demethylation) affect different 
genomic sequences.  Indeed, the passive DNA demethylation in the early phase affects 
the bulk genome, while specific sequences including imprinted genes become fully 
unmethylated only after the Tet1/2-mediated active demethylation phase (Seisenberger et 
al., 2012).  Notably, Tet1 knockout males exhibit hypermethylation of the imprinted 
genes Peg3, Peg10, Impact, Igf2r, Gnas, Grb10, and Kcnq1ot1 DMRs in both sperm and 
E13.5 PGCs, demonstrating the important role of Tet1 in erasure of the DNA methylation 
imprints at the late reprogramming stage in PGCs (Yamaguchi et al., 2013b).  However, 
it should be noted that normal imprint erasure could occur in a fraction of the Tet1/Tet2 
mutant mice progenies (Dawlaty et al., 2013; Yamaguchi et al., 2013b), suggesting that 
replication-dependent dilution of 5mC is probably sufficient for DNA methylation 
reprogramming in PGCs while Tet proteins act as a “safety check” for this process. 
 Establishment of imprints in gametogenesis 
 The re-establishment of DNA methylation in germ cells occurs at different times 
in development in male and female gonads (reviewed in Stewart et al., 2016).  In males, 
global de novo DNA methylation occurs in prospermatogonia from ~E14.5 until birth 
(Davis et al., 1999; Li et al., 2004).  However, in females, de novo methylation initiates 
after follicle activation in the postnatal ovary and is complete in fully-grown oocytes 
(Lucifero et al., 2002).  Notably, the acquisition of DNA methylation imprints in growing 
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oocytes is asynchronous for different maternally methylated gametic DMRs (gDMRs) 
(Lucifero et al., 2004; Obata and Kono, 2002).  For example, of the analyzed maternal 
gDMRs, the Snrpn DMR is the first to acquire DNA methylation, followed by Peg1, 
Peg3, and Impact DMRs (Lucifero et al., 2004; Obata and Kono, 2002).  This 
asynchronous acquisition of DNA methylation at maternal gDMRs suggests that different 
factors affect the imprint establishments at different loci.  In agreement with this, absence 
of the Zfp57 (a KRAB zinc finger protein) in oocytes abolishes the acquisition of DNA 
methylation at Snrpn DMR but not Peg1 and Peg3 DMRs (Li et al., 2008).   
 Besides the asynchronous acquisition of DNA methylation for different gDMRs, 
the same gDMR can exhibit different rates of de novo DNA methylation for the 
maternally and paternally inherited alleles (Davis et al., 2000; Lucifero et al., 2004).  For 
example, in prospermatogonia, H19/Igf2 DMR acquires 5mC on the paternally inherited 
allele prior to maternally inherited allele (Lee et al., 2010).  This phenomenon suggests 
that other epigenetic modifications still recognize the parental alleles in PGCs despite 
both alleles being unmethylated.  It has been found that the insulator CTCF binds to the 
maternal allele in prospermatogonia prior to de novo methylation, potentially delaying the 
acquisition of methylation on this allele (Lee et al., 2010).  Further, the chromatin 
composition of the parental alleles at H19/Igf2 DMR is different prior to acquisition of 
DNA methylation with the maternal allele being enriched with H3K4me3 compared to 
the paternal allele, potentially also contributing to the delayed de novo DNA methylation 
as this histone modification inhibits the binding of Dnmt3l to the Histone 3 tail (Lee et 
al., 2010; Ooi et al., 2007). 
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 The establishment of DNA methylation imprints in both male and female 
germlines requires the de novo DNA methylation machinery, which consists of the de 
novo DNA methyltransferases Dnmt3a/3b/3c and the non-catalytic cofactor Dnmt3l.  
Dnmt3a and Dnmt3l are required for both maternal and paternal imprint establishment 
(Bourc'his et al., 2001; Kaneda et al., 2004; Kato et al., 2007).  Female mice with Dnmt3l 
knockout or conditional knockout of Dnmt3a in oocytes fail to establish DNA 
methylation for all the maternal gDMRs examined and their progeny die around mid-
gestation largely due to the defects of maternal imprinting (Bourc'his et al., 2001; Kaneda 
et al., 2004).  For males, deficient Dnmt3a or Dnmt3l results in meiotic failure in 
spermatocyte most likely due to the derepression of retrotransposons, precluding the 
further analyses of paternal imprints in sperm or offspring (Bourc'his and Bestor, 2004; 
Kaneda et al., 2004; Webster et al., 2005).  However, examination of the spermatogonia 
from the newborn testes of Dnmt3a conditional knockouts indicates that Dnmt3a is 
essential for the de novo methylation of H19/Igf2 and Gtl2/Dlk1 DMR, but not Rasgrf1 
DMR (Kaneda et al., 2004).  Unlike Dnmt3a and Dnmt3l mutants, mice with conditional 
Dnmt3b knockout in germ cells and their offspring show no apparent abnormalities with 
most imprints correctly established except that the Rasgrf1 DMR is moderately affected 
(Kato et al., 2007).  Recently, Dnmt3c, which was previously annotated as a pseudogene, 
has been identified as a de novo methyltransferase and is required for the methylation of 
evolutionarily young repetitive elements and the imprint establishment only at Rasgrf1 
DMR in male germ cells (Barau et al., 2016).   
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 Mechanisms of establishment of differential imprints in sperms and oocytes 
 Prior to determination of the DNA methylome of sperm and oocytes, it was 
hypothesized that the imprinted gDMRs are specifically targeted by the de novo DNA 
methylation machinery.  However, recent whole genome wide DNA methylation 
profiling has led to the reconsideration of this assumption.  Specifically, sperm cells have 
very high levels of global DNA methylation (~80-90%) with methylated CpGs being 
evenly distributed throughout the genome except for a few encountered within 
unmethylated CpG islands (Kobayashi et al., 2012; Smallwood et al., 2011; Smith et al., 
2012).  However, oocytes exhibit a lower level of genome wide DNA methylation (~30-
40%) with alternating hypermethylated and hypomethylated domains (Kobayashi et al., 
2012; Smallwood et al., 2011; Smith et al., 2012).  The disparity in global DNA 
methylation between sperm cells and oocytes led to the discovery of gDMRs beyond the 
classical imprinted gDMRs (Kobayashi et al., 2012; Smallwood et al., 2011; Smith et al., 
2012).  Unlike the imprinted gDMRs, the majority of the newly discovered gDMRs are 
transient and not maintained throughout development (Kobayashi et al., 2012; 
Smallwood et al., 2011; Smith et al., 2012).  Therefore, the imprinted gDMRs are 
selectively maintained after fertilization (discussed in detail later, page 17) instead of 
specifically targeted by de novo DNA methylation machinery over non-imprinted 
gDMRs during gametogenesis.   To date, 26 definitive imprinted gDMRs have been 
identified in mice with 23 being maternally methylated and 3 being paternally methylated 
(reviewed in Stewart et al., 2016).   
 Although the mechanism that involves the establishment of different patterns of 
DNA methylation in sperm cells and oocytes remains elusive, the recent findings 
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highlight that the acquisition of DNA methylation, at least in oocytes, is coordinately 
regulated by transcription and histone modifications (reviewed in Hanna and Kelsey, 
2014).  The first piece of evidence that connects histone modification and DNA 
methylation comes from the finding that the specific interaction between the amino 
terminus of histone H3 and Dnmt3l is strongly inhibited by methylation at lysine 4 of H3 
(Ooi et al., 2007).  Further, it was found that histone H3, but not H3K4me3, can release 
the catalytic domain of Dnmt3a from the auto-inhibition by its Atrx-Dnmt3-Dnmt3l 
(ADD) domain and stimulate the enzymatic activity of Dnmt3a (Guo et al., 2015).  In 
agreement with this, DNA methylation in oocytes is strongly anti-correlated with the 
broad H3K4me3 domain that covers ~22% of the genome (Dahl et al., 2016).  Further, 
oocytes deficient of Kdm1b (also known as Aof1 or Lsd2), a H3K4 demethylase, fail to 
establish DNA methylation at hundreds of CpG islands including several maternal 
gDMRs such as Mest, Grb10, Zac1 and Impact DMR (Ciccone et al., 2009; Stewart et al., 
2015).  Most importantly, profiling of H3K4me2/3 enrichment in primary and growing 
oocytes indicates that removal of H3K4me2/3 occurs prior to the onset of de novo DNA 
methylation (Stewart et al., 2015), suggesting that the methylation machinery is directed 
by pre-existing chromatin marks in female germ cells.  Lastly, H3K4me2/3-enriched 
regions in male germ cells are resistant to acquiring DNA methylation, highlighting the 
critical role of H3K4me2/3 in protection against de novo DNA methylation (Singh et al., 
2013). 
 Besides histone modifications, several lines of evidence indicate that transcription 
plays a role in the establishment of maternal imprints in oocytes (reviewed in Hanna and 
Kelsey, 2014).   For example, in the Gnas cluster, truncation of a transcript Nesp, which 
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is transcriptionally active in oocytes and overlaps with the ICR, leads to the failure of 
maternal DNA methylation establishment at this locus (Chotalia et al., 2009).  In 
addition, similar results were obtained for the maternal imprinted gDMRs Snrpn and 
Plagl1 (Smith et al., 2011; Veselovska et al., 2015).  Notably, comprehensive profiling of 
the oocyte transcriptome and DNA methylome indicates that transcription events 
correlate with ~90% of the DNA methylation established in the oocyte, including the 
methylated CpG islands and imprinted gDMRs (Veselovska et al., 2015).  Although a 
small portion of actively transcribed genes escape DNA methylation, it is likely that 
transcription is a universal mechanism that contributes to the acquisition of DNA 
methylation at both imprinted and non-imprinted loci in female germ cells (Veselovska et 
al., 2015).  
 A question that remains to be answered is how exactly transcription and histone 
modifications coordinately direct de novo DNA methylation in oocytes.   Current 
understanding is that activation of oocyte transcriptome accumulates H3K36me3 at gene 
bodies, a histone modification that is associated with transcript elongation and can recruit 
Dnmt3a to target regions (Dhayalan et al., 2010).  Further, prior to the onset of de novo 
methylation, the H3K4 methylation at regions destined for DNA methylation has to be 
removed by Kdm1b, a process that appears to be also dependent on transcription (Stewart 
et al., 2015).  In support of this, truncation of a transcript that overlap with the imprinted 
Plagl1 DMR leads to the failure of DNA methylation establishment, which is coupled 
with the absence of H3K36me3 and retention of H3K4me2 at the imprinted gDMR 
(Stewart et al., 2015).  Further, RNA-seq profiling of Kdm1b mutant oocytes indicates 
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that the transcriptome is largely normal, suggesting Kdm1b removal of H3K4 
methylation is downstream of transcription (Stewart et al., 2015).      
 The Rasgrf1 DMR is distinct from the other two paternal imprinted gDMRs 
because it relies on Dnmt3b and Dnmt3c (Barau et al., 2016; Kato et al., 2007).  Dnmt3c 
is evolved as a duplication of Dnmt3b, and both are responsible for the methylation of 
retrotransposons (Barau et al., 2016; Kato et al., 2007).  In male germ cells, DNA 
methylation of retrotransposons also relies on a class of small RNA called PIWI-
interacting RNAs, or piRNAs (reviewed in Weick and Miska, 2014).  piRNA can silence 
repetitive elements transcriptionally by recruiting machinery for de novo DNA 
methylation to the target regions through sequence complementarity (Aravin et al., 2008; 
Carmell et al., 2007; Itou et al., 2015; Kuramochi-Miyagawa et al., 2008).  It has been 
shown that the Rasgrf1 DMR contains repetitive elements that can be targeted by 
piRNAs (Watanabe et al., 2011), suggesting that de novo DNA methylation at the Rasgtf1 
DMR depends on the piRNA pathway.  In agreement with this, disruption of key piRNA 
pathway components such as Mili, Miwi2, and Mitopld leads to reduction of DNA 
methylation of Rasgrf1 DMR in sperm cells (Watanabe et al., 2011).   Although other 
piRNA dependent gDMRs exist in the male germline, they do not maintain their 
methylation status after fertilization suggesting that other mechanisms exist to maintain 
the imprinted Rasgrf1 DMR during development (Watanabe et al., 2011).  
 Maintenance of imprints during pre-implantation development 
 Following fertilization, both oocyte- and sperm-derived genomes undergo global 
DNA demethylation but the demethylation mechanism is distinct between the parental 
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genomes (reviewed in Messerschmidt et al., 2014).  The maternal genome undergoes 
replication-dependent passive DNA demethylation as the methylation maintenance 
enzyme Dnmt1o is excluded from the nucleus (Howell et al., 2001; Inoue et al., 2011; 
Inoue and Zhang, 2011).  Conversely, the DNA demethylation process on the paternal 
genome occurs before DNA replication, indicating an active mechanism.  It was 
previously suggested that this active DNA demethylation is the result of Tet3-mediated 
oxidation of 5mC (Gu et al., 2011; Inoue and Zhang, 2011).  In support of this, deletion 
of Tet3 in oocytes leads to undetectable 5hmC and results in the hypermethylation of 
pluripotent genes such as Oct4 and Nanog in zygotes, demonstrating the role of Tet3 in 
active DNA demethylation (Gu et al., 2011).  Recently, it was reported that DNA 
replication is a major contributor of DNA demethylation of both parental genomes, with 
Tet3 being critical for demethylation only at certain loci (Shen et al., 2014), raising the 
question whether active demethylation by Tet3 for paternal pronuclei is required for 
development.  Indeed, live offspring can be derived from round spermatid-injected 
oocytes, in which the paternal DNA is bound by histones and does not undergo active 
demethylation in zygotes (Polanski et al., 2008).  Further, it has been demonstrated that 
haploinsufficiency, instead of defective paternal 5mC oxidation, contributes to the 
developmental defects previously ascribed to lack of maternal Tet3 in the zygote (Inoue 
et al., 2015).  In fact, a similar rate of neonatal sublethality is observed when Tet3 is 
deleted from either parental germline (Inoue et al., 2015).  In addition, reconstructed 
zygotes with either oxidized or non-oxidized paternal genome can equally develop to 
term, indicating that the paternal 5mC oxidation is dispensable for mouse development 
(Inoue et al., 2015).  Thus, Tet3-mediated active demethylation may function as an 
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“accelerator” for DNA demethylation, while replication-dependent dilution of 5mC alone 
is probably sufficient for the DNA methylation reprogramming purpose in early embryos. 
 Unlike in PGCs, the imprinted gDMRs and some repetitive elements such as IAP 
and centromeric repeats can retain their DNA methylation patterns in the wave of global 
DNA demethylation in early embryos (reviewed in Messerschmidt et al., 2014).   How 
imprinted gDMRs escape the DNA methylation reprogramming is not completely 
understood, but several factors have been identified to be responsible for the maintenance 
of the DNA methylation imprints in pre-implantation embryos.  In zygotes, it is well 
defined that the protein Stella (also known as Pgc7 or Dppa) specifically protects the 
maternal genome from Tet3-mediated oxidation (Nakamura et al., 2007; Nakamura et al., 
2012).  The Stella protein distinguishes the maternal genome from the paternal genome 
by interacting with H3K9me2, which is enriched in the maternal genome but not paternal 
pronuclei (Nakamura et al., 2012).  Aside from its protection of global maternal genome 
from active demethylation, Stella is also required to maintain the allele-specific DNA 
methylation at several maternal gDMRs such as Peg1, Peg3, and Peg10 and paternal 
gDMRs such as H19/Igf2 and Rasgrf1 DMR (Nakamura et al., 2007).  However, not all 
imprinted gDMRs are equally affected by the deletion of Stella, suggesting that the 
imprinted gDMRs are differentially enriched with H3K9me2 (Nakamura et al., 2007), or 
other mechanisms may act in partial redundancy with Stella to maintain DNA 
methylation imprints in zygotic stage.  
 The exclusion of Dnmt1 from the nucleus for passive DNA demethylation in pre-
implantation embryos poses a challenge for the maintenance of DNA methylation imprint 
(Howell et al., 2001).  It has been found that Dnmt1o, the oocyte-specific isoform of 
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Dnmt1, is detected mostly in the cytoplasm with transient localization in the nucleus at 
the eight-cell stage, suggesting its role in maintenance of genomic imprints at this cell 
cycle (Howell et al., 2001).  Indeed, Dnmt1o deficient embryos exhibit loss of DNA 
methylation at certain imprinted gDMRs including H19/Igf2, Snrpn, and Peg3 (Howell et 
al., 2001).  Further investigation demonstrated that disruption of both oocyte-specific and 
zygotic Dnmt1 completely eliminates the DNA methylation imprints, indicating that 
Dnmt1 contributes to DNA methylation maintenance at imprinted gDMRs during pre-
implantation even though most of the proteins are not located in the nucleus (Hirasawa et 
al., 2008).  
 The scarce amount of Dnmt1 in the nucleus during pre-implantation development 
suggests that a non-canonical mechanism attracts Dnmt1 to imprinted gDMRs in early 
embryos in order to maintain the methylation imprints.  Zfp57 was the first maternal 
factor that was identified to target and maintain DNA methylation at imprinted gDMRs in 
early embryos (Li et al., 2008; Quenneville et al., 2011).  Embryos with disruption of 
both maternal and zygotic Zfp57 die prenatally and exhibit loss of methylation of 
multiple imprinted gDMRs such as Snrpn ICR, H19 ICR, and Gtl2/Dlk1 ICR (Li et al., 
2008).  Further, as Zfp57 specifically binds to a methylated hexanucleotide, which can be 
found in most imprinted gDMRs (MacDonald and Mann, 2014; Quenneville et al., 2011), 
it is believed that Zfp57 selects the imprinted gDMRs out of the thousands CpG islands 
with differential DNA methylation between sperm cells and oocytes (reviewed in Hanna 
and Kelsey, 2014). After binding to imprinted gDMRs, Zfp57 recruits its co-factor 
Trim28, which is a component of a multifunctional complex containing H3K9 
methyltransferase Setdb1, Dnmt1, and Dnmt3a/3b (Messerschmidt et al., 2012; Zuo et 
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al., 2012).  Therefore, Trim28 could be a mediator for Zfp57 to recruit Dnmts to the 
imprinted gDMRs.  In support of this, embryos derived from Trim28-deficient oocytes 
exhibit variable defects with hypomethylation of several maternal and paternal imprinted 
gDMRs (Messerschmidt et al., 2012).  In summary, it is proposed that Zfp57/Trim28-
mediated recruitment of DNA methylation maintenance machinery to imprinted gDMRs 
compensates for the scarce amount of Dnmt1 in the nucleus and ensures the faithful 
maintenance of methylation imprints in pre-implantation embryos (reviewed in 
Messerschmidt et al., 2014). 
 Maintenance of unmethylated ICRs in post-implantation development 
 Around the time of implantation, parental genomes undergo another wave of 
genome-wide de novo DNA methylation to establish cell lineage-specific methylation 
patterns (reviewed in Smith and Meissner, 2013).  In this process, the parental genomes, 
now in the same compartment, are treated equally by the de novo DNA methylation 
machinery.  Therefore, it is important to protect the unmethylated alleles of imprinted 
gDMRs from acquisition of de novo DNA methylation.  For imprinted gDMRs, the 
unmethylated alleles are usually characterized by active chromatin marks including 
H3K4me2/me3, histone modifications that can prevent the interaction of Dnmt3a/3l 
complex with the H3 tails (Ooi et al., 2007).  Therefore, active chromatin marks on the 
unmethylated allele could be a general mechanism that protects against de novo DNA 
methylation.  Recent findings also indicate that different imprinted DMRs may apply 
distinct mechanisms to prevent de novo DNA methylation on the unmethylated allele.  
For H19/Igf2 ICR, ablation of the CTCF binding sites leads to hypermethylation of this 
locus in neonatal mice but not in oocytes and blastocysts (Schoenherr et al., 2003; Szabo 
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et al., 2004), indicating that CTCF binding plays a role in protection against de novo 
methylation on the unmethylated allele post-fertilization.  In addition, for Gtl2/Dlk1 
gDMR, it has been demonstrated that polycomb repressive complex 2 (PRC2), a complex 
that catalyzes the repressive chromatin mark H3K27me3, is essential to prevent 
recruitment of Dnmt3a, Dnmt3b, and Dnmt3l to the DMR for de novo DNA methylation 
in embryonic stem cells (Das et al., 2015).  
 
1.3  Functional roles of imprinted genes in mammalian development 
1.3.1 Imprinted gene network and pre- and post-natal development 
 The distinct phenotypes of androgenetic and gynogenetic embryos indicate that 
parental genomes play different roles in embryonic development (Barton et al., 1984) and 
the discovery of imprinted genes (i.e., Igf2, Igf2r, and H19) demonstrated that imprinted 
genes are responsible for the functional asymmetry of parental alleles (Barlow et al., 
1991; Bartolomei et al., 1991; DeChiara et al., 1991).  Igf2 is a paternally expressed fetal 
growth factor (DeChiara et al., 1991).  Biallelic expression of Igf2 leads to embryonic 
overgrowth while its reduction results in growth restriction (DeChiara et al., 1991).  
Contrary to Igf2, its scavenger mannose receptor Igf2r is maternally expressed and its 
deletion leads to overgrowth and embryonic death (Barlow et al., 1991; Ludwig et al., 
1996).  It has been shown that the lethal phenotype of Igf2r mutants can be rescued when 
they carry a mutation that abolishes Igf2, indicating an antagonistic relationship between 
Igf2 and Igf2r in regulation of embryonic development (Ludwig et al., 1996).  Unlike 
Igf2 and Igf2r, the functional role of the maternally expressed ncRNA H19 is still not 
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completely understood.  H19 was first proposed as a tumor suppressor gene (Hao et al., 
1993) and the tumor suppressor activity of H19 was suggested to be mediated by its 
regulation of Igf2 in cis.  However, transgenic experiments indicate that H19 can act as a 
trans factor to control embryonic growth and Igf2 is not the only target of H19 (Gabory et 
al., 2009).  In support of this, deletion of the H19 gene leads to overgrowth while 
transgenic mice that overexpress H19 exhibit reduced bodyweight (Gabory et al., 2009; 
Ripoche et al., 1997).  Further, the expression of multiple imprinted genes that are 
important embryonic growth regulators such as Igf2, Igf2r, Cdkn1c, Dlk1, and Rtl1 are 
altered when H19 is overexpressed or deleted (Gabory et al., 2009).  Therefore, it has 
been proposed that H19 is a regulator for an imprinted gene network in which multiple 
imprinted genes are coordinately regulated to precisely control embryonic growth 
(Gabory et al., 2009).    
 As the H19 gene expresses both a 2.3kb ncRNA and a microRNA (miR-675) 
(Brannan et al., 1990; Cai and Cullen, 2007), it is still not completely clear whether 
imprinted gene network is regulated by the ncRNA or the miRNA or both. 
Overexpression of miR-675 in a variety of embryonic cell lines can lead to reduced 
proliferation (Keniry et al., 2012).  However, miR-675 can only be detected with high 
abundance in placenta, suggesting that only in placenta this miRNA mediates the H19’s 
growth repressive properties (Keniry et al., 2012).  Recently, it has been shown that H19 
ncRNA controls gene expression of the imprinted gene network through recruiting the 
methyl-binding protein 1 (Mbd1) (Monnier et al., 2013).  Specifically, the H19-Mbd1 
complex can bring repressive histone mark H3K9me3 to the DMRs of the Igf2, Peg1, and 
Slc38a4 loci and regulate the expression of imprinted genes in an allele-specific-
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independent manner (Monnier et al., 2013).  However, how H19 ncRNA specifically 
recognizes the DMR sequences and why only these DMRs are targeted by H19-Mbd1 
complex remain to be addressed.  In addition to H19, a paternally expressed transcription 
factor Plagl1 has also been demonstrated as a critical regulator of an imprinted gene 
network to control embryonic growth (Arima et al., 2005; Varrault et al., 2006).  Paternal 
deletion of Plagl1 leads to intrauterine growth restriction and affects embryonic bone 
development (Varrault et al., 2006).  Further, misregulation of Plagl1 can alter the 
expression of multiple imprinted genes including Igf2, H19, Cdkn1c, and Dlk1 (Varrault 
et al., 2006).  In addition, the Plagl1 protein can directly regulate the Igf2/H19 locus 
through binding the downstream enhancers shared by H19 and Igf2 (Varrault et al., 2006).  
In summary, the imprinted gene network may serve to fine-tune the expressed allele of 
imprinted genes for precise control of embryonic growth.   
 In addition to controlling embryonic growth, the imprinted gene network can also 
be an important indicator for postnatal obesity (Dalgaard et al., 2016).  It has been shown 
that the isogenic mice with Trim28 haploinsufficiency (i.e., Trim28+/-) can randomly 
develop an obese phenotype, which is associated with the reduced expression of an 
imprinted gene network including Nnat, Peg3, Cdkn1c, and Plagl1 (Dalgaard et al., 
2016).  Notably, the fact that no altered DNA methylation is detected at the ICRs of these 
imprinted genes is consistent with the findings that imprinted gene network regulation is 
not dependent on alteration of DNA methylation or loss of allele-specific expression of 
imprinted genes (Al Adhami et al., 2015; Dalgaard et al., 2016; Monnier et al., 2013).  
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1.3.2 Roles of imprinted genes in placenta  
 Numerous mouse models with deletion or overexpression of imprinted genes have 
demonstrated that precise control of genomic imprinting is essential for normal placental 
development.  For instance, embryos with deletion of the maternally expressed Ascl2 fail 
to develop spongiotrophoblast and cannot survive beyond embryonic day 10.5 (Guillemot 
et al., 1994).  Conversely, another maternally expressed imprinted gene Phlda2, when 
deleted, causes the expansion of spongiotrophoblast and increased placental weight 
(Frank et al., 2002).  Further, deletion of Sfmbt2 (paternally expressed) leads to reduction 
of all trophoblast cell types and embryos die before E12.5 (Miri et al., 2013).  Notably, a 
retrotransposon-derived imprinted gene Rtl1 (paternally expressed) is essential to 
maintain the fetal capillaries in placenta and both its deletion and its overexpression 
result in late-fetal and/or neonatal lethality in mice (Sekita et al., 2008).   In addition to 
regulating placental development, imprinted genes can control the nutrient supply to the 
fetus through the placenta.  For example, deletion of Igf2 P0, a placental-specific isoform 
of Igf2, inhibits the nutrient uptake by placenta and leads to embryo growth retardation 
(Constancia et al., 2002).  Lastly, imprinted gene products may act as endocrine factors 
and modulate maternal metabolic processes.  For instance, the protein product of the 
paternally expressed Dlk1 gene is the source of maternal circulating Dlk1 and 
pregnancies lacking Dlk1 exhibit compromised lipid metabolism (Cleaton et al., 2016).  
1.3.3 Roles of imprinted genes in behavior 
 Many imprinted genes are expressed in the brain and the significance of genomic 
imprinting in neurodevelopment is featured by the evidence that mis-expression of 
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imprinted genes can cause abnormal behaviors.  For example, Peg3 null females exhibit 
defects in maternal care behaviors such as milk release and nest building (Champagne et 
al., 2009).  In addition, Peg3 null newborns show suckling defects (Champagne et al., 
2009).  Similar to Peg3, females with Peg1 deletions also exhibit deficient maternal care 
behaviors such that they do not respond to the neonates appropriately and do not ingest 
their extra-embryonic tissues afterbirth (a normal mammalian behavior termed 
placentophagia) (Lefebvre et al., 1998).  Recent work also indicates that deletion of the 
paternal Grb10 results in social dominance and aggression behaviors while deletion of 
the maternal Grb10 leads to fetal and placental overgrowth (Garfield et al., 2011).   
Grb10 is imprinted on both alleles, however, unlike the maternal isoform, the paternal 
Grb10 transcribes from an alternative promoter and is only expressed in a subset of 
neurons (Garfield et al., 2011).  This indicates distinct physiological and behavioral 
functions of parental alleles of the Grb10 gene.  The other imprinted genes known to 
control social behavior and communication include Ube3a, Snord116, and Ndn, which 
are described in detail in the following section titled “human loss-of-imprinting 
disorders” as these genes in humans are associated with Prader-Willi syndrome and 
Angelman syndrome. 
 
1.4  Human loss-of-imprinting disorders 
1.4.1 Prader-Willi syndrome (PWS) and Angelman syndrome (AS) 
 Both PWS (OMIM ID: 176270) and AS (OMIM ID: 105830) are complex 
neurodevelopmental disorders with an occurrence of 1 in 15,000 to 25,000 live births 
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(reviewed in Buiting, 2010).  Individuals with PWS are typically characterized by low 
birth weight and hypotonia with poor suckling at pre-weaning stage and hyperphagia and 
obesity at post-weaning stage.  Other main features observed in PWS include short statue 
with small hands and feet, hypogonadism, mild intellectual disability, and abnormal 
behavior such as skin picking.  AS, which is also known as “happy puppet syndrome” 
due to a happy disposition, are also characterized by developmental delay, severe 
intellectual disability, speech impairment, seizures, hyperactivity and restless behavior 
(reviewed in Buiting, 2010).  Both PWS and AS are associated with the imprinted 
SNRPN/UBE3A domain at chromosome 15q11-13 region but exhibit distinct 
genetic/epigenetic alterations (reviewed in Clayton-Smith and Laan, 2003; reviewed in 
Ohta et al., 1999).  Most PWS individuals (~70%) have large deletions (~4Mb) at the 
SNRPN/UBE3A imprinted locus on the paternally inherited chromosome, which includes 
multiple paternally expressed protein coding genes (e.g., SNRPN/SNURF, MAGEL2, 
NDN) and ncRNAs (e.g., SNORD115 and SNORD116).  The other PWS individuals are 
characterized by either maternal uniparental disomy of the imprinted locus (~25%) or 
epimutations involving the alteration of DNA methylation at the ICR (~3%) (reviewed in 
Ohta et al., 1999).   For AS, approximately ~60-70% patients also have a large deletion at 
the imprinted SNPRN/UBE3A locus, but unlike PWS, the deletion is always on the 
maternally inherited chromosome (reviewed in Clayton-Smith and Laan, 2003).  Further, 
approximately 10% of individuals with AS have a mutation in the maternally expressed 
gene, ubiquitin protein ligase E3A (UBE3A) and 1-5% exhibit either paternal uniparental 
disomy or imprinting defects at the imprinted domain (reviewed in Clayton-Smith and 
Laan, 2003).  
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   It is well established that the UBE3A gene is responsible for AS (Kishino et al., 
1997; Matsuura et al., 1997).  UBE3A is maternally expressed in a subset of neurons 
while biallelically expressed in peripheral tissues (Yamasaki et al., 2003).  Mice that 
carry a non-functional maternal Ube3a exhibit many phenotypes that recapitulate AS 
such as seizures, learning and gait deficit (Jiang et al., 1998; Miura et al., 2002).  Further, 
activation of the normally silent paternal Ube3a in neurons can partially restore the 
Ube3a protein and alleviate some cognitive defects associated with AS (Meng et al., 2012; 
Meng et al., 2015).  Recently, it has been shown that Ube3a can rescue more symptoms 
in a mouse model of AS when it is re-expressed at earlier stage (i.e., newborns) compared 
to a later stage (i.e., juvenile or adulthood), suggesting the importance of timing for 
Ube3a expression in normal neurodevelopment (Silva-Santos et al., 2015).  In humans, 
the severity of AS symptoms is associated with different types of mutations in UBE3A 
with full deletion of chromosome 15q11-13 most severe and point mutation of UBE3A 
less severe (Gentile et al., 2010; Valente et al., 2013).  Unlike AS, PWS is caused by the 
loss of multiple, rather than a single paternally expressed gene (reviewed in Bervini and 
Herzog, 2013).  Deletion of Ndn, a paternally expressed gene in the Snrpn/Ube3a 
imprinted cluster, leads to behavior defects that recapitulate PWS such as skin scraping 
and modified spatial learning (Muscatelli et al., 2000).  However, Ndn null mice do not 
exhibit obesity, indicating that Ndn gene alone does not account for all the symptoms of 
PWS.  Further, deletion of the Snord116 gene cluster can lead to hyperphagia, but none 
of these mutant mice exhibit obesity (Ding et al., 2008).  Therefore, these genetically 
modified mouse model systems do not recapitulate all PWS phenotypes.  
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1.4.2 Silver-Russell syndrome (SRS) 
 SRS (OMIM ID: 180860) is a rare loss-of-imprinting disorder with an estimated 
frequency of 1 in 300,000 and is mainly characterized by pre- and postnatal growth 
restriction, triangular shaped face, and skeletal asymmetry (reviewed in Azzi et al., 
2014).  SRS is associated with the H19/IGF2 imprinted domain on chromosome 11p15.5.  
Approximately 35-65% SRS patients exhibit hypomethylation of the H19/IGF2 ICR and 
about 10% have maternal uniparental disomy of the same imprinted locus (reviewed in 
Abu-Amero et al., 2008).  Of the individuals with epimutation at H19/IGF2 domain,  
~73% of them also exhibit hypo- or hypermethylation at other imprinted loci, suggesting 
a general defect in DNA methylation imprint establishment or maintenance in these 
individuals (Kannenberg et al., 2012).  Recently, a mouse model with the endogenous 
paternal H19/IGF2 ICR replaced by the human orthologous ICR exhibited impaired 
DNA methylation acquisition at the locus, resembling the growth restriction phenotype of 
SRS (Hur et al., 2016).  Thus, this mouse model could be used to elucidate some 
molecular mechanisms that underlie SRS (Hur et al., 2016).  
1.4.3 Beckwith-Wiedemann syndrome (BWS) 
BWS (OMIM ID: 130650) is the most common loss-of-imprinting disorder with 
occurrence of one in 11,000 live births, although this number is likely underestimated 
(reviewed in Mussa et al., 2016; Weksberg et al., 2010).  BWS is equally represented in 
males and females (reviewed in Pettenati et al., 1986).  The primary features of BWS 
include pre- and postnatal overgrowth, enlarged tongue, ear malformation, and abdominal 
wall defects such as exomphalos and umbilical hernia.  The less common characteristics 
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of BWS include hemihyperplasia, adrenocortical cytomegaly, visceromegaly, congenital 
renal abnormalities, placentomegaly, and neonatal hypoglycemia (reviewed in Weksberg 
et al., 2010).  Individuals with BWS also have an increased frequency to develop 
childhood tumors including Wilms’ tumors of the kidney, hepatoblastoma, 
rhabdomyosarcoma, neuroblastoma, and adrenocortical carcinoma (reviewed in Choufani 
et al., 2013).  
 Most individuals with BWS (~85%) are associated with genetic and/or epigenetic 
alterations at chromosome 11p15.5 region, which harbors two imprinted clusters, the 
KCNQ1 locus and the H19/IGF2 locus (reviewed in Choufani et al., 2013).  
Hypomethylation of the ICR (i.e., KvDMR1) of the KCNQ1 imprinted domain is the 
most frequent molecular alteration of BWS and is seen in approximately 50% BWS cases 
(reviewed in Choufani et al., 2013).  Aberrant DNA hypomethylation of KvDMR1 causes 
derepression of the maternal ncRNA KCNQ1OT1, which leads to repression of the 
flanking maternally expressed genes such as CDK1NC (Diaz-Meyer et al., 2003; 
Fitzpatrick et al., 2002; Smilinich et al., 1999).  CDKN1C is a cyclin-dependent kinase 
inhibitor of G1 cyclin complex that negatively regulates cell proliferation and the 
maternal CDKN1C mutations accounts for ~10% of individuals with BWS (reviewed in 
Choufani et al., 2013).  Hypermethylation of the H19/IGF2 ICR leads to increased 
abundance of the fetal growth factor of IGF2 and is seen in ~5-10% BWS cases 
(reviewed in Choufani et al., 2013).  It has been reported that a subset of BWS 
individuals with hypermethylation of the H19/IGF2 ICR has micro-deletions that disrupt 
the CTCF binding sites at the locus (Beygo et al., 2013; Sparago et al., 2004).  In 
addition, point mutations of OCT4/SOX2 binding sites at the H19/IGF2 ICR have been 
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reported in BWS patients (Abi Habib et al., 2014).  Lastly, approximately 20% BWS 
cases exhibit paternal uniparental disomy of chromosome 11p15.5 region, which affects 
both the H19/IGF2 and KCNQ1 imprinted loci (reviewed in Choufani et al., 2013).  
Besides the KCNQ1 and H19/IGF2 imprinted loci, approximately 22% BWS 
patients with KvDMR1 hypomethylation exhibit DNA methylation defects at other 
imprinted loci such as PLAGl1 DMR, PEG1 DMR, IGF2R DMR, GNAS DMR (Azzi et 
al., 2009; Bliek et al., 2009; Eggermann et al., 2016).  Of these imprinted genes, 
PLAGL1 can bind to the KvDMR1 and induce the transcription of KCNQ1OT1 in a DNA 
methylation-dependent manner (Arima et al., 2005).  It is still unclear what causes the 
DNA methylation defects at multiple imprinted loci in BWS patients.  It has been 
reported that two affected BWS siblings with KvDMR1 hypomethylation have a 
frameshift mutation of the NLRP2 gene, suggesting that NLRP2 is directly or indirectly 
implicated in the establishment and/or maintenance of DNA methylation in humans 
(Meyer et al., 2009). 
1.4.4 Mouse models for BWS   
 Mouse models with Cdkn1c deletion 
 Several mouse models of BWS have been created by deletion of the Cdkn1c gene.  
Maternal deletion of Cdkn1c leads to neonatal lethality and the Cdkn1c null fetuses have 
some defects that resemble BWS, such as abdominal wall defects, cleft palate, and 
adrenal cytomegaly (Yan et al., 1997; Zhang et al., 1997).  However, only prenatal 
overgrowth but not neonatal overgrowth, is observed in the Cdk1nc null mice (Tunster et 
al., 2011).  It has been suggested that the prenatal overgrowth of Cdkn1c null mice is 
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compromised by the intrauterine nutrient competition between fetuses during late 
gestation, as these mutants show larger bodyweight when the litter size is small (Tunster 
et al., 2011).  Further, no neonatal lethality has been reported for BWS, suggesting that, 
unlike the Cdkn1c null mouse models, BWS patients with CDK1C mutation or 
hypomethylation of KvDMR1 still retain partial Cdkn1c activity (Chiesa et al., 2012). 
Mouse model with the overexpression of Igf2    
R/H mice.  In this mouse model, both Igf2r and H19/Igf2 ICR are targeted in order 
to increase Igf2 activity.  “R” refers to the deletion of Igf2r, which degrades excess Igf2 
via receptor-mediated endocytosis (Ludwig et al., 1996).  “H” stands for deletion of the 
maternal H19 gene region (including the H19/Igf2 ICR), which leads to the de-repression 
of Igf2 from the maternal alleles (Leighton et al., 1995a).  On E12.5, approximately 11-
fold higher level of Igf2 is present in R/H mice in serum compared to controls 
(Eggenschwiler et al., 1997).  This mouse model exhibits many BWS characteristics 
including somatic overgrowth, abdominal wall defects, visceromegaly, skeletal 
abnormalities, and cleft palate (Eggenschwiler et al., 1997).  However, some BWS 
features such as macroglossia, renal dysplasia, embryonic tumors and adrenal cytomegaly 
were not observed in this BWS model.  For this mouse model, no pups survive beyond 
E18.5. 
Igf2 transgenic mice.  In this model, ES cell lines with exogenous Igf2 are 
injected into the cavity of blastocyst to make chimeras (Sun et al., 1997).  The Igf2 
overexpressing chimeras died within 24 hours of birth.  On E13.0, transgenic mice with 
40-50% chimeraism exhibit 116-131% overgrowth compared to controls.  In addition to 
	   30 
the somatic overgrowth, this mouse model also has some BWS features including 
macroglossia, visceromegaly. However, no abdominal wall defects, neonatal 
hypoglycemia, and hemihypertrophy are seen in this mouse model (Sun et al., 1997). 
Mouse model with the loss of imprinting of Igf2 and null mutation of Cdkn1c 
In this mouse model, both the maternal H19 region (including the H19/IGF2 ICR) 
and the maternal Cdkn1c are deleted to increase the Igf2 activity and to deplete Cdkn1c, 
respectively (Caspary et al., 1999).  These double mutants exhibit more severe phenotype 
than each single mutant.  For example, no live offspring can be recovered, and the 
parturition date of the double mutants is advanced by at least one day when compared to 
Cdkn1c null mutants. The double mutants exhibit 20% increase in bodyweight at E16.5-
17.5, but are indistinguishable from wild type offspring on E18.5.  Other BWS 
characteristics such as macroglossia (122% of wild type littermates), placentomegaly 
(190% of wild type littermates), kidney dysplasia and abdominal wall defects are 
observed in the double mutant model (Caspary et al., 1999).        
In summary, these mouse models for BWS strongly support that imprinted genes 
are essential for normal embryonic development and provide insights to the mechanisms 
of imprinted gene regulation.  However, these mouse models do not perfectly fulfill the 
criteria of an animal model for BWS.  First, not all the main BWS symptoms are present 
in each mouse model system.  In particular, childhood tumors, which have an increased 
likelihood to be developed within the five years of age in BWS, are not present in the 
mouse models.  The absence of tumors might be due to embryonic/neonatal lethality of 
these mouse models, which is also not seen in BWS patients.  Second, the BWS 
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characteristics observed in these mouse models are induced by genetic manipulations 
(i.e., gene knockout), which do not mimic the epimutations naturally occurring in BWS, 
such as aberrant DNA methylation at the KCNT1 locus, H19/IGF2, and/or other 
imprinted loci.   
 
1.5 Assisted reproductive technologies/therapies (ART) and genomic 
imprinting 
1.5.1 ART can induce loss-of-imprinting in animals  
 In humans, ART refers to a series of procedures that are used to overcome 
infertility/subfertility in order to help establish a successful pregnancy with the ultimate 
goal of giving rise to a healthy child.  In animal industry, ART is commonly used to 
facilitate the rapid multiplication of genetically superior animals.  Common ART 
procedures include ovarian hyperstimulation (also known as superovulation), in vitro 
fertilization (IVF), intracytoplasmic sperm injection (ICSI), in vitro culture (IVC), and 
embryo transfer.  ART manipulations overlap with the critical period for acquisition and 
maintenance of genomic imprints.  For example, the ovarian hyperstimulation coincides 
with the oocyte-growing phase when the maternal gDMRs are acquiring DNA 
methylation (Lucifero et al., 2004; Lucifero et al., 2002).  Further, IVF and IVC are 
implemented when preimplantation embryos undergo global DNA demethylation, in 
which DNA methylation imprints need to be faithfully maintained (reviewed in 
Messerschmidt et al., 2014).  Therefore, ART manipulations take place during the 
sensitive epigenetic reprogramming period and may lead to epigenome perturbations.  
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Indeed, a large body of experiments has demonstrated that ART can induce loss-of-
imprinting in mice, sheep, and cattle (reviewed in Denomme and Mann, 2012).    
 How ART procedure(s) cause loss-of-imprinting is still unclear.  However, it is 
well established that the multiple ART procedures induce more severe loss-of-imprinting 
when compared to the use of a single ART manipulation.  For example, embryo culture 
can exacerbate the adverse effects of embryo transfer on imprinted gene expression in 
E9.5 embryo and placenta (Rivera et al., 2008).  Further, it has been shown that high 
dosage hormone hyperstimulation leads to more frequent imprinted methylation defects 
in mouse blastocysts when compared to the low dosage (Market-Velker et al., 2010).  
Notably, superovulation interrupts the paternal H19 methylation in blastocysts, 
suggesting that superovulation not only disrupts acquisition of imprints in growing 
oocytes, but also affects the maternal-effect gene products required for imprint 
maintenance in early embryos (Market-Velker et al., 2010).   
 It is also intriguing that the placenta is more susceptible than the fetus to loss-of-
imprinting when the ART procedures are applied (de Waal et al., 2014; de Waal et al., 
2015; Mann et al., 2004; Rivera et al., 2008).  It was first suggested that severe loss-of-
imprinting in the placenta could be due to the outer position of trophectoderm, which is 
directly exposed to the artificial environment (e.g., petri-dish) (Mann et al., 2004). The 
trophectoderm gives rise to tissues in the placenta (reviewed in Rossant and Cross, 2001).  
However, the yolk sac, which is derived from primitive endoderm that resides in the inner 
space of the blastocyst, also exhibits similar severity of loss-of-imprinting, suggesting 
that the “position” hypothesis alone cannot explain the differential loss-of-imprinting 
susceptibility between embryonic and extra-embryonic tissues (Rivera et al., 2008).  It 
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also remains to be addressed why isogenic mouse embryos and/or placenta generated 
with the use of ART exhibit variable and stochastic loss-of-imprinting and why the 
occurrence of epimutation can be detected ubiquitously or in specific tissues in an 
individual (de Waal et al., 2014; de Waal et al., 2012a).  It is likely that Trim28 activity is 
impaired in embryos generated with the use of ART as the variability of loss-of-
imprinting observed in the ART-conceived offspring can also be found in mice lacking 
the maternal Trim28 (Messerschmidt et al., 2012). 
1.5.2 ART and BWS 
 Several studies have suggested that children conceived with the use of ART have 
a 3- to 9-fold higher likelihood of being affected with the congenital overgrowth 
condition BWS (DeBaun et al., 2003; Gicquel et al., 2003; Halliday et al., 2004; Lim et 
al., 2009; Maher et al., 2003).  Recently, a meta-analysis of eight epidemiologic studies 
indicated that ART-conceived children have a 5.2-fold increased likelihood of developing 
BWS (Vermeiden and Bernardus, 2013).  It is possible that the increased incidence of 
BWS in ART-conceived offspring could result from the infertility/subfertility of the 
parents.  However, the use of ART can lead to at least some of the imprinting errors as 
ART-induced loss-of-imprinting has been reported in numerous animal models that have 
no infertility issues (reviewed in Denomme and Mann, 2012).  In agreement with this, a 
human immunodeficiency virus serodiscordant couple that had no infertility problems 
sought for ART to conceive a child without the risk of HIV and had a BWS baby after the 
ovarian hyperstimulation and IVF protocols were applied (Kuentz et al., 2011).  
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1.6  Large offspring syndrome 
1.6.1 Characteristics of large offspring syndrome  
 The use of assisted reproduction in farm animals such as bovine and ovine has 
facilitated the rapid multiplication of genetically superior animals.  However, the use of 
ART procedures can also induce unwanted pregnancy outcomes.  For example, 
manipulations of oocytes or preimplantation embryos can result in unusually large 
offspring in ruminants with various congenital abnormalities and the overgrowth 
condition is referred to as large offspring syndrome (LOS) (reviewed in Young et al., 
1998).  During the late 1980s and 1990s, in vitro embryo culture techniques typically 
used a medium supplemented with serum or co-cultured with oviduct epithelia cells 
(reviewed in Young et al., 1998).  At the time, a significant portion of the offspring 
generated with the use of ART exhibited aberrant phenotypic features including large 
size, large internal organs, abnormal placenta, and excess placental fluids (reviewed in 
Young et al., 1998).  By the early 1990s, it was recognized that the addition of serum to 
the medium and the somatic cell co-culture system are major contributors to LOS 
(reviewed in Young et al., 1998).  In addition, offspring produced by somatic cell nuclear 
transfer (SCNT) can be afflicted with LOS (reviewed in Hill, 2014).   
 The major feature of LOS is the increased birthweight.  It is not uncommon for 
LOS offspring to have twice the mean bodyweight compared to controls (reviewed in 
Young et al., 1998).  The largest ovine LOS fetus reported so far was five times larger 
than the normal bodyweight (Walker et al., 1996).  It should be noted that the extent of 
overgrowth is highly variable among LOS individuals, which may depend on the 
	   35 
different ART procedures used, different animal breeds, and/or different embryo handling 
practices (reviewed in Young et al., 1998).  Further, the full siblings from the same 
culture micro-drop can express different degrees of overgrown phenotype (Sinclair et al., 
2000), suggesting that the induction of LOS by the use of ART is a stochastic process.  
The overgrowth phenotype can be detrimental for both the dam and the offspring.  For 
the dam, the over-sized nature of the fetus may cause difficult delivery; therefore 
Caesarean section is commonly used for LOS offspring delivery. For the offspring, the 
newborns tend to experience difficulties to suckle and breathe.  
Another feature of LOS is visceromegaly (internal enlargement of organs in the 
abdomen), and the affected organs usually are liver and heart (Sinclair et al., 1999; 
Sinclair et al., 2000).  Similar enlargement of liver and heart is also a common feature of 
individuals with BWS (reviewed in Choufani et al., 2010).  LOS has also been associated 
with placental dysfunctions such as polyhydraminos (Sinclair et al., 1999), which is 
commonly seen in human BWS (reviewed in Choufani et al., 2010).  In sheep LOS, the 
incidence of polyhydraminos is about 36-62% in embryos generated with the use of ART 
(Sinclair et al., 1999).  In addition, a range of congenital abnormalities can be observed in 
LOS, including cleft palates, skeletal defects, high level insulin at birth, and 
hypoglycemia (Garry et al., 1996) (Schmidt et al., 1996).  
 It is still unclear how ART procedures cause LOS.  It was suggested that ruminant 
blastocysts in culture media supplemented with serum or somatic cells appeared darker 
due to excess lipid accumulation in the cytoplasm (Ferguson and Leese, 1999; 
Thompson, 1997). The accumulation of the lipid droplet was considered to be harmful to 
embryos and disrupt osmotic regulation (Thompson, 1997).  Besides the effect of media 
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components, the time period of exposure of embryos to the serum/somatic cells appears 
critical for the induction of LOS.  An ovine experiment showed that ovine embryos are 
more sensitive to the presence of serum in culture medium before rather than after 
compaction (Rooke et al., 2007).  It is also unclear why induction of LOS by ART is 
variable even though the same in vitro protocol is used in the same laboratory (reviewed 
in Young et al., 1998).  Overall, LOS exhibits unpredictable and broad range 
characteristics even when similar protocols and medium are used to produce embryos. 
1.6.2 Molecular alterations of LOS. 
To elucidate the potential molecular alterations responsible for LOS, a large body 
of experiments has been performed to identify differentially expressed genes between in 
vitro and in vivo-derived embryos (Bertolini et al., 2002; Lazzari et al., 2002; Niemann et 
al., 2002; Rizos et al., 2002; Wrenzycki et al., 1998; Wrenzycki et al., 2001; Wrenzycki 
et al., 2002).  It has been reported that genes affected by the in vitro procedures are 
involved in numerous biological processes such as morula compaction/cavitation, 
metabolism, trophoblastic function and growth factor signaling (reviewed in Wrenzycki 
et al., 2004).  However, pooled embryos are used in these studies and the gene expression 
levels of the in-vitro group represent the average of the embryos that will develop LOS 
and those that will be normal, which may not accurately characterize the molecular 
signatures of LOS.  
Because not every fetus in the in vitro group exhibits an overgrowth phenotype, it 
is more appropriate to compare the gene expression differences between LOS and non-
LOS fetuses instead of between the in vivo and in vitro derived fetuses.  In an ovine 
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study, late gestation (day 125; ovine gestation=145 days) fetuses with bodyweight greater 
than 5.5kg were considered as LOS (bodyweight of the largest in vivo fetus is 4.5kg) and 
were compared to controls (Young et al., 2001).  It was found that LOS calves have 
lower IGF2R mRNA and protein level in the liver and muscle tissues compared to the 
controls (Young et al., 2001).  In a bovine study, it was observed that two LOS calves 
were characterized by hypomethylation at the KvDMR1 and decreased expression of 
CDKN1C (Hori et al., 2010), highlighting the similar molecular alteration of KvDMR1 in 
LOS and BWS, although parental-specific epimutations were not determined in this 
experiment.  Recently, we have determined the allelic DNA methylation and the allelic 
expression of the imprinted genes in the KCNQ1 and the H19/IGF2 loci in day ~105 Bos 
indicus taurus × Bos taurus taurus F1 control and LOS fetuses (Chen et al., 2013).  We 
observed biallelic expression of the ncRNA KCNQ1OT1, loss of methylation of 
KvDMR1 on the maternal allele, and decreased expression of CDKN1C in two out of 
seven LOS fetuses (Chen et al., 2013).   Our study demonstrated that LOS is both 
phenotypically and epigenetically similar to human BWS (Chen et al., 2013). From that 
work we proposed to use LOS as an animal model to study the molecular mechanism that 
underlie BWS (Chen et al., 2013). 
 
1.7  Rationale 
 Most individuals with BWS are associated with genetic and/or epigenetic 
alterations at the KCNQ1 locus and the H19/IGF2 locus, and a subset of BWS individuals 
with hypomethylation at the KCNQ1 locus also exhibit aberrant DNA methylation at 
	   38 
other imprinted loci (Azzi et al., 2009; Bliek et al., 2009; Eggermann et al., 2016).  While 
we have previously described the hypomethylation of the KCNQ1 locus in LOS fetuses 
(Chen et al., 2013), studies have not yet determined the extent of loss-of-imprinting in 
this overgrowth condition.  Due to the fact that LOS is both phenotypically and 
epigenetically similar to human BWS, we hypothesize that LOS exhibits loss-of-
imprinting beyond the KCNQ1 locus.  To test the hypothesis, we determined the allelic 
expression of imprinted genes previously identified in human and/or mouse in somatic 
tissues of day ~105 bovine control and LOS fetuses using high-throughput RNA 
sequencing (Chapter 2).  In this study, we identified 20 imprinted genes exhibiting 
monoallelic expression in control fetal tissues and found that approximately half were 
biallelically expressed in at least one of the tissues analyzed in LOS.  Thus, we conclude 
that LOS is a multi-locus loss-of-imprinting syndrome, which is similar to what has been 
observed in some BWS individuals (Azzi et al., 2009; Bliek et al., 2009; Eggermann et 
al., 2016). 
 Although it is well accepted that loss-of-imprinting can contribute to BWS and 
LOS, and as such both conditions have been coined “loss-of-imprinting” syndromes, it 
remains unknown whether aberrant gene expression and DNA methylation occur at non-
imprinted loci and to what extent these molecular alterations contribute to the variable 
phenotypes observed in these conditions.  To address these questions, we examined the 
transcriptome and DNA methylome of somatic tissues of day ~105 bovine control and 
LOS fetuses using high-throughput RNA sequencing and whole genome bisulfite 
sequencing (Chapter 3).  We found that global misreulgation of non-imprinted genes in 
addition to loss-of-imprinting characterizes the ART-induced overgrowth syndrome.  
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Further, most identified DEGs could not be directly associated with altered DNA 
methylation, highlighting that caution should be exercised when making conclusions 
about the etiology of such syndromes by interpreting time-point-specific DNA 
methylation data.  
 Since discovery of the first three imprinted genes Igf2, Igf2r, and H19 in 1991 
(Barlow et al., 1991; Bartolomei et al., 1991; DeChiara et al., 1991), more than 100 genes 
have been identified to be imprinted in mice and humans 
(http://www.mousebook.org/mousebook-catalogs/imprinting-resource; 
http://www.geneimprint.com/).  Compared to mice and humans, many fewer imprinted 
genes (a total of 34) have been reported in domestic farm animal species (reviewed in 
Tian, 2014).  Further, most imprinted genes in cow, pig, sheep, and rabbit have been 
characterized in studies designed to corroborate the allele-specific expression of genes 
previously described as imprinted in human and/or mouse (Bischoff et al., 2009; Chen et 
al., 2015; Chen et al., 2013; Robbins et al., 2012; Young et al., 2003; Zaitoun and Khatib, 
2008).  For the purpose of de novo identification of imprinted genes in bovine, we 
determined global monoallelic gene expression in fetal and placental tissues of day ~105 
bovine conceptuses using RNA sequencing (Chapter 4).  In this study, we expand the 
imprinted gene list in bovine and demonstrate that monoallelic gene expression can be 
the result of cis-eQTL effects (Chen et al., 2016).   
The following three chapters are the full texts of three manuscripts that have been 
published or under review.  Chapter 2 was published in 2015 in “PNAS” (PMID: 
25825726), Chapter 3 is under review, and Chapter 4 was published in 2016 in 
“Epigenetics” (PMID:27245094).  The text presented is exactly as in the published work.  
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For each chapter, the main figures and tables are included in the body of the text while 
the supplemental figures and tables are included at the end of each chapter immediately 
after the acknowledgements.  
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Chapter 2 Characterization of global loss of imprinting in fetal 
overgrowth syndrome induced by assisted reproduction 
2.1  Abstract 
 Embryos generated with the use of assisted reproductive technologies (ART) can 
develop overgrowth syndromes. In ruminants, the condition is referred to as large 
offspring syndrome (LOS) and exhibits variable phenotypic abnormalities including 
overgrowth, enlarged tongue, and abdominal wall defects. These characteristics 
recapitulate those observed in the human loss-of-imprinting (LOI) overgrowth syndrome 
Beckwith-Wiedemann (BWS).  We have recently shown LOI at the KCNQ1 locus in 
LOS, the most common epimutation in BWS.  Although the first case of ART-induced 
LOS was reported in 1995, studies have not yet determined the extent of LOI in this 
condition.   Here, we determined allele-specific expression of imprinted genes previously 
identified in human and/or mouse in day ~105 Bos taurus indicus × Bos taurus taurus F1 
hybrid control and LOS fetuses using RNAseq.  Our analysis allowed us to determine the 
monoallelic expression of 20 genes in tissues of control fetuses.  LOS fetuses displayed 
variable LOI when compared to controls.  Biallelic expression of imprinted genes in LOS 
was associated with tissue-specific hypomethylation of the normally methylated parental 
allele.  In addition, a positive correlation was observed between bodyweight and the 
number of biallelically expressed imprinted genes in LOS fetuses.  Further, not only was 
there loss of allele-specific expression of imprinted genes in LOS, but we also observed 
differential transcript amounts of these genes between control and overgrown fetuses.  In 
summary, we characterized previously unidentified imprinted genes in bovine and 
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identified misregulation of imprinting at multiple loci in LOS.  We conclude that LOS is 
a multi-locus LOI syndrome, as is BWS. 
 
2.2 Introduction 
 Genomic imprinting is a series of precisely regulated epigenetic processes that 
lead to parental allele-specific expression of a subset of genes in mammals (Bartolomei 
and Ferguson-Smith, 2011). Proper allelic expression of imprinted genes plays an 
important role in embryonic and neonatal growth, placental function, and postnatal 
behavior (Miyoshi et al., 2006). Allele-specific DNA methylation at discrete regions 
established during gametogenesis defines the functional asymmetry of parental alleles 
(Bartolomei and Ferguson-Smith, 2011). These regions, termed as differentially 
methylated regions (DMRs), are required to regulate the imprinted expression of these 
genes.  DNA methylation of DMRs is erased in primordial germ cells, re-established 
during gametogenesis, and maintained when the global DNA demethylation occurs 
during preimplantation development (Bartolomei and Ferguson-Smith, 2011). In addition 
to DNA methylation, other epigenetic modifications and mechanisms such as ncRNAs 
and histone post-translational modifications may contribute to parental-allele specific 
expression of these genes (Bartolomei and Ferguson-Smith, 2011). 
Because of the dynamic epigenetic reprogramming that occurs during oocyte 
growth and preimplantation development (Morgan et al., 2005), environmental 
perturbations during this time period, such as the use of assisted reproductive 
technologies (ART), can affect imprint establishment and maintenance (Denomme and 
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Mann, 2012).  Numerous prospective studies in animals (de Waal et al., 2012a; de Waal 
et al., 2012b; Market-Velker et al., 2010; Rivera et al., 2008) and retrospective studies in 
humans (Vermeiden and Bernardus, 2013) have shown that ART can induce improper 
regulation of genomic imprinting. ART is commonly used in clinics to treat subfertility 
and infertility, and each year as high as 5.9% of infants born in developed countries are 
conceived by the use of these technologies (CDC, 2013; Kupka et al., 2014).  In 
agriculture, ART is also widely used to increase the number of offspring produced from 
genetically superior individuals in a shortened period of time (IETS, 2013).  Multiple 
reports have indicated that ART-conceived offspring are more likely to develop 
imprinting disorders such as Beckwith-Wiedemann syndrome (BWS) in human (Halliday 
et al., 2004; Lim et al., 2009; Vermeiden and Bernardus, 2013) and large offspring 
syndrome (LOS) in ruminants (Behboodi et al., 1995; Bertolini et al., 2002; Farin and 
Farin, 1995; Farin et al., 2006).   
BWS is the most common pediatric overgrowth syndrome characterized by 
complex and variable symptoms such as prenatal and postnatal overgrowth, ear creases, 
macroglossia, umbilical hernia, and predisposition to develop childhood tumors 
(Weksberg et al., 2010). BWS has an estimated worldwide frequency of 1 in 13,700 live 
births (Weksberg et al., 2010) with no noted sex bias (Pettenati et al., 1986) and a 
weighted relative risk of 5.2 in children conceived with the use of ART (Vermeiden and 
Bernardus, 2013).  Most BWS cases are sporadic and are associated with epimutations in 
human chromosome 11p15.5, a region that harbors KCNQ1 and H19/IGF2 imprinted loci 
(Weksberg et al., 2010).  Approximately 50% of BWS cases are associated with the loss 
of methylation at the KvDMR1 (i.e. KCNQ1 locus) and 2-7% are associated with the 
	   44 
gain-of-methylation of the DMR at the H19/IGF2 locus (Weksberg et al., 2010). Recent 
studies have shown that a subset of BWS individuals with hypomethylation at the 
KCNQ1 locus also exhibited aberrant DNA methylation at other imprinted loci (Azzi et 
al., 2009; Bliek et al., 2009; Court et al., 2013; Eggermann et al., 2014; Lim et al., 2009; 
Maeda et al., 2014; Poole et al., 2013; Tee et al., 2013).  
LOS in ruminants exhibits a variable combination of anomalies that recapitulate 
the phenotypes commonly observed in BWS (Young et al., 1998).  These anomalies can 
have detrimental effects on both the dam and offspring including difficult delivery due to 
the oversized nature of the fetus and the inability of the newborn to suckle and breathe.  
We have recently reported that phenotypic and epigenetic similarities exist between LOS 
and BWS, such as macroglossia, macrosomia, and ear malformation, as well as loss of 
methylation at the KvDMR1 (i.e. KCNQ1 locus) on the maternal allele (Chen et al., 
2013).   These parallels make LOS an appropriate animal model for the study of BWS 
and the understanding of the etiology of these overgrowth syndromes (Chen et al., 2013).  
The incidence of LOS complications is variable and little is known about the 
molecular cause(s) of this complex phenotype.   Given the variable phenotypes of BWS 
and LOS and the fact that only 50% of individuals exhibit LOI at the KCNQ1 locus 
(Chen et al., 2013; Weksberg et al., 2010), we hypothesize that these overgrowth 
syndromes exhibit LOI at loci beyond those primarily used for diagnosis of BWS, namely 
KCNQ1 and H19/IGF2 DMRs. 
In this study, we assessed the allelic expression of imprinted genes previously 
identified in human and/or mouse in somatic tissues of day ~105  (d105) bovine control 
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and LOS fetuses (term ≈ 280 days). We identified 20 genes exhibiting monoallelic 
expression in control fetal tissues and found that approximately half were biallelically 
expressed in at least one tissue in LOS. Furthermore, we observed that biallelic 
expression of imprinted genes was associated with loss of DNA methylation at DMRs in 
a tissue-specific manner. Lastly, our data show that misregulation of imprinted genes 
goes beyond loss of allele-specific expression and provide insights into the variable gene 
expression observed in this condition.  
 
2.3 Results 
Control and LOS bovine fetal tissues preparation and RNA sequencing reads 
processing 
 In the current study, we used high throughput RNA sequencing (from here on 
referred to as RNAseq) to determine allelic expression of imprinted genes previously 
identified in human and/or mouse in somatic tissues of ~d105 control and LOS bovine 
female fetuses (Fig. 1A).  Fetuses used in this study were Bos taurus indicus (B. t. 
indicus) × Bos taurus taurus (B. t. taurus) F1 hybrids (Chen et al., 2013).  Only females 
were used in this study to avoid any potential sex-specific effects on gene expression 
(Ingleby et al., 2014a).   On average, control fetuses weighed 405g while LOS fetuses 
weighed 592g (P = 0.008, Fig. S1 and Table S1).  Kidney, brain, skeletal muscle (from 
here on referred to as muscle), and liver from each fetus were used for RNAseq analysis.  
These tissues were selected as they are representative of the primary germ cell lineages:  
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31.4 0 0 35 
Figure 1. Loss-of-imprinting in large offspring syndrome (LOS). (A) Flowchart of 
methodology.   (B) Allele-specific expression analysis of imprinted genes identified by 
RNAseq in day ~105 B. t. indicus × B. t. taurus fetal kidney.  The results for brain, muscle, 
and liver may be found in Figure S2-4.  Gene symbols are ordered from top to bottom in 
alphabetical order. The parental origin of imprinted gene expression (IGE) is defined 
according to the known imprinting status in human and/or mouse (maternal = white box; 
paternal = black box).  Samples are arranged from left to right in ascending order by weight 
(Figure S1) and by treatment group.  DNA polymorphisms identified by RNAseq analysis of 
each F1 hybrid were used to discriminate between the parental alleles in control samples in 
order to establish baseline expression of each gene.  A sample with at least 15% expression 
from the repressed allele was considered biallelically expressed (grey box).  Genes that 
showed biallelic expression in LOS but not in control fetuses are indicated by red boxes. 
Missing data for RTL1 indicate lack of discriminating SNPs between parental alleles in the 
reads. We obtained the allelic expression of the long noncoding RNA KCNQ1OT1 (indicated 
by asterisk) in a previous study (Chen et al., 2013).  (C) Heat map illustrating the degree of 
loss-of-imprinting for the genes indicated by red boxes in panel (B). Numbers represent the 
percentage of transcripts expressed from the normally repressed allele. 0 represents <15% 
expression from the repressed allele (actual percentages may be found in Table S3). A 
summary of the number genes with loss-of-imprinting may be found in Figure S5.  
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ectoderm (brain), mesoderm (kidney and muscle) and endoderm (liver).  Moreover, 
kidney and liver are organs that have been documented to be susceptible to tumors in 
children affected by BWS (Weksberg et al., 2010).   
We first aligned the reads to the bovine whole genome assembly B. t. taurus 
UMD3.1 (Table S2).  The reads that aligned to the known imprinted genes were then 
compared between all four tissues of each fetus and genes with at least one consistent 
variant nucleotide in at least two tissues were used for subsequent analysis.  Of the 105 
known imprinted genes detected by RNAseq in our study, 72 genes (Table S4) had at 
least one single nucleotide polymorphism (SNP) with sufficient reads depth (≥10) to 
assess allelic expression.  A gene was considered to be monoallelically expressed if the 
expression of the allele with the fewer reads accounted for less than 15% of the total 
reads.  The other 33 genes were not used for further analysis as the heterozygous nature 
of the bovine makes it impossible for us to determine with any certainty if the reads 
originated from one or both alleles. For example, if all reads have a base which differs 
from the reference genome two scenarios are possible; 1) the gene is monoallelically 
expressed or 2) the gene is biallelically expressed and both alleles contain the same base.  
 Allelic determination of imprinted genes in ~d105 control fetal tissues 
Of the 72 genes assessable for allelic expression, 52 (Table S4) were biallelically 
expressed in ~d105 fetal kidney, brain, muscle, and liver.  The remaining 20 genes were 
observed to be imprinted in at least one tissue from any fetus.  Of these, 18 were 
expressed monoallelically in the kidney and 14, 17, and 14 in brain, muscle, and liver, 
respectively (Fig. 1B and Table S3 and Figs. S2-S4). Thirteen genes (i.e. DIRAS3, DLK1, 
GNAS, GTL2, H19, MAGEL2, NAP1L5, NNAT, PEG3, PEG10, PLAGL1, RTL1, and 
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SNRPN) exhibited monoallelic expression in all the tissues analyzed where the genes 
were expressed, whereas seven genes (i.e. BEGAIN, CDKN1C, IGF2, IGF2R, INPP5F, 
PHLDA2, and SGCE) showed tissue-specific imprinting (Fig. 1B and Figs. S2-S4 and 
Table S3).  
Allelic expression of imprinted genes in LOS 
Allelic expression of the 20 genes identified to be imprinted in control tissues was 
then determined in tissues of LOS fetuses.  For a gene to be described as experiencing 
loss-of-imprinted gene expression (as defined by our 15% cutoff), that gene must be 
monoallelically expressed in the same tissue in all control fetuses.  We observed loss-of-
imprinted gene expression in 9, 8, 8, and 6 genes in kidney, brain, muscle and liver, 
respectively (Fig. 1B, 1C and Figs. S2-S4). Of these, IGF2R showed universal LOI in 
LOS kidney, muscle, and liver while INPP5F was biallelically expressed in the brain of 
all LOS fetuses.  In other tissues, however, these genes had variable allelic expression in 
control and/or LOS fetuses (Table S3).  Fetuses LOS #3 and #4 displayed LOI of NNAT 
in all the tissues analyzed while LOS #4 had loss-of-imprinted expression of PLAGL1 in  
brain, kidney and muscle.  Notably, there is a positive correlation between the number of 
imprinted genes showing LOI in each LOS fetus and their bodyweights (Fig. S5). 
Confirmation of SNPs identified by RNAseq  
 We first performed Sanger sequencing of genomic DNA from eight B. t. taurus 
animals, the B. t. indicus sire and several of the B. t. indicus × B. t. taurus F1 hybrids to 
verify 37 of the SNPs identified by RNAseq.  For 35 SNPs, both the chromosome 
position and allele variants matched between RNAseq and Sanger sequencing (Table S6). 
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The other two SNPs were not confirmed by Sanger sequencing possibly due to RNAseq 
alignment errors. The confirmed SNPs indicated that SGCE, PEG10, NAP1L5, SNRPN, 
PEG3, and MAGEL2 were paternally expressed in the ~d105 bovine fetal tissues 
analyzed, showing conservation of maternal-allele silencing of these genes in bovine, 
human and mouse. We were not able to determine parental allele-specific expression of 
NNAT, since the five SNPs within the exons are heterozygous in both B. t. indicus and B. 
t. taurus (Fig. 2B and Table S6).  
Confirmation of loss-of-imprinted expression identified by RNAseq  
To exclude potential false positive imprinted expression caused by RNAseq 
systemic errors (DeVeale et al., 2012), we verified allele-specific expression of PEG3, 
NNAT, SNRPN, and PLAGL1 by conventional methods (Fig. 2). Paternal expression was 
validated for PEG3, SNRPN, and PLAGL1 in control fetuses.  In addition, imprinted 
expression was also confirmed for NNAT although parental origin of the transcript was 
not assessable due to the lack of subspecies specific polymorphisms (Fig. 2B).  In 
contrast to controls, PEG3, SNRPN, NNAT, and PLAGL1 were biallelically expressed in 
LOS fetuses (Fig. 2 and Fig. S6). 
Association between allelic expression and transcript abundance of imprinted 
genes  
 To assess if the biallelic expression of imprinted genes was associated with the 
increased amount of transcripts, we normalized the read counts aligned to each gene 
locus to determine the transcript abundance. We found that loss of imprinted gene  
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Figure 2. Verification of the allelic expression of PEG3, NNAT, SNRPN, and PLAGL1 
in control and LOS fetuses. The top left parts of (A), (B), (C), and (D) are genotyping 
results obtained by Sanger sequencing of B. t. indicus, B. t. taurus and/or F1 hybrid fetuses 
for the SNPs identified by RNAseq analysis. SNP positions are indicated by arrows. 
Pedigree diagrams indicate the SNPs identified by Sanger sequencing for B. t. indicus 
(square; i.e. paternal allele in F1), B. t. taurus (top circle; maternal allele in the F1), and 
female F1 ~d105 fetus (bottom circle).  The bottom parts of (A) and (C) are Sanger 
sequencing results of RT-PCR amplicons of PEG3 and SNRPN, respectively. Double 
peaks demonstrate biallelic expression. The bottom parts of (B), and (D) show allele-
specific restriction of RT-PCR amplicons followed by acrylamide gel electrophoresis for 
NNAT and PLAGL1, respectively. Restriction enzyme (i.e. SfcI for NNAT, and BstUI for 
PLAGL1), restriction site and fragment length are illustrated on the bottom left of each 
panel. 
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expression in LOS tissues did not always correlate with the amount of transcript (Fig. 
S7).  For example, increased number of transcripts of SNRPN, NNAT and PLAGL1 were 
associated with biallelic expression in kidney and muscle (P < 0.01), but not in brain.  
Further, IGF2R had lower total level of expression in both liver and muscle of all LOS 
fetuses, although IGF2R was biallelically expressed in both tissues. 
 DNA methylation analysis of PLAGL1, SNRPN, and NNAT DMRs 
 As described above, SNRPN, NNAT and PLAGL1 exhibited LOI in several of the 
LOS fetuses. These genes have also been demonstrated to be associated with BWS (Azzi 
et al., 2009; Bliek et al., 2009; Court et al., 2013; Tee et al., 2013). Thus we assessed 
allele-specific DNA methylation of the three DMRs. 
 DNA methylation of PLAGL1 was examined in a region within the DMR 
(O'Doherty et al., 2012) that contained 28 CpGs on the paternal (B. t. indicus) and 29 
CpGs on the maternal (B. t. taurus) allele (Fig. 3A and Table S7). PLAGL1 is maternally 
repressed and acquires maternal methylation during oocyte growth in bovine (O'Doherty 
et al., 2012). As expected, we observed methylated maternal alleles and unmethylated 
paternal alleles in kidney, brain, muscle, and liver of the control fetus analyzed (Fig. 3A 
and Fig. S8A).  Methylation of CpGs within this region was substantially reduced on the 
maternal allele in the kidney of LOS #4 (Fig. 3A) coincident with the biallelic expression 
of this gene in this tissue (Fig. 1B).  However, biallelic expression of PLAGL1 did not 
coincide with a reduction in DNA methylation in brain and muscle (Fig. S8A).  
  We next examined the methylation at the DMR (O'Doherty et al., 2012) of the 
maternally imprinted gene SNRPN (Fig. 3B).   The SNRPN DMR displayed differential 
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methylation in the brain of the control fetus analyzed (Fig. 3B and Table S7) but showed 
a substantial loss of methylation in the brain of LOS #4 fetus.  Loss of methylation of this 
DMR in this tissue (Fig. 3B) is associated with the gain of maternal expression of this 
gene (Fig. S2).  
 Lastly, we analyzed DNA methylation at NNAT in control and LOS fetuses. Since 
the NNAT DMR has not been previously reported in bovine, we chose to analyze a CpG 
island at the NNAT promoter region (Fig. 3C) that was syntenic to the human NNAT 
DMR (Hubertus et al., 2013). We examined a region within the CpG island that 
contained 33 CpGs on the paternal and 34 CpGs on the maternal allele (Fig. 3C and 
Table S7). Control fetus #2 displayed an unmethylated paternal allele and methylated 
maternal allele in both kidney and brain (Fig. 3C and Fig. S8B), which strongly suggests 
that NNAT is maternally imprinted in bovine as in human and mouse (Evans et al., 2001; 
Kagitani et al., 1997). LOS fetus #4 showed reduced DNA methylation on the maternal 
allele in kidney but not in brain (Fig. 3C and Fig. S8B).  
Determination of the transcript level of imprinted genes previously identified in 
human and/or mouse in bovine ~d105 fetuses.  
 Given the diverse phenotype and various loss-of-imprinted gene expression in 
LOS, we compared imprinted gene transcript abundance of each LOS fetus to the average 
of four controls to identify differentially expressed imprinted genes for each LOS 
individual using edgeR (McCarthy et al., 2012; Robinson et al., 2010). With the threshold 
of false discovery rate set at < 0.05 we identified 53, 21, 47, and 35 imprinted genes as 
being differentially expressed in kidney, brain, muscle, and liver, respectively, in at least  
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Figure 3. Allele-specific DNA methylation of the PLAGL1, SNRPN, and NNAT DMRs in 
control and LOS fetuses.  The top parts of (A), (B), and (C) are schematic representation of 
regions analyzed by allele-specific bisulfite sequencing. The bent arrows and black boxes 
represent the transcription start site and first exon of each gene, respectively. Vertical lines 
illustrate the CpGs distributed across the region (drawn to scale). The positions of bisulfite-
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examined within the region of interest (the unmethylated B. t. taurus maternal allele is shown as 
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PLAGL1, SNRPN, and NNAT DMRs, respectively. Open circles represent unmethylated CpG sites 
and filled circle represent methylated CpG sites. Missing circles are due to SNPs or undetermined 
bases because of sequencing issues. Each row represents one strand of DNA. 
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one LOS fetus (Fig. S9). The fetuses differed in the type of tissue which displayed the 
highest number of misregulated genes with the kidney of LOS #3 exhibiting 
inappropriate levels of expression in 50 of the 53 genes and the muscle of LOS #4 
showing altered expression in 40 of the 47 genes  (Fig. S9).  
 
2.4  Discussion 
Beckwith-Wiedemann syndrome and large offspring syndrome are similar fetal 
overgrowth conditions (Chen et al., 2013; Kalish et al., 2014).   Phenotypically, these are 
heterogeneous syndromes characterized by variable developmental anomalies including 
macrosomia, macroglossia, abdominal wall defect, and ear malformations.  These 
syndromes also share LOI at the KCNQ1 locus (Chen et al., 2013), the most common 
epimutation in BWS, observed in 50% of patients (Weksberg et al., 2010).  Even though 
reports describing BWS date back to the early 1960’s (Weksberg et al., 2005) and the 
first cases of ART-induced LOS were reported in 1995  (Behboodi et al., 1995; Farin and 
Farin, 1995), no molecular signature has been identified that can consistently and reliably 
predict and diagnose these syndromes and/or their varied phenotypes.  To date, only a 
small set of imprinted genes have been queried in LOS (Chen et al., 2013; Hori et al., 
2010; Young et al., 2001).  With the current study, we advance the field by describing the 
imprinted signature of ~d105 unaffected bovine fetuses and identifying misregulated 
imprinted loci in LOS. 
Approximately 200 imprinted genes have been identified in human and mouse 
[http://igc.otago.ac.nz/Search.html and http://www.mousebook.org/imprinting-gene-list, 
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respectively], and little is known about the allele and tissue specificity of these genes in 
bovine.  In our study we detected expression of 105 of these genes with 52 being 
biallelically expressed and 20 having monoallelic expression in the fetal tissues analyzed.  
The remaining 33 genes were not assessable in our system.  RNAseq analysis confirmed 
the maternal expression of CDKN1C, H19, PHLDA2 and the paternal expression of IGF2 
and PLAGL1 (Chen et al., 2013; Robbins et al., 2012).  In addition, we demonstrate 
paternal expression of NNAT, NAP1L5, MAGEL2, PEG3¸PEG10, SGCE, and SNRPN, 
which is similar to what has been reported for human and mouse (Morison et al., 2005).  
Further, we also show that BEGAIN, DIRAS3, DLK1, GNAS, GTL2¸ IGF2R, INPP5F, 
and RTL1 are monoallelically expressed, although our analysis precludes us from 
ascribing the allelic origin of the transcripts.   Since monoallelic expression of imprinted 
genes is tissue- and stage-specific (Bartolomei and Ferguson-Smith, 2011), it is possible 
that the biallelically expressed genes in the present study are imprinted in other tissues 
and/or developmental stages.  An example is TSSC4 which has been previously reported 
to be imprinted in bovine placenta (Zaitoun and Khatib, 2008), however, this gene 
exhibited biallelic expression in fetal ~d105 kidney, brain, muscle, and liver. 
We demonstrate that half of the imprinted genes in controls displayed biallelic 
expression in LOS, making this a multi-locus LOI syndrome, as is BWS (Azzi et al., 
2009; Bliek et al., 2009; Court et al., 2013; Eggermann et al., 2014; Lim et al., 2009; 
Maeda et al., 2014; Poole et al., 2013; Tee et al., 2013).   The profile of LOI was 
dependent on the tissue, fetus and degree of macrosomia and may provide insights into 
the understanding of the etiology of the anomalies observed in LOS and BWS.  For 
instance, Wilm’s tumor of the kidney, a high-risk childhood cancer in BWS, displayed 
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hypomethylation at the NNAT promoter, which coincided with upregulation of NNAT 
transcript (Hubertus et al., 2013).  In our study we observed a similar situation where 
biallelic expression and increased transcript amount of NNAT was associated with 
hypomethylation of its DMR in LOS kidney. Further, we detected biallelic expression of 
the paternal gene PLAGL1, which corresponded with the increased transcript amount of 
this gene in the muscle and kidney of the largest LOS fetus.  PLAGL1 is a known 
regulator of embryonic growth and mice lacking the paternal allele of this gene exhibit 
growth retardation (Varrault et al., 2006).  Interestingly, PLAGL1 has been documented 
to bind the DMR of the KCNQ1 locus in a methylation dependent manner suggesting the 
involvement of this molecule in the misregulation of this locus, as has been suggested by 
others (Arima et al., 2005).  
In the current study, we also determined the transcript amount of imprinted genes 
to determine if their misregulation in LOS transcends parental-allele specific expression.  
Similar to what others have reported in the mouse, biallelic expression of imprinted genes  
does not always correlate with increased transcript level in bovine (de Waal et al., 2012a; 
Susiarjo et al., 2013).   For example, even though IGF2R was biallelically expressed in 
liver and muscle of LOS fetuses, the total transcript amount was lower than in the 
controls where monoallelic expression of this gene was observed.  Lower IGF2R levels 
have been previously observed in LOS (Young et al., 2001).   
 Further, differentially expressed imprinted genes in each LOS fetus were analyzed 
in the GeneCard database [http://www.genecards.org, (Table 1)] in order to assess the 
attributes of these genes (e.g. gene ontology, disorders, phenotypes, expression patterns).  
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The analysis showed that these genes were most significantly enriched with the 
descriptors “Beckwith-Wiedemann syndrome”, “growth size and body phenotype”, 
“cellular phenotypes”, and “tumors” indicating similarities in the types of imprinted 
genes misregulated in LOS and BWS.  In addition, differentially expressed genes were 
implicated in tumor and/or body size control, which suggests that misregulation of these 
genes may contribute to the overgrowth phenotype of LOS.  The analysis not only 
allowed us to confirm the imprinted genes previously known to be associated with LOS 
such as IGF2R (Young et al., 2001) and CDKN1C (Chen et al., 2013), but also to identify 
new candidates that can be used to predict or diagnose LOS at the molecular level.  A 
gene of interest, for example, is FBXO40, which was downregulated by at least 2 fold in 
the muscle of all LOS fetuses.  Recently, Shi and coworkers demonstrated that FBXO40 
is a negative regulator of IGF1 signaling in muscle differentiation and observed increased 
bodyweight and muscle mass in FBXO40 null mice at six weeks of age (Shi et al., 2011).   
Other genes with a potential link to the overgrowth seen in LOS are MKRN3 and NNAT 
which were upregulated in the muscle of the two largest LOS fetuses by >3.5 and 2.37 
folds, respectively, when compared to controls.  MKRN3 and NNAT are protein-coding 
genes with currently undefined function in muscle.  
In summary, our study characterizes previously unknown expression of imprinted 
genes in unaffected and LOS bovine fetuses.  We conclude that LOS is a multi-locus LOI 
syndrome, as is BWS.  Future studies will assess if genes identified in this study are 
similarly misregulated in BWS. 
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2.5 Materials and Methods 
Fetal Tissue Collection and Illumina RNAseq 
Day ~105 B. t. indicus X B. t. taurus F1 hybrid control and LOS fetuses were 
used to analyze allele-specific expression and DNA methylation of imprinted genes.  
Fetuses used in this study were produced by us as part of a previous study (Chen et al., 
2013).  Serum was purposely used in that study to supplement the culture media in order 
to increase the incidence of the overgrowth phenotype.  This method enables us to have a 
reliable system to study the etiology and progression of LOS.  In our previous study, we 
generated 9 controls fetuses (5 females and 4 males) and 7 LOS fetuses (4 females and 3 
males).  In the current study, all four females in the LOS group were used. For the control 
group, we randomly chose four of the five females to analyze the same number of 
samples in each treatment group.  
Total RNA was isolated from kidney, brain, muscle, and liver of four control and 
four LOS females using Trizol Reagent (Invitrogen) according to manufacturer’s 
instructions. RNA quality was assessed using spectrometry and agarose gel 
electrophoresis. RNAseq libraries were prepared using standard Illumina protocol and 
sequenced on Illumina HiSeq 2000 platform as single-end reads. The raw FASTQ files 
are publically available at Gene Expression Omnibus (GEO; accession no. GSE63509). 
Bioinformatics Analysis  
After quality trimming, RNAseq reads were aligned to the bovine genome 
reference (UMD3.1) using TopHat2 (Kim et al., 2013). Only reads that had >95% 
identity with the reference genome were used for the analyses. Uniquely aligned RNAseq 
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reads were normalized to the library size to compute counts per million (CPM). Known 
imprinted genes were selected based on the human and mouse imprinted gene databases 
(http://igc.otago.ac.nz/Search.html; http://www.geneimprint.comsite/genes-by-species; 
http://www.mousebook.org/mousebook-catalogs/imprinting-resource). Imprinted genes 
annotated by RefSeq or Ensembl were analyzed.  
SNPs between B. t. indicus and B. t. taurus were identified by the following 
criteria: 1) at least 10 reads coverage at a given chromosome position; 2) presence of only 
one variant allele (different from the reference allele); 3) at least 3 reads for the lower 
expressed allele. In order to further reduce the false positive SNPs, only the SNPs that 
exist in at least two of the four tissues (e.g. liver and muscle) from a single individual 
were kept for further analysis.  Only genes that had one or more SNPs and at least 10 
SNP-containing read counts were analyzed. Only genes with at least 15% of reads from 
the repressed allele were considered biallelically expressed. 
SNP validation by Sanger sequencing 
DNA was isolated from B. t. taurus, B. t. indicus, and B. t. indicus × B. t. taurus 
F1 hybrid tissues by phenol-chloroform extraction. PCR amplifications were performed 
using GoTaq Hot Start polymerase (Promega) and amplicons were sequenced at the 
University of Missouri DNA core using the 96-capillary applied Biosystems 3730 DNA 
analyzer with Big Dye Terminator.  
Analysis of allelic expression 
Allele-specific expression of PEG3 and SNRPN were validated using RT-PCR 
followed by Sanger sequencing. The PCR reactions were prepared and sequenced as 
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described above. Allelic expression of NNAT and PLAGL1 were determined using RT-
PCR followed by RFLP and PAGE. 
DNA methylation analysis 
 Genomic DNA was mutagenized with sodium bisulfite using the Imprint DNA 
Modification Kit (Sigma) according to the manufacturer’s instructions. Amplified PCR 
products were ligated with pCC1 vector and cloned using CopyControl PCR cloning kit 
according to manufacturer’s instructions except all the cloning incubation procedures 
were performed at room temperature. Colonies were usually visible within two days. 
Positive colonies were sequenced as described above.  
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2.7 Supplemental information for Chapter 2  
Supplemental material and methods 
 Fetal tissue collection 
 Day ~105 control and ART-induced LOS fetuses were generated in a previous 
study by our laboratory (Chen et al., 2013).  Briefly, for the ART group, cumulus-oocyte 
complexes (COCs) from B. t. taurus (Holstein breed) were matured in vitro and fertilized 
in vitro using the semen from one B. t. indicus bull (Nelore breed; ABS CSS MR N OB 
425/1677344 29NE0001 97155).  Five days post fertilization, embryo culture medium 
was supplemented with 10% estrus cow serum.  On day 7 post-fertilization, blastocysts 
were transferred into synchronized B. t. taurus recipients (two blastocysts per recipient; 
one blastocyst per uterine horn).  For control group, B. t. taurus females were artificially 
inseminated with the semen from the same B. t. indicus bull used in the ART group.  On 
day ~105, B. t. indicus × B. t. taurus F1 hybrid conceptuses (fetus + placental tissues) 
from both control and ART groups were collected from gravid uteri at caesarean section. 
For the control group, all fetuses were singleton pregnancies. For the ART group, 11 
fetuses were singleton pregnancies and 16 were twins (Chen et al., 2013). Two of the 
LOS females used here were twins (one fetus/uterine horn; LOS #1 and LOS #3) and two 
were singletons (LOS #2 and LOS #4).  Statistical analysis showed that bodyweight was 
not different between twins and singletons (P= 0.9 between ART-produced singletons 
and twins).  At collection, liver, skeletal muscle (from here referred to as muscle), brain, 
and kidney were well diced, mixed, and snap frozen in liquid nitrogen and stored at -
80°C. All animal surgery procedures were performed at TransOva Genetics (IA) by 
veterinarians and in accordance with TransOva’s animal care and use committee.  
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 Illumina RNA sequencing (RNAseq) 
 Liver, muscle, brain, and kidney RNA samples from four control females and four 
LOS females were subjected to RNAseq at the University of Missouri-Columbia’s DNA 
core. Total RNA from fetal tissues was isolated using Trizol Reagent (Invitrogen) 
according to the manufacturer’s instructions. RNA quality was determined by both 
spectrometry and agarose gel electrophoresis. For each sample, 5µg RNA was submitted 
to the DNA core for RNAseq library preparation using Illumina TruSeq RNA sample 
preparation kit. Briefly, poly-A containing RNA was purified using magnetic beads with 
oligo-dT attached. The purified RNA was fragmented and used as a template for cDNA 
synthesis using random primers. In the following end-repair procedure, an “A” was added 
to the 3’ end of the cDNA. The cDNA fragments with A-tailing were then ligated with T-
tailing adaptors. PCR amplifications of cDNA fragments were followed to generate the 
final RNAseq libraries.    
 Initially, liver, muscle, and brain RNAseq libraries from one control fetus (i.e. 
Control #2) were sequenced in one lane on Illumina HiSeq 2000 platform to test the 
sequencing quality and sequencing depth with our RNA samples. We obtained 223.7 
million single-end reads (read length 50 bp) for the three samples. Subsequent RNAseq 
libraries were sequenced using Illumina HiSeq 2000 platform with single-end read length 
as 100 bp.  
 RNAseq reads quality trimming 
 Raw RNAseq reads were subjected to quality trimming before being aligned to 
the reference genome. Briefly, adaptor sequences of the reads were removed with the use 
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of FastqMcf program (version 1.04.636; ref Aronesty, 2011). Low quality reads (i.e. 
reads with high percentage of ambiguous base calls) were filtered out using 
DynamicTrim (version 1.13; ref Cox et al., 2010). DynamicTrim generates the longest 
contiguous segment of a read in which the phred sequencing score of each base is greater 
than 20 (base call accuracy > 99%).  Only reads with a length above 30 bp were kept for 
further analysis.  Lastly, read quality was confirmed by FastQC (version 0.10.1; 
http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The number of reads before 
and after trimming for each sample is summarized in Table S2. 
 RNAseq reads alignment 
 RNAseq reads were aligned to the bovine reference genome assembly UMD3.1 
using TopHat2 (version 2.0.10; Kim et al., 2013). By default, TopHat first aligns the 
reads to the reference genome allowing for a maximum of two mismatches. Reads that 
span exon-exon junctions would not be aligned and set aside at this step. TopHat then 
breaks up the exon-exon junction reads into smaller segments and aligns them to the 
reference genome independently. The aligned smaller segments are then assembled 
together to generate a final read alignment. The de novo identification of splicing junction 
sites by TopHat is based on the aligning of exon-exon junction reads. Any two segments 
pairs that are closer or farther than these parameters are not considered as exon-exon 
junction reads.  
In our analysis, we adjusted the number of allowed mismatches based on read 
length (i.e. shorter reads were allowed fewer mismatches than longer reads) by passing 
Bowtie2 scoring option (--score-min L,0,-0.2  --mp 6,6; http://bowtie-
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bio.sourceforge.net/bowtie2/manual.shtml - Scoring-options) through Tophat2 (Kim et 
al., 2013; Langmead and Salzberg, 2012).  This allows us to achieve unique alignment of 
any read length at greater than 96.7% identity.   In this method, the score for a perfect 
alignment (i.e. 100% identity) is 0 while a single nucleotide mismatch within the aligned 
fragment will be penalized by -6 units.  Therefore, the closer the number is to 0 the 
greater the similarity between the read and the reference genome.  For an alignment to be 
considered valid, then the minimum score cannot be less than (-0.2) x (read length). 
For example; for a 100bp read, the minimum required mapping score is (-0.2) x 
(100) = -20. Since each mismatch receives a penalty of -6, then -20/-6 = 3.33 mismatches 
allowed.   At this level, the alignment identity is >97%.  So using the formula above, the 
score for a 30 bp read = -6 thus only 1 mismatch is allowed for such a read length.   
Furthermore, gene and exon models from the Ensembl (http://www.ensembl.org) 
and the RefSeq (http://www.ncbi.nlm.nih.gov/refseq/) databases were provided to 
TopHat in order to increase mapping depth at any base. When known gene and exon 
models are provided, TopHat extracts the transcripts sequences and align the reads to the 
transcriptome first. This step improves the alignment accuracy of exon-exon junction 
reads by taking advantage of known splice junctions. The reads that were not aligned to 
the transcriptome are then aligned to the genome as described above.   
Only reads that were uniquely aligned to the reference genome were kept for the 
subsequent analysis. Percentage of uniquely aligned reads for each sample is summarized 
in Table S2. 
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 Transcript assembly from aligned RNAseq reads 
 Cufflinks (version 2.1.1;  Trapnell et al., 2010) was used to assemble transcripts 
from the aligned reads for each sample. Assembled transcripts of each sample (i.e. total 
32 samples) were merged into a single set of genes and transcripts using Cuffmerge 
(version 2.1.1;  Trapnell et al., 2010) for gene expression analysis. Known gene and exon 
models from the Ensembl and the RefSeq databases were provided to Cuffmerge to 
maximize the assembly accuracy. Cuffmerge also performs Cuffcompare (version 2.1.1;  
Trapnell et al., 2010) to compare the merged transcripts to known gene models. 
Cuffcompare classifies each transcript into different categories depending on how they 
match the gene annotation (e.g. class code “=” stands for complete match of a transcript 
to a known gene intron chain; “u” stands for unknown, intergenic transcript, etc.). 
Merged transcripts that completely match a known gene intron chain (i.e. class code “=”) 
were assigned with either the Ensembl gene ID or the RefSeq ID if it is not annotated in 
Ensembl database. Both overall gene expression and allele-specific gene expression were 
analyzed based on the gene models generated from Cuffmerge.  
 RNAseq based gene expression analysis 
 Gene expression was determined by the total read counts from a gene locus. Total 
read counts for each gene was generated using the Htseq (version 0.5.4) with default 
union-counting mode (Anders et al., 2013). In union-counting mode, reads that are 
located at the overlapping regions of different genes are discarded (Anders et al., 2013). 
The rationale for this action is that true differential expression of one gene may 
inaccurately appear as differential expression another gene with overlapped regions.  
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Bioconductor package edgeR is a read-counts based RNAseq differential 
expression analysis tool and determines expression at a gene level based on the total read 
counts from a gene locus (McCarthy et al., 2012; Robinson et al., 2010). EdgeR 
normalizes the raw read counts of genes with several parameters (e.g. sequencing depth) 
excluding gene length (McCarthy et al., 2012; Robinson et al., 2010). Thus edgeR 
presents gene expression unit as counts per million (CPM) instead of reads per kilobase 
per million (RPKM) (McCarthy et al., 2012; Robinson et al., 2010). Genes that have less 
than 10 CPM for the sum of all 8 samples (i.e. control group: n=4 and LOS group: n = 4) 
were considered as low expression and not included in the subsequent analysis.  
 About 100 known imprinted genes in humans and 150 in mouse (~50 overlapped 
with humans’) were obtained from human (http://igc.otago.ac.nz/Search.html; 
http://www.geneimprint.comsite/genes-by-species) and mouse imprinted gene database 
(http://www.har.mrc.ac.uk/research/genomic_imprinting/). Approximately 130 known 
imprinted genes are annotated in bovine Ensembl and/or RefSeq databases and included 
in Cuffmerge gene models. In the annotated known imprinted gene list, 105 genes were 
expressed in at least one of the tissues analyzed (i.e. liver, muscle, brain, and kidney) 
based on the criteria described above.   
 Gene expression for each tissue from each LOS fetus was compared to the 
average gene expression of control fetuses. Differential gene expression between each 
LOS fetus and the average of the controls was identified using edgeR (McCarthy et al., 
2012; Robinson et al., 2010). Differentially expressed imprinted genes were uploaded to 
GeneCards database (http://www.genecards.org/) to identify their shared descriptors. 
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 RNAseq based allele-specific expression analysis of known imprinted genes 
Single nucleotide polymorphisms (SNPs) between B. t. indicus and B. t. taurus 
are needed to determine parental-allele specific gene expression. In order to ascertain the 
allele-specific expression in F1 fetuses, we identified SNPs from the B. t. indicus × B. t. 
taurus F1 hybrid fetal RNAseq data.  
 Reads that were uniquely aligned to the UMD3.1 reference genome (B. t. taurus) 
were used to identify SNPs. The following criteria were initially applied to identify 
heterozygous SNPs for each sample: 1) coverage by at least 10 reads at a given 
chromosome position; 2) presence of only one variant allele (different from the reference 
allele); 3) at least 3 reads for the lower expressed allele. In order to further reduce the 
false positive SNPs, only the SNPs that exist in at least two of the four tissues (e.g. liver 
and muscle) from a single individual were kept for further analysis.  In addition, SNPs 
that could not be assigned to a single gene (i.e. a SNP that is located in a region with two 
different genes with sense and antisense transcription) were not used for allele-specific 
expression analysis. 
 With the identified SNPs and SNP-containing read counts, we determined the 
allele-specific expression of the known imprinted genes by the relative counts of 
reference and alternative alleles. Only genes that had one or more SNPs and at least 10 
SNP-containing read counts were analyzed.  
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 Determination of Loss-of-imprinting  
Eleven imprinted genes (i.e. PEG3, SNRPN CDKN1C, H19, IGF2, SGCE, 
PEG10, NAP1L5, PLAGL1, PHLDA2, MAGEL2) were selected to compute the standard 
deviation of the expression from the repressed allele.  These were chosen because Sanger 
sequencing was performed on this subset of genes as part of validations performed in this 
and our previous study (Chen et al., 2013) to confirm allelic parental origin.   
We assumed that an imprinted gene is monoallelically expressed and hence has no 
expression from the repressed allele.  Therefore, the low level of expression detected 
from the repressed allele of these genes was categorized as noise, which is expected to 
follow a normal distribution.  We calculated 2 × SD using all of the aforementioned 
genes.  That number was ~12%.  We decided to use the more stringent cutoff of 15% 
expression from the repressed allele to ascribe an imprinted gene as being biallelically 
expressed.   Further, we used Pearson correlation to determine associations between 
allelic expression and transcript amount.  
 SNPs validation by Sanger sequencing 
DNA was isolated using the phenol-chloroform method. For eight B. t. taurus 
animals (four Holstein breed and four Angus breed), DNA was isolated from the uterine 
tissues. DNA of the B. t. indicus bull and B. t. indicus × B. t. taurus F1 hybrid fetuses was 
isolated from semen and tails, respectively. PCR primers were designed to amplify 14 
genomic regions that contain 37 SNPs identified by RNAseq using IDT primer design 
program (http://www.idtdna.com/Primerquest/Home/Index).  PCR in a 20µl reaction 
containing 1× colorless GoTaq Flexi Buffer (Promega), 0.3µM forward and reverse 
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primer (IDT), 2.5mM MgCl2 (Promega), 200µM dNTP (Invitrogen), and 0.5U GoTaq 
Hot Start polymerase (Promega) were under the following cycling program: initial 
denaturation at 94.0°C for 2 minutes 15 seconds, 35 cycles of 94.0°C for 15 seconds, 
58.4-62.3°C for 30 seconds, and 72.0°C for 1 minute, and final extension at 72.0°C for 5 
minutes (For detailed PCR and primer condition information see Table S8).  PCR 
products were resolved by 1% agarose gel electrophoresis and products at expected size 
were excised and cleaned using Wizard DNA Clean Up system (Promega). Cleaned PCR 
products were sequenced at the University of Missouri DNA core using the 96-capillary 
applied Biosystems 3730 DNA analyzer with Big Dye Terminator. Sequencing data was 
aligned to references using MacVector software.  
 Validation of allele-specific expression of imprinted genes by Sanger sequencing 
and restriction fragment length polymorphism (RFLP) 
RNA was treated with RNase-free DNase (Fisher Scientific) before cDNA 
synthesis. First strand cDNA synthesis was performed with 80ng RNA in a 20µl reaction; 
10mM DTT (Invitrogen), 1× First Strand Buffer (Invitrogen), 0.5µg random primer 
(Promega), 1mM dNTP (Invitrogen), 100U Superscript II reverse transcriptase 
(Invitrogen), and 20U RNase Inhibitor (Fisher Scientific). The cDNA synthesis reaction 
was first incubated at 42°C for 1 hour, followed by 95°C for 10 minutes, and stored at -
20°C until further use. In order to ensure no genomic DNA contamination, a cDNA 
synthesis reaction without reverse transcriptase (RT) for each sample was also included. 
Allele-specific expression of PEG3 and SNRPN were validated using RT-PCR 
followed by Sanger sequencing (Chen et al., 2013). The PCR reactions were prepared and 
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sequenced as described above. Allelic expression of NNAT and PLAGL1 were determined 
using RT-PCR followed by RFLP and polyacrylamide gel electrophoresis (PAGE). 
Briefly, SNPs in NNAT and PLAGL1 exons were used to discriminate parental alleles by 
applying allele-specific restriction enzyme digestion (i.e. SfcI for NNAT, and BstUI for 
PLAGL1). Detailed PCR and primer information is included in Table S8. 
 DNA methylation analysis of PLAGL1, SNRPN, and NNAT DMRs 
Bisulfite mutagenesis of DNA was conducted using the Imprint DNA 
Modification Kit (Sigma) according to the manufacturer’s instructions. During this 
process, unmethylated cytosines are converted into uracil, and replaced by thymine 
during PCR amplifications, whereas methylated cytosines remain cytosines. PLAGL1 
DMR (ref|AC_000166.1: 82473331-82474137) and SNRPN DMR (ref|AC_000178.1: 
25826-26186) have been reported as gametic DMRs in bovine (O'Doherty et al., 2012). 
PCR Primers for these regions were designed using the Methyl Primer Express Software 
(version 1.0, Applied Biosystems). Since NNAT DMR had not been previously reported 
in bovine, a CpG island (ref|AC_000170.1: 67118285-67119013) at NNAT promoter 
region identified by MethPrimer (Li and Dahiya, 2002) was used to design primers. All 
the amplicons cover SNPs between B. t. indicus and B. t. taurus identified by Sanger 
sequencing. Primer information is included in Table S8. 
Bisulfite PCR conditions were similar to those described above except that 4mM 
MgCl2 was used. For PLAGL1 DMR, the PCR cycling program was as follows: initial 
denaturation at 94.0°C for 2 minutes 15 seconds, 45 cycles of 94.0°C for 30 seconds, 
60.5°C for 45 seconds, and 72.0°C for 1 minute, and final extension at 72.0°C for 5 
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minutes. For NNAT and SNRPN DMRs, touchdown PCR cycling program was used to 
optimize the amplification of product. Briefly, after initial denaturation, the annealing 
temperature was gradually decreased by 1°C/cycle for five cycles to the optimized 
temperature (i.e. 60.5°C). The optimized temperature was used as the annealing 
temperature for the subsequent 40 cycles. 
PCR products were resolved by 1% agarose gel electrophoresis and isolated as 
described above. PLAGL1 DMR amplicon (298bp contains 29 CpGs; ref|AC_000166.1: 
82473614-82473911), SNRPN DMR amplicon (566bp contains 37 CpGs; 
ref|AC_000178.1: 25757-26322), and NNAT DMR amplicon (342bp contains 34 CpGs; 
ref|AC_000170.1: 67118612-67118953) were ligated with pCC1 vector and cloned using 
CopyControl PCR cloning kit according to manufacturer’s instructions except all the 
cloning incubation procedures were performed at room temperature. Colonies were 
usually visible within two days. Individual colonies were picked up and diluted with 10µl 
H2O, from which 2µl mix was used as template for colony PCR. PCR products were then 
precipitated with isopropanol. Briefly, 20µl PCR product was added with 4µl 3M sodium 
acetate and 20ul 100% isopropanol and placed at -80°C for at least 15 minutes. After 
centrifuging at 16,000g for 20 minutes, supernatant was removed and pellet (generally 
invisible) was washed with 70% ethanol. After repeating the centrifuge step, pellet was 
suspended in H2O and sent for Sanger sequencing as described above. 
	   73 
 
 
Control #1: 392g 
LOS #1: 514g 
Control #4: 416g Control #2: 404g Control #3: 408g 
 LOS #3: 620g LOS #2: 518g LOS #4: 714g 
Figure S1. Day ~105 fetuses used in this study.  Each fetus is a B. t. indicus and B. t. taurus 
hybrid females. Fetus number and bodyweight are shown. Each square on the background = 
2.54 cm2. Information on the fetus beyond that obtained in this study may be found in the 
publication (Chen et al., 2013). 
Supplemental figures and tables for Chapter 2 
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Figure S2. Allele-specific expression analysis of known imprinted genes using RNAseq in 
brain of the fetuses.  Details are as in Figure 1. LE=low expression (fewer than 10 reads). 
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Figure S3. Allele-specific expression analysis of known imprinted genes using RNAseq in 
liver of the fetuses.  Details are as in Figure 1. LE=low expression (fewer than 10 reads). 
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Figure S4. Allele-specific expression analysis of known imprinted genes using RNAseq in 
skeletal muscle of the fetuses.  Details are as in Figure 1.  NA: not assessable due to lack of 
subspecies-specific SNPs. 
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Figure S5. Positive correlation between number of genes showing LOI and 
bodyweight of LOS fetuses. Each bar represents the number of imprinted genes 
showing abnormal allelic expression in kidney, brain, liver and muscle of each LOS 
fetus. The bodyweight of each LOS fetus is illustrated by the connected black dots. 
The Pearson correlation coefficient between the number of genes showing LOI and 
the bodyweight of LOS fetuses is 0.90 (P = 0.049). Allelic expression of KCNQ1OT1 
was also included in the analysis. 
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Figure S6. Verification of the allelic expression of PEG3, and SNRPN in control and LOS 
fetuses.  Shown is Sanger sequencing of RT-PCR amplicons of PEG3 and SNRPN. Double 
peaks pointed by arrows demonstrate biallelic expression. PEG3 in LOS #3 and #4 liver, and 
SNRPN in LOS#3 kidney were not considered biallelically expressed because the ratios 
expressed from the repressed allele were below 15% according to RNAseq data. Other details 
are the same as described in Figure 2.  
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Figure S7. Lack of association between allelic expression and transcript abundance of 
imprinted genes. Transcript abundance was determined by the normalization of total 
RNAseq reads that aligned to the gene locus. Black dots represent genes with monoallelic 
expression and red dots represent genes with biallelic expression.  
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Figure S8. Allele-specific DNA methylation analysis of PLAGL1 and NNAT DMRs. (A). 
Methylation prolife of PLAGL1 DMR in liver, muscle, and brain of Control #4 and LOS #4 
fetus. (B). Methylation profile of NNAT DMR in brain of Control #2 and LOS #4 LOS fetuses. 
Other details are the same as described in Figure 3.  
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Figure S9. Differential expression of imprinted genes in LOS compared to controls. Heat map 
illustrating the differentially expressed imprinted genes identified using edgeR (false discovery rate 
<0.05) in each tissue of each LOS fetus (Blue = downregulated; Red = upregulated). Relative 
intensity of the color represents the level of fold change. Numbers in the table represent the 
transcript level relative to the average of controls.  
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#1 #3 #2 #4 
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#1 #3 #2 #4 
ANO1    3.46 
ATP10A    1.51 
AXL    1.38 
BEGAIN   1.64 2.73 
BLCAP    0.72 
CALCR    0.59 
CASD1   0.65 0.64 
CDKN1C   1.53  
CNTN3    0.53 
COBL    0.63 
COMMD1   0.73 0.72 
COPG2    0.61 
CPA4 0.51  0.6 0.38 
DCN 2.04    
DHCR7    1.29 
DNMT1   1.34 1.43 
FBXO40 0.3 0.23 0.37 0.45 
GATM    0.48 
GLIS3    2.17 
GTL2 0.38    
H13   1.34 1.36 
HTRA3 1.62  1.47  
IGF2R 0.38 0.49 0.48  
IMPACT    0.7 
JADE1 0.54    
KCNQ1 0.45   1.91 
L3MBTL1 0.41   1.35 
MAGEL2 1.39   1.94 
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NDN    1.51 
NNAT   2.44 2.41 
NTM 0.51    
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PEG3   1.61 2.25 
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PON3 0.14  0.27 3.36 
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SNRPN 1.57   1.67 
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WIF1 2.59   5.62 
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COMMD1 1.43    
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IGF2 0.61    
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CD81   1.99  
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Organ Weight (g) 
Fetus  Sex Fetal age BW (g) Liver Muscle Brain Kidney 
Control #1 Female d104 392 13.4 (3.4%) ND 12.8 (3.3%) 5.6 (1.4%) 
Control #2 Female d105 404 14.9 (3.7%) ND 11.3 (2.8%) 6.0 (1.5%) 
Control #3 Female d106 408 13.9 (3.4%) ND 12.0 (2.9%) 5.2 (1.3%) 
Control #4 Female d106 416 14.1 (3.4%) ND 11.7 (2.8%) 5.6 (1.3%) 
LOS #1 Female d106 514* 23.3 (4.5%) ND 11.6 (2.3%) 8.7 (1.7%) 
LOS #2 Female d105 518* 19.4 ( 3.7%) ND 11.6 (2.2%) 6.7 (1.3%) 
LOS #3 Female d106 620* 27.7 (4.5%) ND 11.7 (1.9%) 6.2 (1.0%) 
LOS #4 Female d105 714* 26.8 (3.8%) ND 11.2 (1.6%) 13.3 (1.9%) 
Table S1. B. t. indicus X B. t. taurus F1 hybrid fetus information. 
LOS: large offspring syndrome; BW: body weight (student t-test: LOS vs. Control *P=0.008). Organ weights 
were also presented as the percentage of the bodyweight (as shown in parentheses), which were not 
statistically different between LOS and control fetuses. ND: not determined, only a piece of skeletal muscle 
was collected for analysis.  
Table S1. B. t. indicus × B. t. taurus F1 hybrid fetus information 
Fetus ID Organ Read length 
# reads before quality 
trimming 
# reads after quality 
trimming 
# total reads mapped to 
UMD3.1 
% total reads 
mapped 
# uniquely mapped 
to UMD3.1 
% uniquely mapped 
reads 
Control #1 Liver 100bp  49,324,460  39,771,401 37,440,644 94.14 34,805,066 87.51 
Control #1 Muscle 100bp  35,012,854  28,164,307 25,873,674 91.87 24,593,143 87.32 
Control #1 Brain 100bp  39,114,786  31,602,386 28,431,993 89.97 27,434,118 86.81 
Control #1 Kidney 100bp  44,168,361  35,748,305 32,663,416 91.37 31,188,516 87.24 
Control #2 Liver 50bp  89,453,260  45,661,628 43,683,972 95.67 37,402,160 81.91 
Control #2 Muscle 50bp  56,538,563  29,854,108 28,126,835 94.21 26,296,827 88.08 
Control #2 Brain 50bp  77,691,951  38,651,699 36,395,229 94.16 33,913,437 87.74 
Control #2 Kidney 100bp  60,857,482  43,334,190 39,760,139 91.75 37,999,230 87.69 
Control #3 Liver 100bp  47,032,906  37,570,762 35,616,256 94.80 32,918,922 87.62 
Control #3 Muscle 100bp  36,876,793  29,969,941 27,970,927 93.33 26,636,566 88.88 
Control #3 Brain 100bp  45,716,097  37,136,173 34,133,616 91.91 32,718,553 88.10 
Control #3 Kidney 100bp  60,174,902  41,681,288 38,143,750 91.51 36,302,479 87.10 
Control #4 Liver 100bp  48,359,824  39,244,627 36,949,505 94.15 34,378,296 87.60 
Control #4 Muscle 100bp  32,704,016  26,326,185 23,929,859 90.90 22,866,008 86.86 
Control #4 Brain 100bp  47,403,478  38,145,390 34,476,641 90.38 33,229,226 87.11 
Control #4 Kidney 100bp  57,133,460  40,562,200 36,830,958 90.80 35,088,062 86.50 
LOS #1  Liver 100bp  43,702,500  35,039,540 32,617,194 93.09 29,689,819 84.73 
LOS #1  Muscle 100bp  36,677,201  29,433,490 26,969,294 91.63 25,400,463 86.30 
LOS #1 Brain 100bp  34,368,056  27,188,866 25,718,282 94.59 24,477,407 90.03 
LOS #1 Kidney 100bp  52,656,189  39,385,040 35,992,962 91.39 34,353,786 87.23 
LOS #2 Liver 100bp  38,657,402  31,204,376 29,457,242 94.40 27,117,333 86.90 
LOS #2 Muscle 100bp  46,224,766  37,352,304 34,653,583 92.77 32,965,587 88.26 
LOS #2 Brain 100bp  43,052,038  34,693,252 32,524,533 93.75 31,100,002 89.64 
LOS #2 Kidney 100bp  62,356,428  43,043,803 39,206,473 91.09 37,295,278 86.64 
LOS #3 Liver 100bp  67,410,973  49,344,697 46,497,196 94.23 43,052,525 87.25 
LOS #3 Muscle 100bp  66,164,453  48,644,403 45,352,608 93.23 43,488,821 89.40 
LOS #3 Brain 100bp  76,645,582  56,760,249 52,959,888 93.30 50,911,766 89.70 
LOS #3 Kidney 100bp  44,825,859  32,386,152 29,141,781 89.98 27,305,679 84.31 
LOS #4 Liver 100bp  53,967,229  43,237,304 40,707,119 94.15 37,594,353 86.95 
LOS #4 Muscle 100bp  56,742,110  45,144,209 41,889,305 92.79 40,379,885 89.45 
LOS #4 Brain 100bp  79,150,645  62,861,848 58,386,058 92.88 56,343,425 89.63 
LOS #4 Kidney 100bp  56,302,574  38,654,962 35,183,985 91.02 33,495,182 86.65 
Table S2. Control and LOS fetal tissues RNAseq summary 
LOS: large offspring syndrome; bp: base pairs 
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Table S3. Allelic expression of the monoallelically expressed imprinted genes in ~d105 bovine 
fetuses.  For each tissue, left table shows the actual percentage of the expression from the repressed 
allele for each gene in each fetus.  Right table shows the number of the reads covering the SNPs used 
for ascribing allelic expression of the imprinted gene in each fetus.  Genes with biallelic expression in 
LOS but not in controls are delineated by a red box.  LE = low expression (fewer than 10 reads); ND 
= not detectable; NA = not assessable due to lack of subspecies-specific SNPs. 
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Control LOS 
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Brain (% of the repressed allele)  
#3 #2 #4 #1 #3 #2 #4 
0.1 0.0 0.3 0.2 
0.0 0.0 0.0 0.0 
0.5 1.3 0.4 0.5 
0.0 0.2 0.1 0.1 
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1.2 1.8 1.1 2.7 
ND ND ND ND 
0.0 0.0 0.0 0.0 
6.1 6.3 33.4 31.9 
LE LE 0.0 0.0 
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58.6 14.6 43.1 40.3 
18.2 18.7 34.8 32.0 
0.0 23.3 34.4 25.0 
54.2 49.7 47.5 41.5 
21.0 24.6 46.5 20.3 
LE LE LE 70.0 
0.0 1.0 1.2 2.0 
Im
printed in all tissues analyzed 
Tissue-specific im
printing 
PEG10 
NAP1L5 
PLAGL1 
GNAS 
IGF2R 
NNAT 
PEG3 
SNRPN 
DLK1 
INPP5F 
RTL1 
PHLDA2 
CDKN1C 
DIRAS3 
SGCE 
IGF2 
H19 
GTL2 
MAGEL2 
BEGAIN 
Control LOS 
#1 
Brain ( # of reads containing the SNPs 
used to ascribe the allelic expression) 
#3 #2 #4 #1 #3 #2 #4 
3627 696 2777 4629 
28 18 59 62 
1932 1012 2071 2052 
877 929 885 719 
41 30 21 25 
109 50 99 165 
2004 308 805 1715 
3390 1037 3804 11825 
5225 3585 6097 7762 
262 154 230 225 
81 57 95 73 
0 0 0 0 
1971 498 1758 2477 
783 821 2022 2993 
3 7 11 191 
1425 1390 1579 2326 
508 735 1180 1959 
9 20 160 577 
60 62 96 177 
102 140 309 979 
733 4883 2355 13430 
6327 5430 7472 11290 
137 154 900 1770 
40 67 124 221 
0 0 0 0 
1823 1472 1760 2311 
63 30 103 82 
44 18 50 76 
72 79 7 36 
223 173 194 180 
5133 1013 589 733 
14 3 6 6 
186 77 265 254 
29 48 58 139 
11 16 66 72 
17 43 122 776 
306 316 547 695 
2123 3055 6452 1132 
3 4 6 10 
119 198 257 350 
PEG10 
NAP1L5 
PLAGL1 
GNAS 
IGF2R 
NNAT 
PEG3 
SNRPN 
DLK1 
INPP5F 
RTL1 
PHLDA2 
CDKN1C 
DIRAS3 
SGCE 
IGF2 
H19 
GTL2 
MAGEL2 
BEGAIN 
Control LOS 
#1 
Kidney (% of the repressed allele)  
#3 #2 #4 #1 #3 #2 #4 
1.5 0.0 0.5 0.0 
0.2 0.0 0.3 0.1 
1.1 0.8 1.3 0.9 
1.0 0.7 0.5 0.5 
3.3 3.3 3.5 3.6 
0.0 0.0 0.0 0.0 
0.0 13.0 0.0 2.4 
0.9 5.3 2.2 2.5 
0.1 0.2 0.1 0.1 
0.1 0.4 0.3 0.4 
0.6 0.4 0.6 1.3 
2.1 0.0 4.5 7.5 
0.0 0.0 0.0 0.0 
3.0 3.5 51.3 41.2 
0.2 0.1 0.1 0.1 
1.7 1.2 1.0 1.2 
1.1 0.6 1.6 1.2 
3.8 3.8 3.8 3.8 
10.2 3.9 8.7 35.6 
25.8 6.5 6.5 15.5 
7.3 0.6 43.1 41.8 
0.1 0.1 0.4 0.1 
0.6 13.6 52.4 47.6 
0.3 0.7 0.5 35.5 
NA 2.2 12.0 3.4 
5.1 9.1 11.8 33.9 
0.0 7.4 3.0 5.9 
3.1 3.9 1.7 4.3 
0.2 0.1 0.2 0.1 
9.0 7.7 9.5 11.3 
36.5 36.5 2.0 3.4 
17.6 18.6 11.2 9.7 
0.2 0.2 0.0 0.0 
3.6 0.0 21.3 1.8 
6.3 4.1 3.5 8.5 
0.4 0.1 0.1 0.1 
17.7 15.1 32.2 21.7 
49.7 38.6 50.6 13.4 
15.7 8.7 5.8 12.7 
0.6 0.0 2.1 0.9 
Tissue-specific im
printing 
PEG10 
NAP1L5 
PLAGL1 
GNAS 
IGF2R 
NNAT 
PEG3 
SNRPN 
DLK1 
INPP5F 
RTL1 
PHLDA2 
CDKN1C 
DIRAS3 
SGCE 
IGF2 
H19 
GTL2 
MAGEL2 
BEGAIN 
Control LOS 
#1 
Kidney ( # of reads containing the SNPs 
used to ascribe the allelic expression) 
#3 #2 #4 #1 #3 #2 #4 
132 202 211 105 
2391 2564 2672 2817 
1184 1470 1351 1322 
706 839 547 650 
10705 13994 12275 16069 
53 67 65 38 
52 46 46 42 
3390 19 185 276 
4571 5922 4568 4776 
1755 1855 2048 1091 
1257 1547 1396 1076 
48 18 44 40 
348 433 379 355 
199 144 386 262 
3352 3324 8785 3686 
1295 1691 1240 1836 
797 637 124 650 
14507 13336 15148 15991 
59 76 57 101 
93 61 62 71 
41 326 65 491 
5395 4591 972 4311 
1316 1541 248 2195 
1263 1225 425 2966 
NA 46 67 89 
375 482 382 613 
22 27 33 34 
292 281 290 276 
9227 11520 11107 11709 
2674 3459 3002 2706 
356 389 50 29 
262 306 259 421 
556 510 569 465 
28 24 47 55 
159 318 517 200 
9578 10549 8825 10075 
1754 1661 556 1601 
541 485 259 67 
210 392 1003 291 
514 663 517 633 
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PEG10 
NAP1L5 
PLAGL1 
GNAS 
IGF2R 
NNAT 
PEG3 
SNRPN 
DLK1 
INPP5F 
RTL1 
PHLDA2 
CDKN1C 
DIRAS3 
SGCE 
IGF2 
H19 
GTL2 
MAGEL2 
BEGAIN 
Control LOS 
#1 
Liver (% of the repressed allele)  
#3 #2 #4 #1 #3 #2 #4 
ND ND ND ND 
0.2 1.4 0.5 0.5 
1.1 3.7 1.0 0.6 
0.0 0.6 0.5 0.5 
3.6 1.8 5.8 6.2 
0.0 0.0 0.0 0.0 
0.0 4.3 0.0 0.0 
0.1 0.1 0.9 0.3 
0.0 0.0 0.1 0.1 
0.1 0.0 0.1 0.1 
0.1 0.1 0.1 0.1 
ND ND ND ND 
0.0 0.0 0.0 0.0 
ND ND ND ND 
0.4 0.3 0.0 0.1 
2.1 0.7 0.7 1.7 
0.0 0.2 0.3 1.1 
5.5 7.1 5.8 5.4 
3.8 3.8 19.6 23.5 
21.9 5.4 27.0 3.0 
1.0 0.4 34.8 19.5 
0.2 0.3 0.1 0.1 
1.1 0.1 14.1 12.5 
0.1 0.1 3.7 8.6 
ND ND ND ND 
7.9 4.5 18.7 30.1 
13.3 0.0 21.1 13.3 
5.0 5.0 7.3 9.9 
0.1 0.0 0.0 0.0 
14.2 13.6 14.8 14.0 
32.4 37.4 2.0 3.4 
5.0 LE 0.0 0.0 
25.2 33.1 24.0 30.1 
LE 0.0 21.7 0.0 
36.1 7.5 9.4 6.0 
0.0 0.0 0.0 0.1 
42.0 23.2 27.4 21.7 
50.3 35.5 44.1 19.0 
LE LE LE 21.1 
36.2 24.1 26.8 16.3 
Tissue-specific im
printing 
PEG10 
NAP1L5 
PLAGL1 
GNAS 
IGF2R 
NNAT 
PEG3 
SNRPN 
DLK1 
INPP5F 
RTL1 
PHLDA2 
CDKN1C 
DIRAS3 
SGCE 
IGF2 
H19 
GTL2 
MAGEL2 
BEGAIN 
Control LOS 
#1 
Liver ( # of reads containing the SNPs 
used to ascribe the allelic expression) 
#3 #2 #4 #1 #3 #2 #4 
0 0 0 0 
4330 1898 4290 3919 
807 815 894 837 
628 787 424 650 
7771 4854 7997 8778 
44 23 11 43 
240 116 251 175 
12020 4039 9643 20024 
15788 10197 15286 16663 
1366 1232 1648 1430 
3864 3815 2727 2890 
0 0 0 0 
296 125 272 294 
0 0 0 0 
3883 2570 4452 3875 
807 568 1069 922 
185 432 953 1008 
6513 4520 22867 24216 
26 26 56 34 
333 204 392 305 
2822 14834 7381 30639 
7629 12360 17495 12801 
179 1125 5778 4650 
1660 2896 5092 6560 
0 0 0 0 
302 262 417 418 
15 12 19 15 
219 100 246 242 
6849 6880 7332 7043 
2461 1693 2580 2357 
278 99 18 23 
20 4 17 15 
856 293 890 730 
5 10 23 14 
61 133 394 283 
3167 4655 12894 11801 
295 1159 1842 2314 
260 214 383 90 
1 8 5 19 
828 605 761 576 
Im
printed in all tissues analyzed 
PEG10 
NAP1L5 
PLAGL1 
GNAS 
IGF2R 
NNAT 
PEG3 
SNRPN 
DLK1 
INPP5F 
RTL1 
PHLDA2 
CDKN1C 
DIRAS3 
SGCE 
IGF2 
H19 
GTL2 
MAGEL2 
BEGAIN 
Control LOS 
#1 
Muscle (% of the repressed allele)  
#3 #2 #4 #1 #3 #2 #4 
ND ND ND ND 
0.4 1.0 0.3 0.2 
0.4 2.8 0.4 0.6 
0.2 0.2 0.5 0.3 
3.8 4.5 4.6 5.7 
0.0 0.0 0.0 4.2 
0.0 2.5 0.0 0.0 
6.3 3.4 4.0 13.5 
0.2 0.1 0.2 0.2 
0.6 0.0 0.3 0.0 
1.9 1.1 0.6 1.9 
2.1 2.7 3.1 7.0 
0.0 0.0 0.0 0.0 
ND ND ND ND 
0.5 0.4 0.1 0.1 
1.0 0.2 1.4 1.6 
0.5 0.2 0.4 0.3 
4.7 4.4 4.4 5.3 
10.3 10.9 24.7 36.1 
19.3 10.0 14.1 16.2 
31.0 2.6 45.7 45.7 
0.2 0.3 0.1 0.8 
0.0 7.2 20.5 39.2 
0.5 1.2 0.4 39.2 
NA 2.8 5.4 1.4 
18.6 11.4 21.3 41.6 
0.0 0.0 0.0 5.3 
5.9 4.2 6.0 5.3 
0.5 0.5 0.6 0.5 
8.9 7.7 11.1 8.6 
47.2 52.5 1.1 1.4 
LE LE LE ND 
1.6 2.2 1.8 0.9 
3.3 3.2 24.5 10.8 
4.7 2.7 4.2 11.7 
0.4 0.2 0.4 1.0 
20.7 20.7 24.0 20.9 
51.9 46.3 53.5 19.0 
LE LE ND LE 
2.2 0.8 2.4 10.3 
Tissue-specific im
printing 
PEG10 
NAP1L5 
PLAGL1 
GNAS 
IGF2R 
NNAT 
PEG3 
SNRPN 
DLK1 
INPP5F 
RTL1 
PHLDA2 
CDKN1C 
DIRAS3 
SGCE 
IGF2 
H19 
GTL2 
MAGEL2 
BEGAIN 
Control LOS 
#1 
Muscle ( # of reads containing the SNPs 
used to ascribe the allelic expression) 
#3 #2 #4 #1 #3 #2 #4 
0 0 0 0 
5274 1868 4470 4261 
1702 1185 1780 1350 
3663 5394 3597 4144 
8841 4663 8245 6604 
50 31 50 47 
59 39 64 48 
288 59 273 297 
9361 7093 12023 11439 
173 202 341 203 
881 541 1056 619 
47 37 64 57 
234 101 269 205 
0 0 0 0 
3925 5722 7932 7287 
1517 2408 3476 3336 
1348 4016 5536 5248 
7834 8613 32769 34196 
97 73 89 119 
62 100 71 74 
116 699 341 1862 
9742 11932 18427 12250 
86 293 1457 1972 
854 1109 1700 4509 
NA 72 242 142 
397 525 684 730 
33 15 21 19 
603 237 547 436 
9937 10007 9942 8423 
2109 1510 2537 1989 
593 312 88 71 
2 1 2 0 
872 214 841 697 
30 31 57 92 
360 563 970 468 
8188 11964 25527 23919 
807 1599 1899 2887 
839 973 976 121 
1 1 0 6 
694 1197 970 1014 
Im
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Weight  → 392g 404g 408g 416g 514g 518g 620g 714g Alllelic
Fetus → Control #1 Control #2 Control #3 Control #4 LOS #1 LOS #2 LOS #3 LOS #4 Exrssion
Gene # Tissue Gene Name↓ Gene ID ↓ Mean LOS #1 LOS #2 LOS #3 LOS #4 LOS #1 LOS #2 LOS #3 LOS #4 in Control
1 Brain AIM1 ENSBTAG00000017527 14.92 13.55 10.35 27.33 16.54 8.77 11.33 11.84 16.02 0.53 0.69 0.72 0.97 0.41 0.90 0.73 0.97 Biallelic
Kidney AIM1 ENSBTAG00000017527 55.80 58.91 53.05 53.49 55.31 57.90 64.92 34.21 51.56 1.05 1.17 0.62 0.93 1.00 1.00 0.00 0.83 Biallelic
Liver AIM1 ENSBTAG00000017527 18.72 16.12 20.52 21.26 19.15 18.07 19.66 17.43 17.49 0.94 1.03 0.91 0.91 0.55 1.00 0.54 0.53 Biallelic
Muscle AIM1 ENSBTAG00000017527 12.09 11.55 14.03 18.61 14.07 14.43 13.37 13.65 20.54 1.03 0.95 0.97 1.46 0.93 1.00 0.84 0.20 Bialelic
2 Brain AMPD3 ENSBTAG00000015821 15.17 7.10 15.79 15.46 13.38 1.61 2.05 5.93 4.23 0.12 0.15 0.44 0.32 0.00 0.00 0.19 0.10 NA
Kidney AMPD3 ENSBTAG00000015821 4.44 4.90 5.21 4.42 4.74 5.23 3.84 5.99 6.38 1.10 0.81 1.26 1.35 1.00 1.00 0.65 0.57
 Liver AMPD3 ENSBTAG00000015821 NE
Muscle AMPD3 ENSBTAG00000015821 NE
3 Brain ANO1 ENSBTAG00000009997 2.32 1.25 3.34 1.98 2.22 0.54 0.54 1.33 3.34 0.24 0.24 0.60 1.50 0.12 0.20 0.63 0.95 NA
Kidney ANO1 ENSBTAG00000009997 16.46 12.15 13.47 15.92 14.50 10.05 12.75 15.85 13.84 0.69 0.88 1.09 0.95 0.80 1.00 0.98 0.96
Liver ANO1 ENSBTAG00000009997 18.56 27.72 20.46 21.36 22.02 11.50 26.11 22.92 20.59 0.52 1.19 1.04 0.94 0.00 0.44 0.55 0.91
Muscle ANO1 ENSBTAG00000009997 2.03 2.21 2.13 3.78 2.54 1.62 2.22 2.95 8.80 0.64 0.87 1.16 3.46 0.36 1.00 0.85 0.00
4 Brain ART5 ENSBTAG00000037826 NE NA
Kidney ART5 ENSBTAG00000037826 NE
Liver ART5 ENSBTAG00000037826 19.53 16.85 65.16 21.13 30.67 46.53 68.44 31.52 62.00 1.52 2.23 1.03 2.02 0.59 0.58 0.91 0.26
Muscle ART5 ENSBTAG00000037826 2.69 1.99 1.92 1.74 2.08 2.66 1.16 1.77 1.05 1.28 0.56 0.85 0.50 0.64 0.80 0.77 0.09
5 Brain ASB4 ENSBTAG00000018185 NE NA
Kidney ASB4 ENSBTAG00000018185 NE
Liver ASB4 ENSBTAG00000018185 2.34 0.82 2.14 1.16 1.62 1.41 2.32 1.76 1.93 0.87 1.43 1.09 1.19 0.60 1.00 0.95 0.97
Muscle ASB4 ENSBTAG00000018185 26.59 19.17 35.95 21.68 25.84 25.21 20.90 21.92 18.84 0.98 0.81 0.85 0.73 0.73 0.89 0.44 0.09
6 Brain ATP10A ENSBTAG00000027081 3.70 2.88 2.18 2.94 2.92 3.12 3.02 2.95 3.65 1.07 1.03 1.01 1.25 0.98 1.00 1.00 0.96 LE
Kidney ATP10A ENSBTAG00000027081 15.19 12.28 14.78 13.76 14.00 15.70 13.03 15.17 18.12 1.12 0.93 1.08 1.29 1.00 1.00 0.95 0.45 LE
Liver ATP10A ENSBTAG00000027081 NE
Muscle ATP10A ENSBTAG00000027081 9.07 14.21 9.80 10.33 10.85 6.80 13.12 10.46 16.44 0.63 1.21 0.96 1.51 0.20 0.81 0.81 0.01 LE
7 Brain AXL ENSBTAG00000003166 49.94 44.97 25.23 32.40 38.13 13.72 21.27 26.53 48.49 0.36 0.56 0.70 1.27 0.07 0.68 0.74 0.87 Biallelic
Kidney AXL ENSBTAG00000003166 44.39 43.00 38.66 37.44 40.87 42.52 47.02 54.70 56.15 1.04 1.15 1.34 1.37 1.00 1.00 0.13 0.07 Biallelic
Liver AXL ENSBTAG00000003166 16.94 23.31 17.79 17.64 18.92 14.32 15.81 18.12 22.38 0.76 0.84 0.96 1.18 0.23 1.00 0.88 0.13 Biallelic
Muscle AXL ENSBTAG00000003166 56.15 81.93 50.93 60.02 62.26 67.36 60.48 61.57 86.03 1.08 0.97 0.99 1.38 0.26 1.00 0.61 0.00 Biallelic
8 Brain BEGAIN ENSBTAG00000017716 39.81 53.25 48.86 45.47 46.85 20.92 28.86 34.30 52.22 0.45 0.62 0.73 1.11 0.09 0.67 0.73 0.95 Biallelic
Kidney BEGAIN ENSBTAG00000017716 23.96 25.75 22.08 24.96 24.19 33.94 20.49 38.18 38.76 1.40 0.85 1.58 1.60 0.18 1.00 0.01 0.00 Paternal
Liver BEGAIN ENSBTAG00000017716 10.09 20.14 13.05 11.44 13.68 4.58 8.15 16.86 14.45 0.34 0.60 1.23 1.06 0.00 0.60 0.06 0.29 Variable
Muscle BEGAIN ENSBTAG00000017716 29.28 37.75 24.84 22.85 28.68 25.16 23.79 47.14 78.37 0.88 0.83 1.64 2.73 0.95 1.00 0.00 0.00 Paternal
9 Brain BLCAP ENSBTAG00000003209 244.15 198.90 278.30 362.57 270.98 215.21 154.30 123.31 145.91 0.79 0.57 0.46 0.54 0.55 0.23 0.047 0.19 Biallelic
Kidney BLCAP ENSBTAG00000003209 59.01 60.73 59.89 60.07 59.93 59.96 63.92 87.29 67.50 1.00 1.07 1.46 1.13 1.00 1.00 0.01 0.61 Biallelic
Liver BLCAP ENSBTAG00000003209 145.28 169.40 137.41 122.22 143.58 128.22 175.99 121.96 117.55 0.89 1.23 0.85 0.82 0.72 0.16 0.61 0.40 Biallelic
Muscle BLCAP ENSBTAG00000003209 236.38 236.13 234.50 195.04 225.51 196.76 242.64 213.36 163.29 0.87 1.08 0.95 0.72 0.54 1.00 0.91 0.03 Biallelic
10 Brain CALCR ENSBTAG00000017458 39.69 8.49 10.31 15.19 18.42 1.29 3.91 2.95 10.04 0.07 0.21 0.16 0.55 0.00 0.06 0.02 0.63 Biallelic
Kidney CALCR ENSBTAG00000017458 NE
Liver CALCR ENSBTAG00000017458 NE
Muscle CALCR ENSBTAG00000017458 16.48 17.93 16.99 19.84 17.81 14.03 16.75 20.05 10.44 0.79 0.94 1.13 0.59 0.32 1.00 0.63 0.01 Biallelic
11 Brain CASD1 ENSBTAG00000009109 115.57 122.09 169.26 179.98 146.73 104.73 146.83 110.82 101.14 0.71 1.00 0.76 0.69 0.44 1.00 0.62 0.61 Biallelic
Kidney CASD1 ENSBTAG00000009109 130.12 129.78 131.85 123.48 128.81 134.40 133.28 80.27 107.05 1.04 1.03 0.62 0.83 1.00 1.00 0.00 0.35 Biallelic
Liver CASD1 ENSBTAG00000009109 20.18 15.80 19.37 20.68 19.01 22.30 20.69 14.41 14.61 1.17 1.09 0.76 0.77 0.56 1.00 0.07 0.06 Biallelic
Muscle CASD1 ENSBTAG00000009109 135.21 125.17 161.12 162.94 146.11 160.18 133.00 95.40 93.44 1.10 0.91 0.65 0.64 0.83 1.00 0.00 0.00 Biallelic
12 Brain CD81 ENSBTAG00000047495 227.68 142.42 138.33 172.39 170.21 128.99 114.46 104.78 164.33 0.76 0.67 0.62 0.97 0.55 0.61 0.34 0.95 Biallelic
Kidney CD81 ENSBTAG00000047495 158.59 151.67 145.15 150.57 151.49 151.07 158.74 302.12 192.02 1.00 1.05 1.99 1.27 1.00 1.00 0.00 0.11 Biallelic
Liver CD81 ENSBTAG00000047495 120.49 154.14 150.09 132.14 139.22 158.50 122.69 135.60 129.99 1.14 0.88 0.97 0.93 0.21 0.99 0.95 0.92 Biallelic
Muscle CD81 ENSBTAG00000047495 213.42 176.38 183.69 182.11 188.90 205.18 213.26 202.03 237.90 1.09 1.13 1.07 1.26 0.77 1.00 0.80 0.19 Biallelic
13 Brain CDKN1C ENSBTAG00000031184 16.88 19.30 8.24 17.86 15.57 8.93 8.94 21.96 17.84 0.57 0.57 1.41 1.15 0.59 0.87 0.64 0.95 Variable
Kidney CDKN1C ENSBTAG00000031184 98.97 87.04 86.17 98.96 92.78 50.68 90.51 208.35 65.57 0.55 0.98 2.25 0.71 0.00 1.00 0.00 0.047 Maternal
Liver CDKN1C ENSBTAG00000031184 51.32 106.69 61.21 59.87 69.77 19.78 48.00 103.09 75.98 0.28 0.69 1.48 1.09 0.00 0.76 0.00 0.04 Maternal
Muscle CDKN1C ENSBTAG00000031184 189.34 252.95 152.50 134.21 182.25 130.93 150.49 278.60 143.77 0.72 0.83 1.53 0.79 0.36 1.00 0.00 0.54 Maternal
14 Brain CMAH ENSBTAG00000003892 NE NA
Kidney CMAH ENSBTAG00000003892 2.37 2.34 1.80 1.45 1.99 1.22 1.23 1.44 1.76 0.61 0.62 0.72 0.88 1.00 1.00 0.31 0.93
Liver CMAH ENSBTAG00000003892 39.89 32.27 37.36 34.50 36.01 41.02 40.14 36.64 37.64 1.14 1.11 1.02 1.05 0.58 1.00 0.97 0.94
Muscle CMAH ENSBTAG00000003892 NE
15 Brain CNTN3 ENSBTAG00000007615 20.74 15.76 28.53 37.63 25.67 59.65 24.10 17.27 10.39 2.32 0.94 0.67 0.40 0.16 0.98 0.51 0.15 Biallelic
Kidney CNTN3 ENSBTAG00000007615 6.93 7.57 10.32 6.41 7.81 7.50 6.67 5.13 9.08 0.96 0.85 0.66 1.16 1.00 1.00 0.07 0.83 Biallelic
Liver CNTN3 ENSBTAG00000007615 NE Biallelic
Muscle CNTN3 ENSBTAG00000007615 44.35 38.68 41.83 53.32 44.55 57.56 55.00 32.99 23.45 1.29 1.23 0.74 0.53 0.24 0.95 0.10 0.00 Biallelic
16 Brain COBL ENSBTAG00000023806 11.71 23.73 15.97 9.51 15.23 42.87 24.18 57.28 21.16 2.81 1.59 3.76 1.39 0.00 0.48 0.00 0.70 Biallelic
Kidney COBL ENSBTAG00000023806 32.76 36.67 30.41 35.99 33.96 38.89 27.66 30.16 24.78 1.15 0.81 0.89 0.73 1.00 1.00 0.11 0.14 Biallelic
Liver COBL ENSBTAG00000023806 7.91 11.54 6.72 10.37 9.13 8.02 7.82 8.90 9.50 0.88 0.86 0.97 1.04 0.92 1.00 0.89 0.71 Biallelic
Muscle COBL ENSBTAG00000023806 162.94 148.27 165.52 142.28 154.75 173.62 141.27 149.05 97.72 1.12 0.91 0.96 0.63 0.58 1.00 0.85 0.00 Biallelic
17 Brain COMMD1 ENSBTAG00000019867 23.50 22.93 32.60 30.76 27.45 23.08 27.77 23.48 22.75 0.84 1.01 0.86 0.83 0.76 1.00 0.82 0.87 NA
Kidney COMMD1 ENSBTAG00000019867 40.76 38.16 41.25 42.97 40.79 39.77 43.96 68.83 44.48 0.98 1.08 1.69 1.09 1.00 1.00 0.00 0.78
Liver COMMD1 ENSBTAG00000019867 18.31 14.09 14.79 16.80 16.00 22.96 18.04 14.88 14.28 1.43 1.13 0.93 0.89 0.04 1.00 0.72 0.54
Muscle COMMD1 ENSBTAG00000019867 54.97 36.91 55.81 50.10 49.45 62.39 57.53 36.15 35.62 1.26 1.16 0.73 0.72 0.37 1.00 0.03 0.01
18 Brain COPG2 ENSBTAG00000017245 43.10 43.41 45.70 56.79 47.25 56.69 50.67 43.59 35.33 1.20 1.07 0.92 0.75 0.86 1.00 0.91 0.78 Biallelic
Kidney COPG2 ENSBTAG00000017245 18.83 18.93 18.28 20.04 19.02 15.31 25.37 12.02 11.73 0.81 1.33 0.63 0.62 1.00 0.90 0.00 0.04 Biallelic
Liver COPG2 ENSBTAG00000017245 9.56 9.51 9.82 10.37 9.82 10.71 12.04 10.19 8.35 1.09 1.23 1.04 0.85 0.79 0.94 0.94 0.60 Biallelic
Muscle COPG2 ENSBTAG00000017245 41.56 35.45 46.53 43.10 41.66 47.02 46.59 37.57 25.24 1.13 1.12 0.90 0.61 0.72 1.00 0.50 0.00 Biallelic
19 Brain CPA4 ENSBTAG00000046648 14.92 12.16 7.15 11.77 11.50 4.68 5.72 6.22 4.93 0.41 0.50 0.54 0.43 0.28 0.71 0.57 0.52 Biallelic
Kidney CPA4 ENSBTAG00000046648 15.46 21.34 14.65 14.27 16.43 12.80 15.74 15.13 9.42 0.78 0.96 0.92 0.57 1.00 1.00 0.42 0.10 Biallelic
Liver CPA4 ENSBTAG00000046648 1.62 2.52 1.52 1.13 1.70 0.66 1.28 1.76 1.48 0.39 0.76 1.03 0.87 0.12 1.00 0.75 0.95 Biallelic
Muscle CPA4 ENSBTAG00000046648 95.97 114.68 88.19 107.26 101.52 51.95 99.51 61.02 38.67 0.51 0.98 0.60 0.38 0.00 1.00 0.01 0.00 Biallelic
20 Brain DCN ENSBTAG00000003505 56.40 45.77 21.16 77.35 50.17 27.65 65.02 62.83 59.33 0.55 1.30 1.25 1.18 0.42 0.99 0.88 0.97 Biallelic
Kidney DCN ENSBTAG00000003505 520.13 544.29 442.26 436.89 485.89 560.10 537.37 447.09 497.02 1.15 1.11 0.92 1.02 1.00 1.00 0.15 0.96 Biallelic
Liver DCN ENSBTAG00000003505 79.32 71.37 67.44 75.63 73.44 92.84 69.27 74.07 94.42 1.26 0.94 1.01 1.29 0.08 1.00 0.98 0.08 Biallelic
Muscle DCN ENSBTAG00000003505 1788.34 1253.83 1724.73 2079.08 1711.50 3496.55 2021.10 1847.74 1859.22 2.04 1.18 1.08 1.09 0.00 1.00 1.00 0.94 Biallelic
21 Brain DDC ENSBTAG00000020869 NE Biallelic
Kidney DDC ENSBTAG00000020869 6.93 7.60 5.77 8.13 7.11 5.93 6.17 6.80 6.42 0.83 0.87 0.96 0.90 1.00 1.00 0.63 0.91 Biallelic
Liver DDC ENSBTAG00000020869 14.73 20.23 17.89 19.64 18.12 19.61 12.91 19.93 22.77 1.08 0.71 1.10 1.26 0.57 0.61 0.58 0.15 Biallelic
Muscle DDC ENSBTAG00000020869 NE
22 Brain DHCR7 ENSBTAG00000016465 135.74 101.99 86.75 96.20 105.17 123.77 106.45 118.11 97.57 1.18 1.01 1.12 0.93 0.86 1.00 0.91 0.96 Biallelic
Kidney DHCR7 ENSBTAG00000016465 40.45 41.93 40.76 34.17 39.33 33.56 36.00 39.17 30.75 0.85 0.92 1.00 0.78 1.00 1.00 0.44 0.30 Biallelic
Liver DHCR7 ENSBTAG00000016465 93.12 111.89 94.52 76.67 94.05 99.14 82.22 157.78 116.83 1.05 0.87 1.68 1.24 0.43 1.00 0.00 0.03 Biallelic
Muscle DHCR7 ENSBTAG00000016465 27.91 39.30 21.83 19.53 27.14 22.36 21.57 28.27 35.02 0.82 0.79 1.04 1.29 0.92 1.00 0.42 0.048 Biallelic
Table S4 Transcript amount and allelic expression of the imprinted genes in d105 bovine fetues
Fold Change FDR (False Discovery Rate)
read counts/million read counts/million
	   84 
  
Weight  → 392g 404g 408g 416g 514g 518g 620g 714g Alllelic
Fetus → Control #1 Control #2 Control #3 Control #4 LOS #1 LOS #2 LOS #3 LOS #4 Exrssion
Gene # Tissue Gene Name↓ Gene ID ↓ Mean LOS #1 LOS #2 LOS #3 LOS #4 LOS #1 LOS #2 LOS #3 LOS #4 in Control
Table S4 Transcript amount and allelic expression of the imprinted genes in d105 bovine fetues
Fold Change FDR (False Discovery Rate)
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23 Brain DIO3 NE NA
Kidney DIO3 ENSBTAG00000043578 8.23 6.76 9.40 7.42 7.95 7.64 7.43 27.82 9.94 0.96 0.93 3.50 1.25 1.00 1.00 0.00 0.66
Liver DIO3 NE
Muscle DIO3 NE
24 Brain DIRAS3 ENSBTAG00000012182 676.74 254.81 459.65 688.40 519.90 209.89 146.21 221.82 283.04 0.40 0.28 0.43 0.54 0.01 0.00 0.03 0.17 Paternal
Kidney DIRAS3 ENSBTAG00000012182 19.17 28.65 27.23 15.38 22.61 29.93 22.66 63.75 37.27 1.32 1.00 2.82 1.65 1.00 1.00 0.00 0.13 Paternal
Liver DIRAS3 ENSBTAG00000012182 NE
Muscle DIRAS3 ENSBTAG00000012182 NE
25 Brain DLGAP2 100847272 17.61 32.88 32.78 24.15 26.85 42.33 27.31 37.75 31.39 1.58 1.02 1.41 1.17 0.38 1.00 0.57 0.93 NA
Kidney DLGAP2 100847272 NE
Liver DLGAP2 100847272 NE
Muscle DLGAP2 100847272 NE
26 Brain DLK1 ENSBTAG00000037899 13.34 12.85 4.61 14.13 11.23 2.10 2.17 2.88 38.61 0.19 0.19 0.26 3.44 0.05 0.11 0.18 0.08 Paternal
Kidney DLK1 ENSBTAG00000037899 485.84 478.26 505.79 543.00 503.22 605.83 561.60 1929.80 714.54 1.20 1.12 3.83 1.42 0.76 1.00 0.00 0.01 Paternal
Liver DLK1 ENSBTAG00000037899 834.07 1091.22 893.59 808.18 906.76 979.05 702.84 1058.41 945.46 1.08 0.78 1.17 1.04 0.33 0.75 0.16 0.53 Paternal
Muscle DLK1 ENSBTAG00000037899 1367.87 1637.22 1103.25 1176.30 1321.16 1118.00 1263.38 1827.77 1521.74 0.85 0.96 1.38 1.15 0.73 1.00 0.06 0.32 Paternal
27 Brain DLX5 ENSBTAG00000018645 0.94 9.70 13.07 0.99 6.17 3.33 3.79 10.17 6.99 0.54 0.61 1.65 1.13 0.85 1.00 0.72 0.96 NA
Kidney DLX5 ENSBTAG00000018645 NE
Liver DLX5 ENSBTAG00000018645 NE
Muscle DLX5 ENSBTAG00000018645 NE
28 Brain DNMT1 ENSBTAG00000002736 80.07 91.01 69.29 76.29 79.17 84.72 82.66 86.36 93.53 1.07 1.04 1.09 1.18 0.90 1.00 0.86 0.91 Biallelic
Kidney DNMT1 ENSBTAG00000002736 98.62 94.18 100.19 92.28 96.32 95.58 90.64 69.96 94.35 0.99 0.94 0.73 0.98 1.00 1.00 0.00 0.97 Biallelic
Liver DNMT1 ENSBTAG00000002736 113.14 125.51 110.20 108.23 114.27 78.12 126.09 135.13 131.78 0.68 1.10 1.18 1.15 0.00 0.79 0.10 0.13 Biallelic
Muscle DNMT1 ENSBTAG00000002736 69.85 91.31 67.66 71.37 75.05 60.76 79.17 100.73 107.51 0.81 1.05 1.34 1.43 0.45 0.99 0.01 0.00 Biallelic
29 Brain DRD1A ENSBTAG00000047719 7.28 13.51 35.83 13.65 17.57 73.37 13.81 30.15 13.98 4.18 0.79 1.72 0.80 0.03 0.98 0.70 0.92 NA
Kidney DRD1A ENSBTAG00000047719 NE
Liver DRD1A ENSBTAG00000047719 NE
Muscle DRD1A ENSBTAG00000047719 NE
30 Brain FBXO40 ENSBTAG00000014508 NE NA
Kidney FBXO40 ENSBTAG00000014508 28.13 23.55 25.98 28.77 26.61 29.96 25.77 9.72 28.68 1.13 0.97 0.37 1.08 1.00 1.00 0.00 0.85
Liver FBXO40 ENSBTAG00000014508 NE
Muscle FBXO40 ENSBTAG00000014508 4.01 3.72 3.22 3.48 3.61 1.08 0.84 1.32 1.61 0.30 0.23 0.37 0.45 0.00 0.00 0.02 0.02
31 Brain GATM ENSBTAG00000005586 191.12 91.15 108.32 101.40 123.00 123.99 119.18 81.65 70.08 1.01 0.97 0.66 0.57 0.91 1.00 0.46 0.38 Biallelic
Kidney GATM ENSBTAG00000005586 406.54 375.18 380.69 347.31 377.43 450.09 331.96 219.69 466.10 1.19 0.88 0.58 1.23 0.86 1.00 0.00 0.24 Biallelic
Liver GATM ENSBTAG00000005586 1228.00 943.43 1081.66 1223.62 1119.18 1834.72 1426.25 1036.80 1110.94 1.64 1.27 0.93 0.99 0.00 0.72 0.59 0.84 Biallelic
Muscle GATM ENSBTAG00000005586 17.66 11.15 17.34 14.72 15.22 14.48 14.11 12.67 7.27 0.95 0.93 0.83 0.48 0.61 1.00 0.32 0.00 Biallelic
32 Brain GDAP1L1 ENSBTAG00000002593 53.31 63.78 64.79 63.36 61.31 96.71 75.97 78.22 64.26 1.58 1.24 1.28 1.05 0.32 0.97 0.70 0.99 Biallelic
Kidney GDAP1L1 ENSBTAG00000002593 NE
Liver GDAP1L1 ENSBTAG00000002593 NE
Muscle GDAP1L1 ENSBTAG00000002593 NE
33 Brain GLIS3 ENSBTAG00000014467 10.17 6.72 2.69 5.51 6.27 3.12 3.64 3.19 7.65 0.50 0.58 0.51 1.22 0.58 0.94 0.65 0.96 NA
Kidney GLIS3 ENSBTAG00000014467 12.02 14.39 10.06 11.77 12.06 11.93 10.48 1.89 8.80 0.99 0.87 0.16 0.73 1.00 1.00 0.00 0.49
Liver GLIS3 ENSBTAG00000014467 NE
Muscle GLIS3 ENSBTAG00000014467 1.70 3.63 2.92 2.10 2.59 2.86 2.43 3.58 5.60 1.10 0.94 1.39 2.17 0.63 1.00 0.28 0.01
34 Brain GNAS ENSBTAG00000017475 2080.31 1323.53 1991.16 2068.06 1865.77 1859.64 1440.89 1221.72 1465.72 1.00 0.77 0.65 0.79 0.88 0.83 0.43 0.77 Maternal
Kidney GNAS ENSBTAG00000017475 2550.90 2332.40 2537.77 2283.96 2426.26 2584.77 2643.09 4547.49 3119.53 1.07 1.09 1.87 1.29 1.00 1.00 0.00 0.12 Maternal
Liver GNAS ENSBTAG00000017475 1038.77 1078.07 1102.19 1040.60 1064.91 1600.39 924.31 1103.26 985.37 1.50 0.87 1.04 0.93 0.00 0.92 0.86 0.77 Maternal
Muscle GNAS ENSBTAG00000017475 3009.67 2521.03 2774.96 2665.60 2742.81 3504.88 3111.15 3115.71 3088.79 1.28 1.13 1.14 1.13 0.29 1.00 0.73 0.78 Maternal
35 Brain GPR1 ENSBTAG00000017043 0.49 0.83 0.58 0.86 0.69 0.22 2.01 0.81 14.70 0.31 2.92 1.18 21.35 0.41 0.32 0.90 0.00 NA
Kidney GPR1 ENSBTAG00000017043 NE
Liver GPR1 ENSBTAG00000017043 NE
Muscle GPR1 ENSBTAG00000017043 NE
36 Brain GRB10 ENSBTAG00000017086 18.26 23.73 21.31 30.48 23.44 35.82 25.61 35.73 31.86 1.53 1.09 1.52 1.36 0.54 1.00 0.56 0.88 Biallelic
Kidney GRB10 ENSBTAG00000017086 28.97 29.07 28.64 29.58 29.06 33.21 27.91 36.47 32.30 1.14 0.96 1.25 1.11 1.00 1.00 0.32 0.72 Biallelic
Liver GRB10 ENSBTAG00000017086 37.43 42.72 41.67 38.32 40.04 42.65 41.71 49.72 47.59 1.07 1.04 1.24 1.19 0.63 1.00 0.12 0.20 Biallelic
Muscle GRB10 ENSBTAG00000017086 37.64 40.81 32.24 38.09 37.20 30.97 35.12 44.87 46.06 0.83 0.94 1.21 1.24 0.48 1.00 0.25 0.18 Biallelic
37 Brain GTL2 100335527 2942.28 3185.48 2997.76 2675.69 2950.30 1974.43 2183.02 1977.22 2706.53 0.67 0.74 0.67 0.92 0.50 0.93 0.63 0.97 Maternal
Kidney GTL2 100335527 2743.66 2951.02 2688.35 2852.13 2808.79 3404.54 2508.46 1347.47 3304.71 1.21 0.89 0.48 1.18 0.53 1.00 0.00 0.40 Maternal
Liver GTL2 100335527 1737.81 2498.12 1587.00 1992.35 1953.82 728.59 1696.79 1926.90 2177.65 0.37 0.87 0.99 1.11 0.00 1.00 0.74 0.32 Maternal
Muscle GTL2 100335527 8618.49 12651.22 7314.21 10408.91 9748.21 3701.30 7428.26 6869.11 8211.05 0.38 0.76 0.70 0.84 0.00 1.00 0.54 0.80 Maternal
38 Brain H13 ENSBTAG00000008840 40.10 37.38 28.97 33.66 35.03 34.59 32.18 33.92 39.52 0.99 0.92 0.97 1.13 0.99 1.00 0.99 0.96 NA
Kidney H13 ENSBTAG00000008840 57.14 57.48 58.03 65.23 59.47 57.38 62.91 92.60 63.22 0.96 1.06 1.56 1.06 1.00 1.00 0.00 0.85
Liver H13 ENSBTAG00000008840 47.37 57.02 42.53 46.39 48.33 64.86 39.19 56.86 56.44 1.34 0.81 1.18 1.17 0.00 0.90 0.14 0.13
Muscle H13 ENSBTAG00000008840 38.30 43.42 35.29 33.85 37.71 39.64 41.03 50.35 51.18 1.05 1.09 1.34 1.36 0.62 1.00 0.04 0.03
39 Brain H19 100126192 41.91 77.74 18.75 29.50 41.97 17.94 24.10 48.16 118.40 0.43 0.57 1.15 2.82 0.42 0.97 0.50 0.00 Maternal
Kidney H19 100126192 13054.53 12685.42 13964.67 16180.77 13971.35 13530.67 13092.79 21343.08 13285.92 0.97 0.94 1.53 0.95 1.00 1.00 0.00 0.91 Maternal
Liver H19 100126192 5592.22 7271.85 5284.72 6196.11 6086.23 5676.19 5487.67 6388.35 6632.67 0.93 0.90 1.05 1.09 0.97 1.00 0.67 0.55 Maternal
Muscle H19 100126192 9301.91 10067.82 8241.40 7887.78 8874.73 10559.28 9824.36 9413.54 9083.55 1.19 1.11 1.06 1.02 0.41 1.00 0.75 0.77 Maternal
40 Brain HTR2A ENSBTAG00000013498 17.40 7.28 20.00 13.58 14.57 5.33 13.38 4.10 6.99 0.37 0.92 0.28 0.48 0.06 0.98 0.03 0.36 NA
Kidney HTR2A ENSBTAG00000013498 5.82 6.24 5.77 3.47 5.32 3.63 4.94 4.01 2.52 0.68 0.93 0.75 0.47 1.00 1.00 0.26 0.18
Liver HTR2A ENSBTAG00000013498 1.62 1.26 1.38 1.45 1.43 2.69 1.94 1.80 1.90 1.88 1.36 1.26 1.33 0.13 0.99 0.77 0.65
Muscle HTR2A ENSBTAG00000013498 NE
41 Brain HTRA3 ENSBTAG00000047613 NE NA
Kidney HTRA3 ENSBTAG00000047613 7.62 9.71 6.91 7.05 7.82 7.46 10.67 15.40 11.60 0.95 1.36 1.97 1.48 1.00 1.00 0.01 0.34
Liver HTRA3 ENSBTAG00000047613 NE
Muscle HTRA3 ENSBTAG00000047613 43.69 47.36 24.97 32.98 37.25 60.32 37.23 54.78 40.23 1.62 1.00 1.47 1.08 0.01 1.00 0.04 0.56
42 Brain IGF2 ENSBTAG00000013066 60.96 76.95 14.96 31.37 46.06 10.60 40.54 53.40 288.67 0.23 0.88 1.16 6.27 0.08 1.00 0.70 0.00 Biallelic
Kidney IGF2 ENSBTAG00000013066 9091.27 9586.41 10108.87 10866.42 9913.24 8757.28 8392.55 11957.84 8343.93 0.88 0.85 1.21 0.84 1.00 1.00 0.47 0.45 Paternal
Liver IGF2 ENSBTAG00000013066 4215.26 4920.90 4481.60 4657.53 4568.82 2805.21 3969.01 5539.81 5585.75 0.61 0.87 1.21 1.22 0.01 0.99 0.31 0.30 Paternal
Muscle IGF2 ENSBTAG00000013066 9619.31 12219.01 8995.81 9115.27 9987.35 9970.52 9411.92 12005.32 12735.20 1.00 0.94 1.20 1.28 0.79 1.00 0.41 0.26 Paternal
43 Brain IGF2R ENSBTAG00000002402 50.95 73.55 46.50 37.50 52.12 103.38 74.50 87.96 89.76 1.98 1.43 1.69 1.72 0.02 0.49 0.11 0.22 Biallelic
Kidney IGF2R ENSBTAG00000002402 729.77 765.07 690.98 652.22 709.51 438.47 379.07 231.44 400.39 0.62 0.53 0.33 0.56 0.00 0.00 0.00 0.00 Maternal
Liver IGF2R ENSBTAG00000002402 473.96 606.62 486.72 474.73 510.51 90.46 272.28 307.08 404.97 0.18 0.53 0.60 0.79 0.00 0.00 0.00 0.31 Maternal
Muscle IGF2R ENSBTAG00000002402 648.16 868.58 670.55 650.52 709.45 269.10 348.37 340.94 512.52 0.38 0.49 0.48 0.72 0.00 0.00 0.00 0.11 Maternal
44 Brain IMPACT ENSBTAG00000003035 72.38 71.78 69.73 89.91 75.95 46.96 53.26 51.97 51.15 0.62 0.70 0.68 0.67 0.28 0.75 0.51 0.63 Biallelic
Kidney IMPACT ENSBTAG00000003035 72.33 71.32 72.38 70.56 71.65 78.38 67.73 48.85 67.88 1.09 0.95 0.68 0.95 1.00 1.00 0.00 0.88 Biallelic
Liver IMPACT ENSBTAG00000003035 33.51 32.94 29.16 29.92 31.38 30.49 28.35 23.73 26.01 0.97 0.90 0.76 0.83 0.95 1.00 0.17 0.39 Biallelic
Muscle IMPACT ENSBTAG00000003035 89.92 95.96 96.42 98.52 95.21 84.55 82.30 71.27 66.46 0.89 0.86 0.75 0.70 0.52 1.00 0.10 0.01 Biallelic
45 Brain INPP5F ENSBTAG00000021801 837.85 315.16 734.90 806.53 673.61 469.37 454.27 627.67 534.69 0.70 0.67 0.93 0.79 0.24 0.38 0.76 0.64 Paternal
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Kidney INPP5F ENSBTAG00000021801 64.64 63.75 63.79 54.91 61.77 77.16 69.77 48.71 69.68 1.25 1.13 0.79 1.13 0.63 1.00 0.01 0.64 Variable
Liver INPP5F ENSBTAG00000021801 35.91 28.54 35.22 36.22 33.97 43.09 40.84 39.78 38.98 1.27 1.20 1.17 1.15 0.19 0.91 0.57 0.62 Variable
Muscle INPP5F ENSBTAG00000021801 120.81 118.40 149.23 131.34 129.94 168.55 143.70 114.48 109.12 1.30 1.11 0.88 0.84 0.18 1.00 0.44 0.14 Variable
46 Brain JADE1 ENSBTAG00000017493 40.42 54.53 41.96 35.37 43.07 94.24 55.43 81.67 57.09 2.19 1.29 1.90 1.33 0.02 0.85 0.07 0.76 Biallelic
Kidney JADE1 ENSBTAG00000017493 55.26 63.07 52.92 52.52 55.94 58.15 51.08 22.28 51.11 1.04 0.91 0.40 0.91 1.00 1.00 0.00 0.79 Biallelic
Liver JADE1 ENSBTAG00000017493 27.65 28.77 23.98 24.81 26.31 15.11 28.26 30.80 26.69 0.57 1.07 1.17 1.01 0.00 0.99 0.32 0.82 Biallelic
Muscle JADE1 ENSBTAG00000017493 50.96 76.00 52.81 59.77 59.88 32.25 52.50 64.10 62.52 0.54 0.88 1.07 1.04 0.00 1.00 0.37 0.49 Biallelic
47 Brain KCNK9 ENSBTAG00000047488 11.83 13.41 6.82 6.98 9.76 22.81 13.38 27.20 16.27 2.34 1.37 2.79 1.67 0.10 0.90 0.03 0.66 NA
Kidney KCNK9 ENSBTAG00000047488 NE
Liver KCNK9 ENSBTAG00000047488 NE
Muscle KCNK9 ENSBTAG00000047488 NE
48 Brain KCNQ1 ENSBTAG00000010986 15.94 11.88 6.72 7.83 10.59 6.56 6.81 8.60 12.60 0.62 0.64 0.81 1.19 0.68 0.95 0.92 0.96 Biallelic
Kidney KCNQ1 ENSBTAG00000010986 21.32 27.15 19.20 18.38 21.51 23.75 15.45 12.65 28.61 1.10 0.72 0.59 1.33 1.00 1.00 0.00 0.37 Biallelic
Liver KCNQ1 ENSBTAG00000010986 6.51 14.09 3.92 5.69 7.55 3.17 5.34 8.28 8.13 0.42 0.71 1.10 1.08 0.15 1.00 0.24 0.23 Biallelic
Muscle KCNQ1 ENSBTAG00000010986 34.24 47.85 27.10 35.12 36.08 16.35 23.01 34.70 69.03 0.45 0.64 0.96 1.91 0.00 0.59 0.75 0.00 Biallelic
49 Brain KLF14 785436 NE NA
Kidney KLF14 785436 3.79 2.63 2.92 3.64 3.24 2.55 3.05 3.47 1.07 0.78 0.94 1.07 0.33 1.00 1.00 0.96 0.03
Liver KLF14 785436 NE
Muscle KLF14 785436 5.76 4.51 2.79 4.60 4.42 5.22 4.19 4.29 2.86 1.18 0.95 0.97 0.65 0.73 1.00 0.99 0.30
50 Brain L3MBTL1 529298 39.61 54.98 43.09 41.40 44.77 47.28 37.87 38.89 40.61 1.06 0.85 0.87 0.91 0.89 1.00 0.95 0.98 Biallelic
Kidney L3MBTL1 529298 13.28 16.60 16.42 16.39 15.67 16.67 12.62 12.47 16.70 1.06 0.81 0.80 1.07 1.00 1.00 0.09 0.91 Biallelic
Liver L3MBTL1 529298 6.14 8.87 7.61 7.37 7.49 2.20 5.42 5.79 7.91 0.29 0.72 0.77 1.06 0.00 0.94 0.67 0.76 Biallelic
Muscle L3MBTL1 529298 16.15 20.09 12.37 13.75 15.59 6.35 11.89 14.62 21.10 0.41 0.76 0.94 1.35 0.00 1.00 0.90 0.05 Biallelic
51 Brain LIN28B ENSBTAG00000043973 7.16 4.16 5.23 9.75 6.57 1.94 1.70 2.12 2.60 0.29 0.26 0.32 0.40 0.13 0.16 0.20 0.45 Biallelic
Kidney LIN28B ENSBTAG00000043973 NE
Liver LIN28B ENSBTAG00000043973 32.61 22.49 27.11 29.34 27.89 26.83 25.37 19.04 23.44 0.96 0.91 0.68 0.84 0.58 0.92 0.01 0.22 Biallelic
Muscle LIN28B ENSBTAG00000043973 NE
52 Brain LRRTM1 ENSBTAG00000002967 24.89 33.47 27.15 33.80 29.83 49.43 28.93 28.46 30.38 1.66 0.97 0.95 1.02 0.29 1.00 1.00 0.99 NA
Kidney LRRTM1 ENSBTAG00000002967 NE
Liver LRRTM1 ENSBTAG00000002967 NE
Muscle LRRTM1 ENSBTAG00000002967 NE
53 Brain MAGEL2 ENSBTAG00000045998 34.24 29.90 31.87 45.23 35.31 23.56 19.46 27.08 42.20 0.67 0.55 0.77 1.20 0.43 0.38 0.69 0.96 Paternal
Kidney MAGEL2 ENSBTAG00000045998 19.94 22.02 16.19 18.35 19.12 16.29 23.98 28.32 32.27 0.85 1.25 1.48 1.69 1.00 1.00 0.07 0.01 Paternal
Liver MAGEL2 ENSBTAG00000045998 8.97 9.34 5.67 9.08 8.26 5.24 7.12 13.10 12.69 0.63 0.86 1.59 1.54 0.23 1.00 0.11 0.10 Paternal
Muscle MAGEL2 ENSBTAG00000045998 17.66 20.85 15.12 17.13 17.69 24.67 18.02 24.19 34.37 1.39 1.02 1.37 1.94 0.04 1.00 0.07 0.00 Paternal
54 Brain MAGI2 100298336 51.52 47.46 42.54 46.32 46.96 117.37 67.19 67.33 59.42 2.50 1.43 1.43 1.27 0.01 0.82 0.54 0.90 Biallelic
Kidney MAGI2 100298336 20.63 21.89 20.08 19.50 20.52 20.44 17.21 4.28 16.84 1.00 0.84 0.21 0.82 1.00 1.00 0.00 0.56 Biallelic
Liver MAGI2 100298336 NE
Muscle MAGI2 100298336 NE
55 Brain MEST ENSBTAG00000017223 118.33 147.79 109.91 109.68 121.43 98.22 91.71 101.39 108.28 0.81 0.76 0.83 0.89 0.81 0.94 0.90 0.97 NA
Kidney MEST ENSBTAG00000017223 213.51 233.19 194.26 183.82 206.20 238.63 227.88 218.52 332.13 1.16 1.11 1.06 1.61 1.00 1.00 0.76 0.00
Liver MEST ENSBTAG00000017223 22.11 20.05 20.46 19.35 20.49 31.51 18.12 19.48 42.14 1.54 0.88 0.95 2.06 0.00 0.96 0.86 0.00
Muscle MEST ENSBTAG00000017223 1136.59 969.63 1173.48 1205.39 1121.27 1308.81 1385.65 931.59 1229.94 1.17 1.24 0.83 1.10 0.59 0.97 0.33 0.90
56 Brain MKRN3 517464 14.31 10.46 17.68 16.59 14.76 14.46 12.53 16.69 14.64 1.01 1.20 0.94 0.88 0.90 0.97 0.98 0.96 NA
Kidney MKRN3 517464 NE
Liver MKRN3 517464 NE
Muscle MKRN3 517464 NE
57 Brain MST1R ENSBTAG00000015046 0.37 3.40 2.29 0.89 1.73 2.53 1.74 1.57 2.17 1.46 1.00 0.91 1.25 0.57 0.98 0.89 0.84 NA
Kidney MST1R ENSBTAG00000015046 3.75 2.73 3.60 3.95 3.51 3.87 3.30 5.27 5.04 1.10 0.94 1.50 1.44 1.00 1.00 0.29 0.52
Liver MST1R ENSBTAG00000015046 1.43 2.20 1.75 1.23 1.65 0.48 1.32 1.73 1.43 0.29 0.80 1.05 0.86 0.02 1.00 0.81 0.98
Muscle MST1R ENSBTAG00000015046 NE
58 Brain NAA60 ENSBTAG00000004875 66.16 59.55 60.33 62.44 62.12 74.34 60.73 64.12 65.48 1.20 0.98 1.03 1.05 0.83 1.00 0.99 1.00 Biallelic
Kidney NAA60 ENSBTAG00000004875 29.09 28.45 28.05 31.81 29.35 29.79 31.57 40.07 32.34 1.02 1.08 1.37 1.10 1.00 1.00 0.09 0.76 Biallelic
Liver NAA60 ENSBTAG00000004875 19.87 23.37 19.87 20.13 20.81 14.89 18.66 25.69 23.95 0.72 0.90 1.23 1.15 0.05 1.00 0.14 0.29 Biallelic
Muscle NAA60 ENSBTAG00000004875 34.48 31.60 26.58 29.35 30.50 29.74 36.24 43.03 38.39 0.98 1.19 1.41 1.26 0.97 0.95 0.07 0.25 Biallelic
59 Brain NAP1L4 ENSBTAG00000022160 145.90 135.46 150.93 152.58 146.22 221.67 187.02 153.10 129.37 1.52 1.28 1.05 0.88 0.41 0.96 0.98 0.91 Biallelic
Kidney NAP1L4 ENSBTAG00000022160 114.39 118.41 119.92 122.50 118.81 113.72 121.16 163.15 131.66 0.96 1.02 1.37 1.11 1.00 1.00 0.04 0.66 Biallelic
Liver NAP1L4 ENSBTAG00000022160 111.30 99.56 101.96 114.43 106.81 113.24 119.17 102.70 107.55 1.06 1.12 0.96 1.01 0.82 0.97 0.78 0.97 Biallelic
Muscle NAP1L4 ENSBTAG00000022160 158.73 147.17 158.90 137.07 150.47 156.19 174.63 150.81 144.25 1.04 1.16 1.00 0.96 0.89 0.96 0.99 0.69 Biallelic
60 Brain NAP1L5 ENSBTAG00000010128 218.53 50.34 74.38 156.82 125.02 15.44 18.41 21.72 50.73 0.12 0.15 0.17 0.41 0.00 0.00 0.00 0.12 Paternal
Kidney NAP1L5 ENSBTAG00000010128 6.08 5.10 4.55 4.01 4.94 9.07 6.48 7.92 8.90 1.84 1.31 1.60 1.80 0.27 1.00 0.16 0.13 Paternal
Liver NAP1L5 ENSBTAG00000010128 20.65 15.82 22.11 19.84 19.60 35.25 24.04 24.90 21.26 1.80 1.23 1.27 1.08 0.00 0.90 0.38 0.92 Paternal
Muscle NAP1L5 ENSBTAG00000010128 6.19 4.56 6.93 6.80 6.12 7.63 8.87 5.22 6.05 1.25 1.45 0.85 0.99 0.71 0.94 0.57 0.75 Paternal
61 Brain NDN ENSBTAG00000002186 66.00 57.93 96.34 86.01 76.57 87.79 68.85 71.69 79.51 1.15 0.90 0.94 1.04 0.97 0.97 0.87 0.97 NA
Kidney NDN ENSBTAG00000002186 41.56 41.18 42.14 45.13 42.50 37.50 50.89 90.08 77.37 0.88 1.20 2.12 1.82 1.00 1.00 0.00 0.00
Liver NDN ENSBTAG00000002186 13.83 12.27 12.95 14.89 13.49 12.07 12.25 17.97 15.73 0.90 0.91 1.33 1.17 0.51 1.00 0.22 0.57
Muscle NDN ENSBTAG00000002186 53.04 37.44 45.79 40.49 44.19 62.04 54.22 57.46 66.77 1.40 1.23 1.30 1.51 0.10 0.99 0.29 0.03
62 Brain NNAT ENSBTAG00000003212 872.38 971.34 1199.81 1387.23 1107.69 974.25 721.24 1088.76 909.53 0.88 0.65 0.98 0.82 0.81 0.66 0.96 0.86 Paternal
Kidney NNAT ENSBTAG00000003212 54.31 33.09 38.63 36.73 40.69 49.57 43.93 116.10 65.23 1.22 1.08 2.85 1.60 1.00 1.00 0.00 0.05 Paternal
Liver NNAT ENSBTAG00000003212 2376.18 3377.11 2645.97 2339.23 2684.62 2627.99 2255.50 3887.36 2929.25 0.98 0.84 1.45 1.09 0.75 1.00 0.00 0.40 Paternal
Muscle NNAT ENSBTAG00000003212 77.83 69.00 81.74 49.69 69.57 101.78 79.34 169.78 167.76 1.46 1.14 2.44 2.41 0.09 1.00 0.00 0.00 Paternal
63 Brain NTM ENSBTAG00000010032 206.53 121.64 197.17 273.62 199.74 67.88 74.15 106.20 97.39 0.34 0.37 0.53 0.49 0.00 0.01 0.10 0.07 Biallelic
Kidney NTM ENSBTAG00000010032 8.96 7.99 8.19 8.67 8.45 5.76 9.60 13.19 10.25 0.68 1.14 1.56 1.21 0.92 1.00 0.10 0.69 Biallelic
Liver NTM ENSBTAG00000010032 NE
Muscle NTM ENSBTAG00000010032 42.69 28.77 31.98 35.02 34.62 17.82 35.33 30.77 39.69 0.51 1.02 0.89 1.15 0.00 1.00 0.53 0.79 Biallelic
64 Brain OSBPL5 ENSBTAG00000001077 39.85 38.56 25.77 42.80 36.75 45.29 34.77 36.66 31.20 1.23 0.95 1.00 0.85 0.79 1.00 0.99 0.94 Biallelic
Kidney OSBPL5 ENSBTAG00000001077 36.74 39.62 36.99 45.03 39.60 41.54 41.29 47.63 49.52 1.05 1.04 1.20 1.25 1.00 1.00 0.54 0.34 Biallelic
Liver OSBPL5 ENSBTAG00000001077 16.47 23.02 15.52 14.41 17.35 15.77 10.10 18.07 19.98 0.91 0.58 1.04 1.15 0.94 0.19 0.46 0.11 Biallelic
Muscle OSBPL5 ENSBTAG00000001077 16.72 22.35 15.08 16.16 17.58 18.61 18.12 22.74 27.41 1.06 1.03 1.29 1.56 0.50 1.00 0.09 0.00 Biallelic
65 Brain PDE10A ENSBTAG00000007758 60.31 103.21 204.76 94.32 115.65 148.08 137.01 133.67 122.30 1.28 1.18 1.16 1.06 0.85 1.00 0.93 1.00 Biallelic
Kidney PDE10A ENSBTAG00000007758 24.15 25.75 26.74 25.74 25.59 25.36 21.78 19.18 28.16 0.99 0.85 0.75 1.10 1.00 1.00 0.00 0.78 Biallelic
Liver PDE10A ENSBTAG00000007758 9.37 8.37 15.12 19.13 13.00 12.07 12.50 15.72 27.13 0.93 0.96 1.21 2.09 0.58 1.00 0.87 0.01 Biallelic
Muscle PDE10A ENSBTAG00000007758 32.63 30.85 28.19 35.17 31.71 29.40 23.15 45.87 36.92 0.93 0.73 1.45 1.16 0.73 0.58 0.06 0.53 Biallelic
66 Brain PDE4D ENSBTAG00000000494 106.17 117.38 151.18 185.36 140.02 205.37 193.40 154.53 106.17 1.47 1.38 1.10 0.76 0.60 0.94 0.96 0.76 Biallelic
Kidney PDE4D ENSBTAG00000000494 81.13 86.65 77.59 70.66 79.01 66.21 69.90 40.11 71.54 0.84 0.88 0.51 0.91 1.00 1.00 0.00 0.75 Biallelic
Liver PDE4D ENSBTAG00000000494 17.78 15.62 10.74 14.73 14.72 16.66 14.23 15.85 14.08 1.13 0.97 1.08 0.96 0.59 1.00 0.81 0.97 Biallelic
Muscle PDE4D ENSBTAG00000000494 77.93 84.49 101.39 86.40 87.55 99.56 64.81 89.24 86.00 1.14 0.74 1.02 0.98 0.57 0.49 0.95 0.81 Biallelic
67 Brain PEG10 ENSBTAG00000038093 811.83 760.87 677.37 789.25 759.83 1105.01 801.19 807.21 1126.33 1.45 1.05 1.06 1.48 0.51 1.00 0.95 0.73 Paternal
Kidney PEG10 ENSBTAG00000038093 547.19 548.67 442.65 405.93 486.11 446.98 380.80 50.11 454.71 0.92 0.78 0.10 0.94 1.00 1.00 0.00 0.88 Paternal
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Table S4 Transcript amount and allelic expression of the imprinted genes in d105 bovine fetues
Fold Change FDR (False Discovery Rate)
read counts/million read counts/million
Liver PEG10 ENSBTAG00000038093 1625.91 1897.99 1532.44 1528.99 1646.33 649.28 1581.88 1868.60 1608.91 0.39 0.96 1.14 0.98 0.00 1.00 0.35 0.89 Paternal
Muscle PEG10 ENSBTAG00000038093 1225.38 1988.17 1701.77 1572.22 1621.89 1014.20 1259.79 2231.20 1727.38 0.63 0.78 1.38 1.07 0.07 1.00 0.09 0.62 Paternal
68 Brain PEG3 444864 612.49 583.69 513.81 618.23 582.05 466.47 353.66 553.70 945.75 0.80 0.61 0.95 1.62 0.70 0.48 0.96 0.55 Paternal
Kidney PEG3 444864 3517.10 3799.82 3347.71 3016.32 3420.24 3140.17 3248.56 4049.62 4469.42 0.92 0.95 1.18 1.31 1.00 1.00 0.59 0.13 Paternal
Liver PEG3 444864 3104.77 4228.20 3177.00 3333.73 3460.92 1700.85 2859.57 4424.07 3987.01 0.49 0.83 1.28 1.15 0.00 0.99 0.08 0.29 Paternal
Muscle PEG3 444864 625.59 880.22 632.82 688.56 706.80 583.20 613.81 1140.10 1588.45 0.83 0.87 1.61 2.25 0.58 1.00 0.00 0.00 Paternal
69 Brain PHACTR2 ENSBTAG00000016498 86.78 49.16 58.04 74.85 67.21 31.95 38.68 35.89 72.60 0.48 0.58 0.53 1.08 0.05 0.30 0.16 0.99 Biallelic
Kidney PHACTR2 ENSBTAG00000016498 208.34 207.99 214.45 175.39 201.54 242.75 182.12 85.90 139.46 1.20 0.90 0.43 0.69 0.84 1.00 0.00 0.02 Biallelic
Liver PHACTR2 ENSBTAG00000016498 19.81 21.05 20.72 23.10 21.17 17.54 19.32 22.99 18.44 0.83 0.91 1.09 0.87 0.26 1.00 0.73 0.54 Biallelic
Muscle PHACTR2 ENSBTAG00000016498 104.14 101.49 138.34 141.06 121.26 180.56 125.68 127.39 152.46 1.49 1.04 1.05 1.26 0.05 1.00 0.98 0.36 Biallelic
70 Brain PHLDA2 ENSBTAG00000031194 NE
Kidney PHLDA2 ENSBTAG00000031194 43.21 42.74 50.00 59.84 48.95 27.38 44.97 150.95 41.41 0.56 0.92 3.08 0.85 0.01 1.00 0.00 0.63 Variable
Liver PHLDA2 ENSBTAG00000031194 1.78 2.29 2.24 1.94 2.06 0.31 1.49 1.04 2.26 0.15 0.72 0.50 1.10 0.00 0.99 0.22 0.81 Maternal
Muscle PHLDA2 ENSBTAG00000031194 NE
71 Brain PLAGL1 ENSBTAG00000026523 21.10 22.07 27.59 23.71 23.62 15.33 16.59 21.39 25.00 0.65 0.70 0.91 1.06 0.47 0.85 0.91 1.00 Paternal
Kidney PLAGL1 ENSBTAG00000026523 470.11 431.33 527.64 504.18 483.32 589.16 460.04 365.83 794.09 1.22 0.95 0.76 1.64 0.78 1.00 0.00 0.00 Paternal
Liver PLAGL1 ENSBTAG00000026523 860.67 914.60 945.27 929.01 912.39 838.13 1056.23 960.16 976.15 0.92 1.16 1.05 1.07 0.60 0.86 0.81 0.71 Paternal
Muscle PLAGL1 ENSBTAG00000026523 352.32 333.15 420.19 400.83 376.62 526.53 386.30 368.13 712.79 1.40 1.03 0.98 1.89 0.05 1.00 0.83 0.00 Paternal
72 Brain PON2 ENSBTAG00000008361 70.84 36.55 43.67 58.91 52.49 12.96 17.56 15.01 26.36 0.25 0.33 0.29 0.50 0.00 0.02 0.00 0.22 Biallelic
Kidney PON2 ENSBTAG00000008361 43.74 45.79 44.43 45.23 44.80 41.44 50.16 56.86 46.00 0.93 1.12 1.27 1.03 1.00 1.00 0.24 0.95 Biallelic
Liver PON2 ENSBTAG00000008361 76.11 64.33 80.75 79.06 75.06 115.93 80.24 66.38 72.15 1.54 1.07 0.88 0.96 0.00 1.00 0.31 0.66 Biallelic
Muscle PON2 ENSBTAG00000008361 89.40 55.68 86.53 85.94 79.39 104.54 93.21 66.53 67.08 1.32 1.17 0.84 0.84 0.27 1.00 0.12 0.05 Biallelic
73 Brain PON3 ENSBTAG00000034645 NE NA
Kidney PON3 ENSBTAG00000034645 1.38 0.91 4.26 0.24 1.70 0.87 4.50 3.06 1.73 0.51 2.65 1.81 1.02 1.00 1.00 0.46 0.98
Liver PON3 ENSBTAG00000034645 5.08 4.49 39.47 7.72 14.19 12.38 7.99 21.41 20.65 0.87 0.56 1.51 1.46 0.69 0.88 0.86 0.87
Muscle PON3 ENSBTAG00000034645 4.68 3.23 1.39 3.68 3.25 0.44 7.74 0.87 10.92 0.14 2.39 0.27 3.36 0.00 0.38 0.04 0.00
74 Brain PPP1R9A ENSBTAG00000024426 252.12 259.73 272.02 291.55 268.86 311.55 285.31 284.55 271.60 1.16 1.06 1.06 1.01 0.87 1.00 0.96 0.99 Biallelic
Kidney PPP1R9A ENSBTAG00000024426 157.79 179.89 158.19 156.67 163.13 147.03 139.29 73.79 120.44 0.90 0.85 0.45 0.74 1.00 1.00 0.00 0.05 Biallelic
Liver PPP1R9A ENSBTAG00000024426 40.45 49.59 46.22 36.06 43.08 26.92 39.48 35.08 32.19 0.62 0.92 0.81 0.75 0.01 1.00 0.51 0.22 Biallelic
Muscle PPP1R9A ENSBTAG00000024426 234.87 307.48 308.65 316.98 292.00 221.04 233.35 252.65 240.67 0.76 0.80 0.87 0.82 0.17 0.91 0.61 0.28 Biallelic
75 Brain QPCT ENSBTAG00000013923 36.19 11.85 30.60 35.07 28.43 17.43 15.09 8.79 10.62 0.61 0.53 0.31 0.37 0.21 0.19 0.01 0.04 Biallelic
Kidney QPCT ENSBTAG00000013923 NE
Liver QPCT ENSBTAG00000013923 NE
Muscle QPCT ENSBTAG00000013923 18.84 10.53 15.16 16.62 15.29 17.78 27.55 9.38 5.80 1.16 1.80 0.61 0.38 0.86 0.06 0.02 0.00 Biallelic
76 Brain RASGRF1 ENSBTAG00000019940 68.36 70.81 79.02 96.85 78.76 34.26 37.79 25.41 70.99 0.44 0.48 0.32 0.90 0.03 0.13 0.01 0.93 NA
Kidney RASGRF1 ENSBTAG00000019940 5.78 6.14 6.45 6.51 6.22 4.19 5.10 4.46 7.14 0.67 0.82 0.72 1.15 1.00 1.00 0.11 0.83
Liver RASGRF1 ENSBTAG00000019940 NE
Muscle RASGRF1 ENSBTAG00000019940 NE
77 Brain RB1 ENSBTAG00000006640 47.37 55.67 59.86 46.29 52.30 56.43 49.43 54.38 43.70 1.08 0.95 1.04 0.84 0.92 1.00 0.95 0.92 Biallelic
Kidney RB1 ENSBTAG00000006640 14.01 14.81 14.58 14.03 14.36 19.39 15.26 9.27 16.12 1.35 1.06 0.65 1.12 0.69 1.00 0.00 0.79 Biallelic
Liver RB1 ENSBTAG00000006640 55.81 49.91 57.98 54.76 54.62 55.34 62.73 55.13 51.53 1.01 1.15 1.01 0.94 0.93 0.94 0.97 0.68 Biallelic
Muscle RB1 ENSBTAG00000006640 39.44 46.08 42.79 44.63 43.23 45.20 35.85 34.62 36.72 1.05 0.83 0.80 0.85 0.75 0.99 0.34 0.35 Biallelic
78 Brain RBP5 ENSBTAG00000008127 NE
Kidney RBP5 ENSBTAG00000008127 17.11 20.59 13.53 32.31 20.89 18.38 13.63 36.42 21.53 0.88 0.65 1.74 1.03 1.00 1.00 0.07 0.97 Biallelic
Liver RBP5 ENSBTAG00000008127 6.17 5.99 5.77 9.01 6.73 6.65 3.56 5.96 8.05 0.99 0.53 0.88 1.20 0.92 0.32 0.78 0.74 Biallelic
Muscle RBP5 ENSBTAG00000008127 NE
79 Brain RTL1 ENSBTAG00000046585 6.59 3.26 2.76 4.00 4.15 0.27 0.43 0.36 2.54 0.06 0.10 0.09 0.61 0.01 0.03 0.01 0.82 LE
Kidney RTL1 ENSBTAG00000046585 62.07 46.90 38.79 41.55 47.33 54.59 41.10 65.68 69.57 1.15 0.87 1.39 1.47 1.00 1.00 0.18 0.13 Paternal
Liver RTL1 ENSBTAG00000046585 3.08 7.72 2.67 2.65 4.03 1.85 1.49 13.62 4.55 0.46 0.37 3.38 1.13 0.32 0.56 0.00 0.19 LE
Muscle RTL1 ENSBTAG00000046585 97.86 147.74 95.68 92.38 108.42 57.41 74.95 127.44 86.34 0.53 0.69 1.18 0.80 0.00 0.63 0.049 0.46 Paternal
80 Brain SCIN ENSBTAG00000009786 2.03 1.73 1.38 3.08 2.06 0.70 2.05 2.00 3.03 0.34 1.00 0.97 1.47 0.30 1.00 0.97 0.93 NA
Kidney SCIN ENSBTAG00000009786 55.99 53.56 60.42 67.02 59.25 60.70 65.43 66.13 59.12 1.02 1.10 1.12 1.00 1.00 1.00 0.95 1.00
Liver SCIN ENSBTAG00000009786 NE
Muscle SCIN ENSBTAG00000009786 2.03 3.23 4.01 5.21 3.62 3.00 2.92 3.32 2.66 0.83 0.81 0.92 0.73 0.71 1.00 0.88 0.46
81 Brain SFMBT2 ENSBTAG00000005915 27.16 32.36 50.46 33.49 35.87 33.57 16.48 18.82 28.87 0.94 0.46 0.52 0.81 0.90 0.25 0.31 0.87 Biallelic
Kidney SFMBT2 ENSBTAG00000005915 35.78 32.09 30.80 32.41 32.77 27.80 26.28 22.10 32.03 0.85 0.80 0.67 0.98 1.00 1.00 0.00 0.97 Biallelic
Liver SFMBT2 ENSBTAG00000005915 11.12 10.80 11.70 10.21 10.96 5.68 8.69 11.05 11.79 0.52 0.79 1.01 1.08 0.00 0.89 0.98 0.79 Biallelic
Muscle SFMBT2 ENSBTAG00000005915 33.39 37.67 23.01 36.45 32.63 26.84 31.14 27.48 30.36 0.82 0.95 0.84 0.93 0.62 1.00 0.74 0.90 Biallelic
82 Brain SGCE ENSBTAG00000021282 36.11 29.34 43.27 46.87 38.90 38.14 45.18 32.65 38.57 0.98 1.16 0.84 0.99 0.88 1.00 0.75 0.96 Paternal
Kidney SGCE ENSBTAG00000021282 108.96 99.58 114.19 92.99 103.93 103.67 106.66 107.91 113.64 1.00 1.03 1.04 1.09 1.00 1.00 0.64 0.77 Paternal
Liver SGCE ENSBTAG00000021282 120.65 83.62 121.30 108.68 108.56 171.36 113.22 85.05 71.53 1.58 1.04 0.78 0.66 0.00 1.00 0.01 0.00 Biallelic
Muscle SGCE ENSBTAG00000021282 182.68 120.08 174.98 192.69 167.61 180.61 189.90 115.56 139.36 1.08 1.13 0.69 0.83 0.95 1.00 0.00 0.02 Paternal
83 Brain SGK2 ENSBTAG00000021033 NE NA
Kidney SGK2 ENSBTAG00000021033 15.73 12.05 13.11 18.08 14.74 11.76 12.43 28.45 11.32 0.80 0.84 1.93 0.77 1.00 1.00 0.00 0.58
Liver SGK2 ENSBTAG00000021033 NE
Muscle SGK2 ENSBTAG00000021033 NE
84 Brain SLC22A18 ENSBTAG00000012742 NE
Kidney SLC22A18 ENSBTAG00000012742 44.01 43.19 38.04 52.99 44.56 30.21 40.82 83.87 43.90 0.68 0.92 1.88 0.99 0.22 1.00 0.00 0.99 Biallelic
Liver SLC22A18 ENSBTAG00000012742 24.20 66.50 33.80 24.59 37.27 15.25 22.01 34.51 42.95 0.41 0.59 0.93 1.15 0.00 0.83 0.34 0.01 Biallelic
Muscle SLC22A18 ENSBTAG00000012742 1.94 1.68 1.00 1.69 1.58 0.69 0.74 1.92 2.15 0.44 0.47 1.22 1.36 0.15 0.71 0.70 0.49 LE
85 Brain SLC22A2 ENSBTAG00000012742 NE
Kidney SLC22A2 ENSBTAG00000009583 56.87 34.78 54.88 94.98 60.38 64.32 76.66 65.14 64.33 1.07 1.27 1.08 1.07 1.00 1.00 0.97 0.94 Bialleilc
Liver SLC22A2 ENSBTAG00000009583 5.82 2.20 7.31 9.18 6.13 9.34 6.83 4.60 4.67 1.52 1.11 0.75 0.76 0.53 1.00 0.26 0.26 Biallelic
Muscle SLC22A2 ENSBTAG00000009583 NE
86 Brain SLC22A3 ENSBTAG00000039080 19.32 9.98 8.78 14.09 13.04 2.58 5.84 3.74 8.81 0.20 0.45 0.29 0.68 0.02 0.45 0.09 0.80 Biallelic
Kidney SLC22A3 ENSBTAG00000039080 13.82 8.54 13.17 14.98 12.63 11.16 10.83 22.19 10.35 0.88 0.86 1.76 0.82 1.00 1.00 0.03 0.77 Biallelic
Liver SLC22A3 ENSBTAG00000039080 5.67 4.43 5.11 5.88 5.27 5.60 6.04 8.60 3.44 1.06 1.15 1.63 0.65 0.99 1.00 0.19 0.24 Biallelic
Muscle SLC22A3 ENSBTAG00000039080 12.42 11.11 13.29 17.38 13.55 10.00 11.51 17.10 16.72 0.74 0.85 1.26 1.23 0.19 1.00 0.53 0.60 Biallelic
87 Brain SLC38A4 ENSBTAG00000014197 3.25 3.36 1.34 3.76 2.93 0.91 1.66 1.43 2.08 0.31 0.57 0.49 0.71 0.32 0.94 0.64 0.93 LE
Kidney SLC38A4 ENSBTAG00000014197 6.58 7.37 5.73 4.72 6.10 8.86 7.21 4.19 4.90 1.45 1.18 0.69 0.80 0.98 1.00 0.12 0.77 Biallelic
Liver SLC38A4 ENSBTAG00000014197 272.25 206.72 296.73 315.65 272.84 386.17 336.30 277.09 295.07 1.42 1.23 1.02 1.08 0.01 0.85 0.80 0.97 Biallelic
Muscle SLC38A4 ENSBTAG00000014197 6.80 5.31 5.45 6.80 6.09 9.01 8.48 8.38 10.95 1.48 1.39 1.38 1.80 0.28 0.96 0.42 0.047 LE
88 Brain SNRPN ENSBTAG00000008251 370.70 232.15 341.97 416.35 340.29 387.99 262.83 238.18 270.52 1.14 0.77 0.70 0.79 0.99 0.74 0.40 0.70 Paternal
Kidney SNRPN ENSBTAG00000008251 91.92 90.58 83.22 83.18 87.23 86.96 97.03 139.38 136.14 1.00 1.11 1.60 1.56 1.00 1.00 0.00 0.00 Paternal
Liver SNRPN ENSBTAG00000008251 52.79 55.02 51.29 54.89 53.50 82.49 58.26 65.64 66.78 1.54 1.09 1.23 1.25 0.00 0.97 0.14 0.08 Paternal
Muscle SNRPN ENSBTAG00000008251 83.36 67.85 81.08 74.69 76.75 119.60 106.01 102.52 125.87 1.56 1.38 1.34 1.64 0.00 0.31 0.12 0.00 Paternal
89 Brain TBC1D12 ENSBTAG00000009693 46.93 38.52 38.22 50.32 43.50 26.36 35.59 31.23 39.41 0.61 0.82 0.72 0.91 0.28 0.95 0.59 0.94 Biallelic
Kidney TBC1D12 ENSBTAG00000009693 55.53 56.54 61.83 53.06 56.74 57.45 57.84 32.64 52.35 1.01 1.02 0.58 0.92 1.00 1.00 0.00 0.81 Biallelic
Liver TBC1D12 ENSBTAG00000009693 10.87 9.66 9.49 10.27 10.07 9.12 8.61 9.69 9.81 0.91 0.85 0.96 0.97 0.68 0.99 0.92 0.93 Biallelic
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Weight  → 392g 404g 408g 416g 514g 518g 620g 714g Alllelic
Fetus → Control #1 Control #2 Control #3 Control #4 LOS #1 LOS #2 LOS #3 LOS #4 Exrssion
Gene # Tissue Gene Name↓ Gene ID ↓ Mean LOS #1 LOS #2 LOS #3 LOS #4 LOS #1 LOS #2 LOS #3 LOS #4 in Control
Table S4 Transcript amount and allelic expression of the imprinted genes in d105 bovine fetues
Fold Change FDR (False Discovery Rate)
read counts/million read counts/million
Muscle TBC1D12 ENSBTAG00000009693 38.87 38.29 45.79 46.42 42.34 54.41 43.60 37.86 48.72 1.29 1.03 0.89 1.15 0.21 1.00 0.55 0.63 Biallelic
90 Brain TCEB3 ENSBTAG00000026585 80.72 112.35 87.08 69.59 87.43 108.98 110.86 126.90 126.96 1.25 1.27 1.45 1.45 0.57 0.82 0.32 0.55 Biallelic
Kidney TCEB3 ENSBTAG00000026585 129.20 132.90 120.05 110.36 123.13 125.65 118.05 82.97 123.00 1.02 0.96 0.67 1.00 1.00 1.00 0.00 1.00 Biallelic
Liver TCEB3 ENSBTAG00000026585 72.69 72.37 67.80 69.95 70.70 45.83 64.84 75.78 85.25 0.65 0.92 1.07 1.21 0.00 1.00 0.65 0.14 Biallelic
Muscle TCEB3 ENSBTAG00000026585 86.81 115.21 93.81 91.87 96.92 85.19 90.92 110.45 133.59 0.88 0.94 1.14 1.38 0.75 1.00 0.21 0.00 Biallelic
91 Brain TFPI2 ENSBTAG00000015844 NE
Kidney TFPI2 ENSBTAG00000015844 46.38 49.66 30.34 33.93 40.08 31.64 58.10 36.92 26.26 0.79 1.45 0.92 0.66 1.00 0.69 0.36 0.20 Biallelic
Liver TFPI2 ENSBTAG00000015844 42.26 28.74 56.01 47.59 43.65 53.71 42.66 34.36 26.07 1.23 0.98 0.79 0.60 0.60 0.97 0.07 0.00 Biallelic
Muscle TFPI2 ENSBTAG00000015844 31.17 24.74 28.76 62.37 36.76 45.89 46.59 34.15 19.01 1.25 1.27 0.93 0.52 0.77 1.00 0.72 0.01 Biallelic
92 Brain TH ENSBTAG00000026768 NE NA
Kidney TH ENSBTAG00000026768 NE
Liver TH ENSBTAG00000026768 1.03 3.11 1.58 3.17 2.22 1.28 3.19 2.15 1.62 0.58 1.43 0.97 0.73 0.51 0.88 0.91 0.85
Muscle TH ENSBTAG00000026768 NE
93 Brain TNFRSF23 ENSBTAG00000039129 7.16 6.44 3.88 2.67 5.04 3.01 3.95 5.22 5.05 0.60 0.78 1.04 1.00 0.76 1.00 0.94 0.99 Biallelic
Kidney TNFRSF23 ENSBTAG00000039129 3.33 2.99 3.08 2.56 2.99 2.48 2.61 1.76 2.69 0.83 0.87 0.59 0.90 1.00 1.00 0.07 0.93 Biallelic
Liver TNFRSF23 ENSBTAG00000039129 5.95 11.27 7.87 0.90 6.50 1.63 1.74 2.65 2.12 0.25 0.27 0.41 0.33 0.14 0.68 0.55 0.35 Biallelic
Muscle TNFRSF23 ENSBTAG00000039129 4.06 7.17 4.53 2.76 4.63 2.22 3.48 2.85 4.64 0.48 0.75 0.61 1.00 0.23 1.00 0.57 0.65 Biallelic
94 Brain TP73 ENSBTAG00000005812 2.52 6.69 5.52 1.40 4.03 4.20 6.54 3.60 14.09 1.04 1.62 0.89 3.49 0.86 0.81 0.95 0.12 NA
Kidney TP73 ENSBTAG00000005812 NE
Liver TP73 ENSBTAG00000005812 NE
Muscle TP73 ENSBTAG00000005812 4.86 8.68 3.96 4.60 5.53 6.01 4.96 2.37 1.50 1.09 0.90 0.43 0.27 0.42 1.00 0.10 0.00
95 Brain TRAPPC9 ENSBTAG00000013955 53.60 78.12 58.01 64.90 63.66 57.07 53.61 75.17 67.63 0.90 0.84 1.18 1.06 0.95 1.00 0.72 0.96 Biallelic
Kidney TRAPPC9 ENSBTAG00000013955 28.78 29.33 27.82 32.14 29.52 25.78 27.66 33.36 29.54 0.87 0.94 1.13 1.00 1.00 1.00 0.89 1.00 Biallelic
Liver TRAPPC9 ENSBTAG00000013955 15.85 28.95 18.61 16.90 20.08 13.00 15.72 27.12 25.06 0.65 0.78 1.35 1.25 0.10 1.00 0.00 0.01 Biallelic
Muscle TRAPPC9 ENSBTAG00000013955 11.24 15.58 10.24 7.82 11.22 8.52 10.06 17.26 17.68 0.76 0.90 1.54 1.58 0.69 1.00 0.02 0.01 Biallelic
96 Brain TSPAN32 ENSBTAG00000002702 3.09 2.84 1.23 1.61 2.19 1.18 1.86 3.05 2.64 0.54 0.85 1.39 1.20 0.72 1.00 0.77 0.95 NA
Kidney TSPAN32 ENSBTAG00000002702 NE
Liver TSPAN32 ENSBTAG00000002702 67.95 94.77 61.31 66.62 72.66 46.13 73.62 88.21 72.90 0.63 1.01 1.21 1.00 0.01 0.90 0.02 0.47
Muscle TSPAN32 ENSBTAG00000002702 1.46 1.77 1.26 2.05 1.64 0.69 1.30 1.95 1.58 0.42 0.80 1.19 0.97 0.11 1.00 0.70 0.98
97 Brain TSSC4 ENSBTAG00000047793 11.10 12.16 12.16 12.21 11.91 8.23 9.44 12.05 12.00 0.69 0.79 1.01 1.01 0.69 0.98 0.99 1.00 Biallelic
Kidney TSSC4 ENSBTAG00000047793 11.52 12.60 11.17 13.76 12.26 11.37 12.34 30.57 14.05 0.93 1.01 2.49 1.15 1.00 1.00 0.00 0.78 Biallelic
Liver TSSC4 ENSBTAG00000047793 17.50 22.49 17.76 17.09 18.71 19.83 14.40 22.97 22.38 1.06 0.77 1.23 1.20 0.47 0.82 0.09 0.12 Biallelic
Muscle TSSC4 ENSBTAG00000047793 14.07 14.25 12.85 10.89 13.02 11.47 11.96 14.28 13.13 0.88 0.92 1.10 1.01 0.76 1.00 0.67 0.95 Biallelic
98 Brain UBE3A ENSBTAG00000002487 128.62 160.79 184.29 164.04 159.43 164.97 176.93 173.73 138.96 1.03 1.11 1.09 0.87 0.99 1.00 0.92 0.93 Biallelic
Kidney UBE3A ENSBTAG00000002487 160.93 155.44 160.94 151.75 157.26 163.88 154.05 108.09 144.12 1.04 0.98 0.69 0.92 1.00 1.00 0.00 0.72 Biallelic
Liver UBE3A ENSBTAG00000002487 92.18 82.03 95.97 94.34 91.13 110.42 101.79 87.15 86.51 1.21 1.12 0.96 0.95 0.17 0.98 0.69 0.64 Biallelic
Muscle UBE3A ENSBTAG00000002487 187.78 192.36 203.43 189.78 193.34 225.87 184.13 165.67 142.19 1.17 0.95 0.86 0.74 0.36 1.00 0.38 0.01 Biallelic
99 Brain WIF1 ENSBTAG00000014758 NE LE
Kidney WIF1 ENSBTAG00000014758 10.26 8.96 10.06 11.84 10.28 10.53 13.25 18.50 14.70 1.02 1.29 1.80 1.43 1.00 1.00 0.01 0.30 Biallelic
Liver WIF1 ENSBTAG00000014758 NE
Muscle WIF1 ENSBTAG00000014758 0.94 1.02 0.39 0.77 0.78 2.02 1.13 1.58 4.39 2.59 1.44 2.03 5.62 0.02 0.96 0.12 0.00 LE
100 Brain WT1 ENSBTAG00000047268 NE NA
Kidney WT1 ENSBTAG00000047268 92.27 90.22 110.52 108.20 100.30 113.23 95.80 108.68 99.63 1.13 0.96 1.08 0.99 1.00 1.00 0.89 1.00
Liver WT1 ENSBTAG00000047268 NE
Muscle WT1 ENSBTAG00000047268 NE
101 Brain ZC3H12C ENSBTAG00000008732 39.53 49.26 51.11 46.56 46.62 39.32 41.39 52.26 49.21 0.84 0.89 1.12 1.06 0.82 1.00 0.88 0.99 Biallelic
Kidney ZC3H12C ENSBTAG00000008732 41.14 36.60 43.61 41.55 40.73 47.58 39.18 26.65 34.79 1.17 0.96 0.65 0.85 1.00 1.00 0.00 0.58 Biallelic
Liver ZC3H12C ENSBTAG00000008732 10.74 11.77 10.77 11.34 11.16 12.69 11.75 11.37 10.51 1.14 1.05 1.02 0.94 0.53 1.00 0.92 0.93 Biallelic
Muscle ZC3H12C ENSBTAG00000008732 36.41 36.07 41.04 43.76 39.32 43.87 33.50 35.20 34.03 1.12 0.85 0.90 0.87 0.70 0.95 0.58 0.29 Biallelic
102 Brain ZFAT ENSBTAG00000017731 9.23 15.14 11.65 11.05 11.77 18.83 19.11 18.01 16.79 1.60 1.62 1.53 1.43 0.42 0.66 0.51 0.80 Biallelic
Kidney ZFAT ENSBTAG00000017731 13.28 15.95 13.66 14.13 14.26 13.50 16.65 12.74 15.81 0.95 1.17 0.89 1.11 1.00 1.00 0.29 0.83 Biallelic
Liver ZFAT ENSBTAG00000017731 3.46 4.29 3.33 3.62 3.67 2.56 4.76 4.94 5.39 0.70 1.30 1.35 1.47 0.45 0.93 0.39 0.24 Biallelic
Muscle ZFAT ENSBTAG00000017731 8.64 10.76 9.24 11.20 9.96 7.48 10.03 12.01 14.03 0.75 1.01 1.21 1.41 0.42 1.00 0.46 0.14 Biallelic
103 Brain ZFP64 ENSBTAG00000001512 28.55 39.15 33.25 37.29 34.56 46.96 41.70 47.87 52.03 1.36 1.21 1.39 1.51 0.58 0.97 0.57 0.66 Biallelic
Kidney ZFP64 ENSBTAG00000001512 32.49 34.78 35.03 33.59 33.97 38.23 27.82 24.63 30.78 1.13 0.82 0.72 0.91 1.00 1.00 0.00 0.75 Biallelic
Liver ZFP64 ENSBTAG00000001512 8.03 10.01 7.35 7.46 8.21 7.31 6.25 9.79 9.86 0.89 0.76 1.19 1.20 0.91 0.98 0.46 0.38 Biallelic
Muscle ZFP64 ENSBTAG00000001512 28.05 28.55 27.01 25.61 27.31 30.38 25.09 34.54 33.41 1.11 0.92 1.26 1.22 0.57 1.00 0.21 0.29 Biallelic
104 Brain ZNF215 ENSBTAG00000003638 13.13 20.96 9.84 14.57 14.63 6.62 8.08 6.76 7.22 0.45 0.55 0.46 0.49 0.38 0.86 0.48 0.70 NA
Kidney ZNF215 ENSBTAG00000003638 11.21 11.33 11.14 11.20 11.22 9.77 10.67 11.61 8.83 0.87 0.95 1.04 0.79 1.00 1.00 0.79 0.59
Liver ZNF215 ENSBTAG00000003638 4.70 6.90 2.70 4.65 4.74 4.67 3.27 3.12 2.29 0.99 0.69 0.66 0.48 0.76 1.00 0.67 0.25
Muscle ZNF215 ENSBTAG00000003638 6.71 14.34 5.14 7.16 8.34 4.09 4.54 4.80 3.76 0.49 0.54 0.58 0.45 0.22 0.95 0.49 0.08
105 Brain ZNF331 ENSBTAG00000016513 30.09 32.18 39.42 35.03 34.18 47.71 44.13 31.23 29.29 1.40 1.29 0.91 0.86 0.64 0.97 0.91 0.91 Biallelic
Kidney ZNF331 ENSBTAG00000016513 29.70 32.44 31.95 32.48 31.64 32.48 32.23 30.21 25.81 1.03 1.02 0.95 0.82 1.00 1.00 0.26 0.40 Biallelic
Liver ZNF331 ENSBTAG00000016513 5.45 5.64 5.01 5.78 5.47 5.46 6.29 4.82 4.81 1.00 1.15 0.88 0.88 0.99 1.00 0.84 0.82 Biallelic
Muscle ZNF331 ENSBTAG00000016513 12.28 11.07 12.42 14.52 12.57 14.08 13.23 10.04 10.75 1.12 1.05 0.80 0.86 0.80 1.00 0.37 0.39 Biallelic
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Gene Name↓ Mean CPM Min CPM Max CPM Brain Kidney Liver Muscle
AIM1 26.27 10.35 58.91 0.63 2.11 0.73 0.54
AMPD3 9.06 4.42 15.79 1.48 0.52 0.00 0.00
ANO1 10.32 1.25 27.72 0.22 1.40 2.13 0.25
ART5 16.38 1.74 65.16 0.00 0.00 1.87 0.13
ASB4 13.73 0.82 35.95 0.00 0.00 0.12 1.88 CPM: counts per million
ATP10A 9.26 2.18 15.19 0.32 1.51 0.00 1.17 Mean CPM: average of CPM of all tissue analyzed in control fetues
AXL 40.05 16.94 81.93 0.95 1.02 0.47 1.55 Min: mimum CPM in tissues of control fetuses
BEGAIN 28.35 10.09 53.25 1.65 0.85 0.48 1.01 Max: maximum CPM in tissues of control fetuses
BLCAP 175.00 59.01 362.57 1.55 0.34 0.82 1.29 CPM ratio: the average CPM of each tissue was divded by Mean CPM
CALCR 18.11 8.49 39.69 1.02 0.00 0.00 0.98 Boxed = not expressed
CASD1 110.16 15.80 179.98 1.33 1.17 0.17 1.33
CD81 162.45 120.49 227.68 1.05 0.93 0.86 1.16
CDKN1C 90.09 8.24 252.95 0.17 1.03 0.77 2.02
CMAH 19.00 1.45 39.89 0.00 0.10 1.90 0.00
CNTN3 26.01 6.41 53.32 0.99 0.30 0.00 1.71
COBL 53.27 6.72 165.52 0.29 0.64 0.17 2.91
COMMD1 33.42 14.09 55.81 0.82 1.22 0.48 1.48
COPG2 29.44 9.51 56.79 1.61 0.65 0.33 1.42
CPA4 32.79 1.13 114.68 0.35 0.50 0.05 3.10
DCN 580.25 21.16 2079.08 0.09 0.84 0.13 2.95
DDC 12.61 5.77 20.23 0.00 0.56 1.44 0.00
DHCR7 66.42 19.53 135.74 1.58 0.59 1.42 0.41
DIO3 7.95 6.76 9.40 0.00 1.00 0.00 0.00
DIRAS3 271.25 15.38 688.40 1.92 0.08 0.00 0.00
DLGAP2 26.85 17.61 32.88 1.00 0.00 0.00 0.00
DLK1 685.60 4.61 1637.22 0.02 0.73 1.32 1.93
DLX5 6.17 0.94 13.07 1.00 0.00 0.00 0.00
DNMT1 91.20 67.66 125.51 0.87 1.06 1.25 0.82
DRD1A 17.57 7.28 35.83 1.00 0.00 0.00 0.00
FBXO40 15.11 3.22 28.77 0.00 1.76 0.00 0.24
GATM 408.71 11.15 1228.00 0.30 0.92 2.74 0.04
GDAP1L1 61.31 53.31 64.79 1.00 0.00 0.00 0.00
GLIS3 6.97 1.70 14.39 0.90 1.73 0.00 0.37
GNAS 2024.94 1038.77 3009.67 0.92 1.20 0.53 1.35
GPR1 0.69 0.49 0.86 1.00 0.00 0.00 0.00
GRB10 32.43 18.26 42.72 0.72 0.90 1.23 1.15
GTL2 4365.28 1587.00 12651.22 0.68 0.64 0.45 2.23
H13 45.13 28.97 65.23 0.78 1.32 1.07 0.84
H19 7243.57 18.75 16180.77 0.01 1.93 0.84 1.23
HTR2A 7.11 1.26 20.00 2.05 0.75 0.20 0.00
HTRA3 22.53 6.91 47.36 0.00 0.35 0.00 1.65
IGF2 6128.87 14.96 12219.01 0.01 1.62 0.75 1.63
IGF2R 495.40 37.50 868.58 0.11 1.43 1.03 1.43
IMPACT 68.55 29.16 98.52 1.11 1.05 0.46 1.39
INPP5F 224.82 28.54 837.85 3.00 0.27 0.15 0.58
JADE1 46.30 23.98 76.00 0.93 1.21 0.57 1.29
KCNK9 9.76 6.82 13.41 1.00 0.00 0.00 0.00
KCNQ1 18.93 3.92 47.85 0.56 1.14 0.40 1.91
KLF14 3.83 2.63 5.76 0.00 0.85 0.00 1.15
L3MBTL1 20.88 6.14 54.98 2.14 0.75 0.36 0.75
LIN28B 17.23 4.16 32.61 0.38 0.00 1.62 0.00
LRRTM1 29.83 24.89 33.80 1.00 0.00 0.00 0.00
MAGEL2 20.10 5.67 45.23 1.76 0.95 0.41 0.88
MAGI2 33.74 19.50 51.52 1.39 0.61 0.00 0.00
MEST 367.35 19.35 1205.39 0.33 0.56 0.06 3.05
MKRN3 14.76 10.46 17.68 1.00 0.00 0.00 0.00
MST1R 2.30 0.37 3.95 0.75 1.53 0.72 0.00
NAA60 35.69 19.87 66.16 1.74 0.82 0.58 0.85
NAP1L4 130.58 99.56 158.90 1.12 0.91 0.82 1.15
NAP1L5 38.92 4.01 218.53 3.21 0.13 0.50 0.16
NDN 44.19 12.27 96.34 1.73 0.96 0.31 1.00
NNAT 975.64 33.09 3377.11 1.14 0.04 2.75 0.07
NTM 80.94 7.99 273.62 2.47 0.10 0.00 0.43
OSBPL5 27.82 14.41 45.03 1.32 1.42 0.62 0.63
PDE10A 46.49 8.37 204.76 2.49 0.55 0.28 0.68
PDE4D 80.33 10.74 185.36 1.74 0.98 0.18 1.09
PEG10 1128.54 405.93 1988.17 0.67 0.43 1.46 1.44
PEG3 2042.50 513.81 4228.20 0.28 1.67 1.69 0.35
PHACTR2 102.79 19.81 214.45 0.65 1.96 0.21 1.18
PHLDA2 25.50 1.78 59.84 0.00 1.92 0.08 0.00
PLAGL1 448.99 21.10 945.27 0.05 1.08 2.03 0.84
PON2 62.94 36.55 89.40 0.83 0.71 1.19 1.26
PON3 6.38 0.24 39.47 0.00 0.27 2.23 0.51
PPP1R9A 191.77 36.06 316.98 1.40 0.85 0.22 1.52
QPCT 21.86 10.53 36.19 1.30 0.00 0.00 0.70
RASGRF1 42.49 5.78 96.85 1.85 0.15 0.00 0.00
RB1 41.13 14.01 59.86 1.27 0.35 1.33 1.05
RBP5 13.81 5.77 32.31 0.00 1.51 0.49 0.00
RTL1 40.98 2.65 147.74 0.10 1.15 0.10 2.65
Table S5 Imprinted gene expression profile in each tissue of control fetuses 
CPM ratio to the average
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Gene Name↓ Mean CPM Min CPM Max CPM Brain Kidney Liver Muscle
Table S5 Imprinted gene expression profile in each tissue of control fetuses 
CPM ratio to the average
SCIN 21.64 1.38 67.02 0.10 2.74 0.00 0.17
SFMBT2 28.06 10.21 50.46 1.28 1.17 0.39 1.16
SGCE 104.75 29.34 192.69 0.37 0.99 1.04 1.60
SGK2 14.74 12.05 18.08 0.00 1.00 0.00 0.00
SLC22A18 27.80 1.00 66.50 0.00 1.60 1.34 0.06
SLC22A2 33.25 2.20 94.98 0.00 1.82 0.18 0.00
SLC22A3 11.12 4.43 19.32 1.17 1.14 0.47 1.22
SLC38A4 71.99 1.34 315.65 0.04 0.08 3.79 0.08
SNRPN 139.44 51.29 416.35 2.44 0.63 0.38 0.55
TBC1D12 38.16 9.49 61.83 1.14 1.49 0.26 1.11
TCEB3 94.55 67.80 132.90 0.92 1.30 0.75 1.03
TFPI2 40.16 24.74 62.37 0.00 1.00 1.09 0.92
TH 2.22 1.03 3.17 0.00 0.00 1.00 0.00
TNFRSF23 4.79 0.90 11.27 1.05 0.62 1.36 0.97
TP73 4.78 1.40 8.68 0.84 0.00 0.00 1.16
TRAPPC9 31.12 7.82 78.12 2.05 0.95 0.65 0.36
TSPAN32 25.50 1.23 94.77 0.09 0.00 2.85 0.06
TSSC4 13.97 10.89 22.49 0.85 0.88 1.34 0.93
UBE3A 150.29 82.03 203.43 1.06 1.05 0.61 1.29
WIF1 5.53 0.39 11.84 0.00 1.86 0.00 0.14
WT1 100.30 90.22 110.52 0.00 1.00 0.00 0.00
ZC3H12C 34.46 10.74 51.11 1.35 1.18 0.32 1.14
ZFAT 9.91 3.33 15.95 1.19 1.44 0.37 1.00
ZFP64 26.01 7.35 39.15 1.33 1.31 0.32 1.05
ZNF215 9.73 2.70 20.96 1.50 1.15 0.49 0.86
ZNF331 20.97 5.01 39.42 1.63 1.51 0.26 0.60
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Table S6. Validation of SNPs identified by RNAseq using Sanger sequencing 
Sanger Sequencing of genomic DNA RNAseq (F1 hybrid fetuses) 
Gene symbol Chr Position 
Reference 
(UMD3.1) 
B. t. 
taurus 
B. t. 
indicus 
F1 hybrid 
 fetuses 
Reference 
 allele 
Alternative 
 allele SNP flanking Sequence 
MEST* 4 95073135 A A A A/A(LOS #4) A G 
SGCE 4 11856585 C C T NA C T atcaggttga(C/T)agaacaaagc 
PEG10 4 11921764 T T C NA T C caccttgacc(T/C)ggaacttcag 
PEG10 4 11921800 T T C NA T C gcattgttca(T/C)tggctggaag 
PEG10 4 11921824 G G A NA G A  gccacctgaa(G/A)tcttgggagc 
PEG10 4 11922094 T T C NA T C ctgacttcct(T/C)tagcctggcc 
PEG10 4 11922259 G G C NA G C ctgggagcat(G/C)tgtttcaaca 
PEG10 4 11922533 A A C NA A C tcttaaatca(A/C)ttaaaattga 
NAP1L5 6 37510035 C C T NA C T taaaatacta(C/T)gaaattgacg 
NAP1L5 6 37510055 C C T NA C T gcaatcagat(C/T)atgcccagcg 
NAP1L5 6 37510166 A A G NA A G tgtgaggact(A/G)gagttgagac 
NAP1L5 6 37510180 C C A NA C A ttgagactta(C/A)taagggtgtc 
NAP1L5 6 37510241 A A G NA A G tcgtcacagt(A/G)tcgcactagg 
NAP1L5 6 37510307 G G C NA G C tcttccattt(G/C)ttttgcattt 
NAP1L5 6 37510534 C C T N/A C T atgacctgta(C/T)aatattgtc 
NAP1L5 6 37510546 T T C NA T  C atattgtcaa(T/C)gtgtgtgttc 
NNAT 13 67120130 A A/T A/T A/T(LOS #4) A T cagcaccgac(A/T)atgacgacaa 
NNAT 13 67120164 C C/T C/T C/T(LOS #4) C T ccccacccct(C/T)tgcacccctc 
NNAT 13 67120187 G G/T G/T G/T(LOS #4) G T actgcgggtg(G/T)cctagaggga 
NNAT 13 67120502 G G/A G/A G/A(LOS #4) G A ctttgcctac(G/A)gcatgtgcat 
NNAT 13 67120662 C C/T C/T C/T(LOS #4) C T ccctcactga(C/T)cttgaatccc 
PEG3 18 64275301 C T C NA C T agaagaacat(C/T)gagcgcaaga 
PEG3 18 64275316 C C G NA C  G aggcacgtgc(C/G)aagaagaaga 
PEG3 18 64275553 A A G NA A G gcctcaggga(A/G)gacggggagcc 
PEG3 18 64275646 T T C NA T C gccccgaaga(T/C)ggccaggagg 
PEG3 18 64275685 C C C/T NA C T aggatgagga(C/T)gaagagaagg 
PEG3 18 64275732 G G G/A NA G A gtccatgccc(G/A)gctctcagaa 
PEG3 18 64281735 T T C/T C/T(LOS #3, #4, and Control #4) T  C aggcgatgta(T/C)gagccggaag 
PEG3 18 64281750 T T C/T C/T(LOS #3, #4); T/T(Control #4) T  C tcctggaaga(T/C)tacgaggcga 
MAGEL2 21 783853 A A C A/C(LOS #4) A  C aggtgcaaac(A/C)cccatccaat 
MAGEL2 21 784015 C C T C/T(LOS #4) C T gggccctggg(C/T)ctctgggaaa 
MAGEL2 21 784070 C C T C/T(LOS #4) C T gctccctact(C/T)ttgctcaggg 
MAGEL2 21 784354 T T C T/C(LOS #4) T C tcaacaaggg(T/C)agaaagggtg 
MAGEL2 21 784789 T T C T/C(LOS #3) T C ataaaaccga(T/C)gaccccacca 
SNRPN 21 8725 A A G NA A G agcttgcatt(A/G)tttgtaagag 
SNRPN 21 19911 A A G NA A G gcctcactga(A/G)caaccaggag 
SNRPN* 21 25855 C C C C/C(LOS #4) C  A 
Two SNPs (indicated by asterisk) were not confirmed by Sanger sequencing. Chr: Chromosome. UMD3.1 reference: B. t. taurus reference genome assembly; LOS: large offspring 
syndrome; NA: not analyzed; SNP: single nucleotide polymorphism;  
DMRs Chr Position B. t. taurus B. t. indicus F1 hybrid fetus SNP flanking sequence 
PLAGL1 DMR 9 82473774 G T G/T(LOS #4, Control #4 ) acgggcggac(G/T)gggcggctct 
SNRPN DMR 21 26268 A G A/G(LOS #4, Control #2, #4) ttaacaaaaa(A/G)gaaataccca 
NNAT DMR 13 67118693 G A/G G/G(Control #4), G/A (Control #2, LOS #3, #4) ttctggggac(G/A)cgcatcggga 
Table S7. Identification of SNPs at DMRs by Sanger sequencing 
DMR: differentially methylated region; Chr: Chromosome; The chromosome positions are based on UMD3.1 reference assembly. 
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Table S8. PCR primer information 
Genes Amplicon locations Primer types Primer sequences (5’-3’) Annealing temperature Amplicon size Assays 
MEST  Chr 4: 95072724-95073233 Forward CTAGATGGTACAGCGTTGAG 59.1°C 510bp gDNA-PCR for SNP validation 
Reverse CGTCACTGCCGTTTCTAA 
SGCE  Chr 4: 11856803-11856067 Forward GGACCTAGAAAGGCCAATATAA 59.1°C 737bp gDNA-PCR for SNP validation 
Reverse GTTCCACAGTCTCTGCTTAC 
PEG10  Chr 4: 11921664-11922608 Forward CAGTCATGTATGAGGGCTAATG 62.3°C 945bp gDNA-PCR for SNP validation 
Reverse GCCTCTTATTCACAGTGTTGTA 
NAP1L5  Chr 6:  36808477-36809288 Forward CTGCCGCCAAAGATGAG 59.1°C 812bp gDNA-PCR for SNP validation 
Reverse GGGATTTAATGCTTAAACAATTGGG 
NNAT Chr 13: 67119624-67120409 Forward CCATTGCGAGAAGTGAGGTAT 58.4°C 804bp gDNA-PCR for SNP validation 
Reverse ACACAGGCACAGAGTTGTC 
NNAT  Chr 13: 67120338-67120931 Forward TACACCAGCCAGCAGAATG  58.4°C 615bp gDNA-PCR for SNP validation 
Reverse ACCCAGACCAGTCTTAGAAGTA 
PEG3 Chr 18: 64275728-64275179 Forward CTCAGAAGAGTCACACGATCAC 59.8°C 550bp gDNA-PCR for SNP validation 
Reverse GAGCTACGGACAAAGAACTCTC 
PEG3 Chr 18: 64276162-64275271 Forward CCTGATTGAGCACCAGAAGAT 59.8°C 892bp gDNA-PCR for SNP validation 
Reverse CATCATGGAGGCGTCGTAAT 
PEG3  Chr 18: 64282227-64281459 Forward GGGACATGTGTGTCTCCTTAC 59.8°C 770bp gDNA-PCR for SNP validation 
Reverse GCTGCTGTTGTCGTCTGA 
MAGEL2  Chr 21: 783758-784573 Forward GAGGAGGATAGTAGTGGCAAGA 58.4°C 816bp gDNA-PCR for SNP validation 
Reverse CTCCAGGTACTTCTCCCTTACA 
MAGEL2  Chr 21: 784158-784946 Forward TGCAGTTCCTCTTGGTTAAGG 58.4°C 789bp gDNA-PCR for SNP validation 
Reverse GAAATCCAAACTTACACACACAGA 
SNRPN  Chr 21: 8930-8548 Forward TGGGAGATAAGGTCATCAAATAG 59.1°C 383bp gDNA-PCR for SNP validation 
Reverse CACCTCACACTCTGGAAATC 
SNRPN  Chr 21: 20218-19677 Forward GGGCTAGATTCTGACCATTG 59.1°C 542bp gDNA-PCR for SNP validation 
Reverse GCTGAAGGAGGTAGAACTTTAT 
SNRPN  Chr 21: 26236-25797 Forward ACCACTCTGGGTTGAAGTA 59.1°C 440bp gDNA-PCR for SNP validation 
Reverse CTGGAAGCTCAGGATGATTAAA 
PLAGL1  Chr 9: 82419707-82420135 Forward CTGCGACAGATGCTTCTAC 60.7°C 429bp RT-PCR for allelic expression  
Reverse GCGCTGTACTTGTGATTCT 
PEG3  Chr 18: 64280579-64281817 Forward GGATCAAGCCTTGGGTGTA 64.7°C 299bp RT-PCR for allelic expression 
Spanning 2 introns Reverse GTCCCGTGACTCCATGTC 
SNRPN Chr 21: 8676-19987 Forward CACTTGAGACGGACTACAGAAC 63.7°C 302bp RT-PCR for allelic expression 
Spanning 2 introns Reverse ACCTAAGGGAAGGCTACAGATA 
NNAT Chr 13: 67120319-67120605 Forward CCACAGAGATCCAGACAACTAC 63.1°C 287bp RT-PCR for allelic expression 
Reverse CGTGCTCAGTAGGTCCAAAT 
PALGL1 DMR Chr 9: 82473614-82473911  Forward GTTGAGGGYGGTAAAAGTTTA 60.5°C 298bp DNA methylation assay 
Reverse CRACTACAAACCTCCCCAC 
SNRPN DMR Chr 21: 25757-26322 Forward TGGAAAGTTTGAGGAAATTTGA 60.5°C Touchdown PCR 566bp DNA methylation assay 
Reverse AAAACCCAAATCCCCAATAAAT See SI methods 
NNAT DMR Chr 13: 67118612-67118953  Forward ATTTGGTGTAGTAGGATTTTTTTAT 60.5°C Touchdown PCR 342bp DNA methylation assay 
Reverse CTCATCATCRACTAATACATTTTCC See SI methods 
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Chapter 3 Global misregulation of genes largely uncoupled to DNA 
methylome epimutations characterizes a congenital overgrowth 
syndrome 
3.1 Abstract 
 Assisted reproductive therapies (ART) have become increasingly common 
worldwide and numerous retrospective studies have indicated that ART-conceived 
children are more likely to develop the overgrowth syndrome Beckwith-Wiedemann 
(BWS).  In bovine, the use of ART can induce a similar overgrowth condition, which is 
referred to as large offspring syndrome (LOS).  Both BWS and LOS involve 
misregulation of imprinted genes.  However, it remains unknown whether molecular 
alterations at non-imprinted loci contribute to these syndromes.  Here we examined the 
transcriptome of skeletal muscle, liver, kidney, and brain of control and LOS bovine 
fetuses and found that different tissues within LOS fetuses have perturbations of distinct 
gene pathways.  Notably, in skeletal muscle, multiple pathways involved in myoblast 
proliferation and fusion into myotubes are misregulated in LOS fetuses.  Further, 
characterization of the DNA methylome of skeletal muscle demonstrates numerous local 
methylation differences between LOS and controls; however, only a small percent of 
differentially expressed genes (DEGs), including the imprinted gene IGF2R, could be 
associated with the neighboring differentially methylated regions.  In summary, we not 
only show that misregulation of non-imprinted genes and loss-of-imprinting characterize 
the ART-induced overgrowth syndrome but also demonstrate that most of the DEGs is 
not directly associated with DNA methylome epimutations.    
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3.2 Introduction 
 The use of ART has become increasingly common worldwide and each year 
approximately six percent of infants born in developed countries are conceived 
employing these technologies (European et al., 2016).   The use of ART involves 
manipulation of gametes and/or embryos in an artificial environment, and it has been 
reported that ART-conceived children have increased risk for birth defects 
(Grafodatskaya et al., 2013).  For example, a meta-analysis of eight epidemiologic studies 
indicates that ART-conceived children have a 5.2-fold increased likelihood of developing 
the congenital overgrowth condition BWS (Vermeiden and Bernardus, 2013).  However, 
it is still unresolved whether the use of ART or the infertility per se is the main cause of 
the loss-of-imprinting disorders observed in ART-conceived humans(Vermeiden and 
Bernardus, 2013).  BWS is characterized by complex and variable symptoms including 
pre- and post-natal overgrowth, enlarged tongue, ear malformation, umbilical hernia, and 
predisposition to develop childhood tumors (Weksberg et al., 2010).   In ruminants, 
gametes and embryos subjected to in vitro manipulations can develop into unusually 
large offspring that share phenotypes with BWS (Chen et al., 2013; Young et al., 1998).  
LOS, as the congenital overgrowth syndrome is referred to in ruminants, can cause 
detrimental effects to both the dam and offspring such as delivery difficulty due to the 
oversized fetus and inability for the newborn to stand and to suckle (Young et al., 1998).  
It is not clear what triggers the development of these congenital overgrowth conditions 
and associated phenotypes and why ART potentiates the syndromes.  Numerous animal 
studies have indicated that the use of ART can alter the epigenome of the gametes and 
embryos (de Waal et al., 2012a; de Waal et al., 2012b; Market-Velker et al., 2010; Rivera 
	   94 
et al., 2008) and this can contribute to the etiology of the ART-induced overgrowth 
conditions (Kuentz et al., 2011; Vermeiden and Bernardus, 2013).   
 DNA methylation is an epigenetic modification involving the addition of a methyl 
group to the 5th carbon of cytosine (Smith and Meissner, 2013).  In mammals, DNA 
methylation typically occurs in a CpG context with the exception of CpH methylation, 
which is mostly observed in neural tissues, oocytes and embryonic stem cells (He and 
Ecker, 2015; Shirane et al., 2013).  DNA methylation plays a key role in many biological 
processes such as regulation of tissue-specific gene expression, suppression of parasite 
DNA in the genome, X-chromosome inactivation, and genomic imprinting (Smith and 
Meissner, 2013).  Genomic imprinting is an epigenetic phenomenon in which a subset of 
genes, known as imprinted genes, are transcribed monoallelically in a parental-origin-
dependent manner (Bartolomei and Ferguson-Smith, 2011).  The transcriptional 
asymmetry of the parental alleles is usually directed by allele-specific DNA methylation 
(ASM) at imprinted loci established during gametogenesis (Bartolomei and Ferguson-
Smith, 2011).  Proper allele-specific DNA methylation and allele-specific expression of 
imprinted genes play important roles in the regulation of embryonic and neonatal growth, 
placental function, postnatal behavior, and metabolism (Plasschaert and Bartolomei, 
2014). Altered gene expression and DNA methylation at imprinted loci have been 
associated with congenital overgrowth disorders such as BWS in human (Kalish et al., 
2014) and LOS in bovine (Chen et al., 2015; Chen et al., 2013).  
 Most BWS cases are sporadic and have been linked to two imprinted loci on 
chromosome 11p15.5, the KCNQ1 locus and the H19/IGF2 locus (Weksberg et al., 2010).  
Approximately 50% of the BWS cases are associated with the hypomethylation of 
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KvDMR1 at the KCNQ1 locus and 2-7% are linked to the hypermethylation of the 
differentially methylated region (DMR) at the H19/IGF2 locus (Weksberg et al., 2010).  
In addition, studies have shown that a subset of BWS patients with epimutation at the 
KCNQ1 locus also exhibit abnormal DNA methylation at other imprinted loci 
(Eggermann et al., 2016).  We have observed loss of methylation of the KvDMR1 on the 
maternal allele in LOS (Chen et al., 2013) and have reported that LOS is a multi-locus 
loss-of-imprinting condition in which aberrant imprinted gene expression is associated 
with tissue-specific loss of imprinted DNA methylation (Chen et al., 2015).   
 Although it is well accepted that loss-of-imprinting can contribute to these 
overgrowth syndromes, and as such have been coined “loss-of-imprinting syndromes”, it 
remains unknown whether aberrant gene expression and DNA methylation occur at non-
imprinted loci and to what extent these molecular alterations contribute to the variable 
phenotypes observed in these conditions.  To address this question, we examined the 
transcriptome of skeletal muscle, liver, kidney, and brain of four control and four LOS 
day ~105 Bos taurus indicus (B. t. indicus) × Bos taurus taurus (B. t. taurus) F1 fetuses 
(Chen et al., 2015).  We found that different LOS fetuses exhibit different numbers of 
DEGs and that each tissue within LOS fetuses have perturbations of distinct gene 
pathways.  Notably, in skeletal muscle, multiple pathways involved in myoblast 
proliferation and fusion into myotubes are misregulated in LOS fetuses.  Further, 
characterization of the DNA methylome of skeletal muscle revealed numerous local 
methylation differences between LOS and controls; however, very few DEGs could be 
linked to neighboring identified DMRs.  This study indicates that global misregulation of 
non-imprinted genes in addition to loss-of-imprinting characterizes the ART-induced 
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overgrowth syndrome.  The observation that most identified DMRs could not be directly 
associated with aberrant gene expression suggests that caution should be exercised when 
making conclusions about the etiology of such syndromes by interpreting time-point-
specific DNA methylation data.    
 
3.3 Results 
 Identification and characterization of DEGs in LOS fetuses 
 In order to determine to what extent the transcriptome is altered in bovine LOS 
fetuses, we analyzed RNA sequencing (RNAseq) data of skeletal muscle, liver, kidney, 
and brain from four control and four LOS day ~105 (d104-106) B. t. indicus × B. t. taurus 
F1 fetuses that we generated in a previous study (Chen et al., 2015) (Table 1).  These 
tissues were selected because they represent the three primary germ layers (i.e., liver for 
endoderm, kidney and skeletal muscle for mesoderm, and brain for ectoderm).  Only 
females were used in this study to avoid any potential sex-specific gene expression 
(Ingleby et al., 2014b).  The average bodyweight for control and LOS fetuses was 405g 
[standard deviation (SD) = 10g, range = 24g] and 592g (SD = 95g, range = 200g), 
respectively (p = 0.008) (Table 1).  The bodyweight differences between the control and 
LOS fetuses are not expected to be due to paternal effects because all fetuses were sired 
by one Nelore bull [ABS CSS MR N OB 425/1 677344 29NE0001 97155 (i.e., B. t. 
indicus)](Chen et al., 2013). 
 As LOS fetuses exhibited dramatic difference in bodyweight, each LOS fetus was 
considered individually and was compared to the mean of the four controls to identify 
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DEGs.  To ensure the validity of grouping four control fetuses for DEG identification, 
principle component analyses (PCA) were performed using the normalized RNAseq read 
counts.  For RNAseq the expression libraries of kidney, skeletal muscle, and liver, 
control fetuses clustered while the libraries from the LOS fetuses did not (Fig. S1).  It 
should be noted that the RNAseq libraries of skeletal muscle and liver from Control #2 
fetus were sequenced with 50bp read length; while the RNAseq reads of other fetuses 
were of 100bp.  The read length differences may explain why Control #2 is segregated 
from other control fetuses in these two tissue types.  In brain, both control and LOS 
fetuses exhibited a segregated pattern in the PCA plot (Fig. S1).  In order to minimize the 
false positive DEGs caused by natural biological variation and technical variation, the 
DEGs were identified with the consideration of variance among the controls and the 
RNAseq read length differences using the edgeR package as we previously described 
(Anders et al., 2013; Chen et al., 2015; Robinson et al., 2010).  The number of DEGs 
varied between tissues for different LOS fetuses (Fig. S2).  For example, in the largest 
LOS fetus analyzed (weight = 714g), the number of DEGs was 3868, 1581, 441, and 276 
for skeletal muscle, liver, kidney, and brain, while in the smallest LOS fetus (weight = 
514g), the number of DEGs for those tissues were 2270, 3232, 139, and 1106 (Fig. S2).  
The number of DEGs was not associated with fetal weight, but the fetuses with loss-of-
imprinting at the KCNQ1 locus (i.e., LOS #1 and #4) had more DEGs in liver and 
skeletal muscle than LOS fetuses with correct imprinting at this locus (Fig. S2).   Next, 
we performed Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses 
(Huang da et al., 2009) to gain biological insights of the DEGs identified in the LOS 
fetuses.  We found that several KEGG pathways were shared by DEGs in different  
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Figure 1.  KEGG pathway analyses of DEGs in somatic tissues of LOS fetuses.  A). KEGG 
pathways enriched for DEGs in skeletal muscle and liver (FDR < 0.05).  Shown here are examples of 
tissues with the most DEGs.  B). KEGG pathways enriched for upregulated and downregulated genes 
in skeletal muscle and liver (FDR < 0.05).  DEG: differentially expressed genes; LOS: large offspring 
syndrome. 
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tissues while others were unique for a particular tissue (Fig. 1A and Fig. S2).  For 
example, “ribosome” and “oxidative phosphorylation” were enriched in DEGs in skeletal 
muscle, liver, and kidney, while “pathways in cancer” was unique for skeletal muscle 
(Fig. 1A and Fig. S2), suggesting the over-proliferation of the muscle cells in LOS 
fetuses.  Further analyses revealed that even the common pathways could be 
differentially represented in different tissues.  For instance,  “ribosome” and “oxidative 
phosphorylation” were enriched with downregulated genes in skeletal muscle but 
enriched with upregulated genes in liver and kidney (Fig. 1B and Fig. S2).  For brain, 
however, misregulated genes were only found to enrich two KEGG pathways (Fig. S2).  
Overall, we found that numbers of DEGs varied among LOS fetuses and different tissues 
within LOS fetuses have perturbations of distinct gene pathways. 
 Multiple pathways involved in myoblast proliferation and fusion into myotubes 
are misregulated in LOS  
  To identify DEGs correlated with the overgrowth phenotype of the LOS fetuses, 
weighted gene correlation network analyses (WGCNA) (Langfelder and Horvath, 2008) 
were used to identify clusters of genes that were highly interconnected, namely modules, 
and to determine which modules were correlated with bodyweight of the fetuses.  For all 
the tissues analyzed, three modules [i.e., turquoise, red, and green (Fig. S3)] in skeletal 
muscle were identified to be significantly correlated (p-value < 0.05) with bodyweight 
and were enriched with the KEGG pathways associated with overgrowth phenotype (Fig. 
2A and B).  In both turquoise and red clusters, the enriched pathways were involved in 
cell proliferation and differentiation (e.g., “pathways in cancer” and “cell cycle”), and 
cell-cell adhesion and fusion (e.g., “focal adhesion”, “cell adhesion molecules”, and 
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“adherens junction”) (Fig. 2A and B), while the green module was only enriched with 
genes associated with the “spliceosome” pathway (Fig. S3).   
 Fetal myogenesis involves myoblast proliferation/differentiation and fusion of 
myoblasts into multinucleated muscle fibers (Biressi et al., 2007). Characterization of 
genes that belong to “pathways in cancer” led us to identify multiple upregulated genes in 
LOS fetuses that are known to be involved in myoblast proliferation and differentiation 
(Fig. 2C).  For example, IGF1 is a major regulator for skeletal muscle growth and both 
IGF1 (Schiaffino and Mammucari, 2011) and its downstream signaling component 
PIK3CD (Schiaffino and Mammucari, 2011) exhibited increased expression levels in 
LOS #3 and/or #4, the two largest fetuses.  Besides IGF1, transcript abundance of several 
other growth factors and their receptors such as FGF1, FGF18, FGFR1, FGFR2, 
PDGFB, PDGFRA, PDGFRB, TGFB1, and TGFBR2 were also increased in LOS #3 
and/or #4 (Fig. 2C).  These growth factors may work in synergy to promote myoblast 
proliferation and differentiation (Biressi et al., 2007).   In addition, numerous upregulated 
genes in LOS that belong to the “focal adhesion” and the “cell adhesion molecules” 
pathways have been reported to play a role in myoblast adhesion and fusion.  For 
example, we found DOCK1, a prototypical member of the family of Rho GTPase 
activator that is essential for myoblast fusion (Laurin et al., 2008), to be upregulated in 
both LOS #3 and #4 (Fig. 2C).  Further, a number of extra cellular matrix genes, reported 
to be involved in myoblast migration, adhesion, and fusion (e.g., ADAM12, FN1, ICAM1, 
ITGA3, and ITGA5) (Abmayr and Pavlath, 2012; Thorsteinsdottir et al., 2011) exhibited 
increased transcript abundance in LOS #3 and/or #4 (Fig. 2C).  Although it is likely that 
some of the gene expression changes could be the consequential events of the altered  
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fetal myogenesis, these data suggest that the misregulated pathways may be responsible 
for the increased muscle mass and overgrowth phenotype of the LOS fetuses.  In 
summary, gene co-expression network analyses revealed that multiple pathways involved 
in fetal skeletal muscle development were disrupted in LOS.  
 Whole genome bisulfite sequencing (WGBS) and read processing  
 As differential gene expression can be regulated by differential DNA methylation 
(Smith and Meissner, 2013) and DNA methylation can be altered by the use of ART (de 
Waal et al., 2012a; de Waal et al., 2012b; Market-Velker et al., 2010; Rivera et al., 2008), 
we next sought to address whether altered DNA methylation could be the molecular 
mechanism responsible for the misregulated gene pathways in skeletal muscle of LOS 
fetuses.  To compare the methylome between control and LOS, we generated WGBS data 
of skeletal muscle of the fetuses used for RNAseq analyses.  For each individual, we 
sequenced ~400 million 100bp paired-end reads, which is approximately 26× coverage of 
the bovine reference genome (Table S1).  The average bisulfite conversion rate was 
99.31% (Table S1).  Of note, strong methylation bias was detected at the 5’ end of read 
mate 1 and both ends of read mate 2 (Fig. S4).  As these biases could be introduced 
during the library preparation and/or sequencing steps (Hansen et al., 2012),  the first 3 
base pairs (bp) and last 2bp of each WGBS read were trimmed and not used for 
determination of CpG methylation levels.  Following a series of quality filtering steps, 
~80% CpGs in the reference genome were covered by ≥5 WGBS reads (Table S2).    
  
	   103 
 Genome-wide CpG methylation landscape and its relationship with transcriptome 
in fetal skeletal muscle  
 Prior to making comparisons between LOS and controls, we sought to establish 
the DNA methylation baseline in bovine fetal skeletal muscle.  In controls, the 
distribution of CpG sites across different methylation levels exhibited a bimodal pattern 
(Fig. 3A), which is similar to what have been observed in somatic tissues of human and 
mouse (Messerschmidt et al., 2014).  Further, consistent with the reports that CpG islands 
are usually unmethylated (Messerschmidt et al., 2014), the majority of the CpGs within 
CpG islands in our study were hypomethylated (Fig. 3A and B).   In addition, we 
explored the relationship between the DNA methylome and the transcriptome.  We first 
plotted the average methylation of all the annotated genes along the gene body and 3kb 
upstream of the transcription start site (TSS) and 3kb downstream of the transcription end 
site (TES).  The 3kb range was chosen because the average DNA methylation beyond 
this distance was ~0.6-0.7, which was the overall average methylation of bovine fetal 
skeletal muscle.  As shown in Figure 3C, we found a negative correlation (Spearman rank 
test, p < 0.02) between the gene expression level and the level of DNA methylation at 
regions near the TSS (-500bp to TSS) (Fig. 3C).  Furthermore, we queried the 
relationship between DNA methylation and transcript abundance for genes with different 
levels of CpG density at their promoter regions.  For genes with high (HCP) and 
intermediate (ICP) CpG density promoters, there was a negative correlation (Spearman 
rank test, p < 0.02) between the methylation level at promoter regions and the transcript 
abundance (Fig. 3C).  However, low CpG density promoters (LCP) were usually 
methylated and had no apparent correlation with gene expression levels (Fig. 3C).  
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Figure 3. Genome-wide CpG methylation landscape and its relationship to the 
transcriptome in day ~105 skeletal muscle of control fetuses.  A). Distribution of CpGs 
sites across different methylation levels.  The methylation level of each CpG site was 
calculated as the ratio of the “C” reads to the sum of the “C” and “T” reads.  CpGs from all 
four controls were combined for the generation of this plot.  B). Percent of CpGs at each 
methylation level in control fetuses.  C). Averaged DNA methylation of annotated bovine 
genes along the gene body and 3kb upstream of the TSS and 3kb downstream of the TES.  
Genes were classified into five groups based on their expression levels.  HCP: high CpG 
density promoter; ICP: intermediate CpG density promoter; LCP: low CpG density 
promoter; TSS: transcription start site; TES: transcription end site. 
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Notably, we observed a positive correlation (Spearman rank test, p < 0.02) between DNA 
methylation at gene bodies and transcript abundance, especially with HCP genes (Fig. 
3C).  Overall, in our study, the associations between global DNA methylation and global 
gene expression were consistent with the findings in human and mouse (Messerschmidt 
et al., 2014).  
 Identification and characterization of the ASM regions in bovine fetal skeletal 
muscle  
 As only a limited number of imprinted ASM regions have been characterized in 
bovine (Chen et al., 2015; Chen et al., 2016; Chen et al., 2013; O'Doherty et al., 2012; 
Robbins et al., 2012), one objective of our study was to identify ASM regions at base 
resolution in bovine fetal skeletal muscle using WGBS.  To distinguish the parental 
origins of the alleles in the B. t. indicus × B. t. taurus F1 progenies, we obtained 
heterozygous SNPs of the fetuses from two sources: 1) SNPs identified from the WGBS 
data using Bis-SNP (Liu et al., 2012) and 2) SNPs identified from the RNAseq data of the 
F1 hybrids (Chen et al., 2016) (Fig. S5).  We assigned the WGBS reads overlapping the 
SNPs to their parental origins based on the genotype of the B. t. indicus sire (Chen et al., 
2016) of the F1 fetuses.  As an initial step to screen CpGs with ASM, allelic WGBS reads 
were combined from the four controls and CpGs with at least 4× coverage of each allele 
(n=4,798,414; 17.4% of CpGs in the bovine genome) were subject to Fisher’s exact test 
to determine whether DNA methylation level was significantly different between alleles.  
In total, 109,794 ASM candidate CpGs were identified with a p-value cutoff of 0.01 
[false discovery rate (FDR) ≈ 0.05, Fig. S5].  To further minimize the false positive 
ASM sites, the ASM candidate CpGs were merged into regions using a clustering method  
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Figure 4.  Identification and characterization of ASM regions in skeletal muscle of control 
fetuses.  A). Summary of the ASM regions identified at imprinted and non-imprinted loci.  Red 
color:  DMRs with maternal allele-specific methylation; blue color: DMRs with paternal allele-
specific methylation.  B-D). Genome browser views of the imprinted ASM loci: GNAS/GNASXL 
and NAP1L5/HERC3 and the non-imprinted CPOX.  The –log10(p-value) for ASM significance 
(black) and the CpG methylation levels for total (green), B. t. indicus allele (blue, paternal), and B. 
t. taurus allele (red, maternal) are also shown.  Each bar represents a single CpG site.  E). Allelic 
expression percentage of CPOX in skeletal muscle of the control fetuses.  ASM: allele-specific 
DNA methylation; DMR: differentially methylated region; Mat: maternal allele; Pat: paternal 
allele.  More examples may be found in Figure S7-S8. 
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as previously described (Xie et al., 2012).  In total, 1,070 ASM CpGs were grouped into 
86 discrete genomic regions (Fig. 4A and Table S3).  
  We manually annotated the identified 86 ASM regions (Table S3) and found that 
18 of them were located at known imprinted loci, while others were located >1Mb away 
from any known imprinted gene in bovine (Fig. 4A).  The two types of ASM regions are 
of comparable size; however, the imprinted ASMs have a higher density of CpGs (Fig. 
S6) located within CpG islands.  Both imprinted and non-imprinted ASM loci have 
overall DNA methylation level around 0.5, but ASM regions at imprinted loci exhibit less 
variation (range = 0.43 [imprinted] vs 0.8 [non-imprinted] and SD = 0.11 [imprinted] vs. 
0.19 [non-imprinted]; Fig. S6).  Lastly, the methylation differences between the parental 
alleles for the ASM regions at imprinted loci are also more dramatic when compared to 
the ASM regions that are not close to any known imprinted loci (mean = 0.73 [imprinted] 
vs. 0.51 [non-imprinted]; Fig. S6). 
 Of the 18 imprinted ASM regions, seven have been previously described in 
bovine by us and others including the paternal DMRs: GNAS DMR, H19/IGF2 DMR 
(Chen et al., 2016; Robbins et al., 2012) and the maternal DMRs: GNASXL DMR, 
IGF2R/AIRN DMR, KvDMR1, MEST DMR, and PLAGL1 DMR (Chen et al., 2015; 
Chen et al., 2016; O'Doherty et al., 2012; Robbins et al., 2012) (Fig. 4B and Fig. S7).  Of 
the novel imprinted ASM regions identified in bovine fetal skeletal muscle, eight of 
them, including NAP1L5 DMR, DIRAS3 DMR, GTL2 DMR and DLK1 DMR (Fig. 4C, 
Fig. S7), have been previously reported in human and/or mouse (Table S4).  The other 
three novel ASM regions namely, BEGAIN, MEG8, and MGC157368 DMRs, were 
located within the gene bodies of the known imprinted genes in bovine (Table S3).  All 
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the ASM regions described above could be associated with the nearby imprinted 
transcriptional activities previously reported by us (Chen et al., 2016) with the exception 
of MEST DMR, for which no heterozygous SNP was identified to enable allelic gene 
expression analyses.    
 We also manually inspected the imprinted ASM regions previously described in 
human and/or mouse in our bovine WGBS data.  We found that five ASM regions (i.e., 
GRB10 DMR, H13 DMR, NNAT DMR, PEG3 DMR, and PEG13 DMR) were absent in 
this study due to either poor SNP coverage or low read coverage (Table S4).  A less 
stringent criterion (i.e., 3× coverage per allele instead of 4×) for ASM calling could lead 
to the identification of another three DMRs (i.e., INPP5F DMR, PEG10 DMR, and 
SNRPN DMR) (Table S4).  Lastly, we found that some imprinted DMRs in human and/or 
mouse were simply not subject to ASM in bovine fetal skeletal muscle as these loci were 
either hypomethylated (e.g., RASGRF1 DMR, ZRSR1/IMPACT1 DMR, and COMMD1 
DMR) or partially methylated on both parental alleles (e.g., MKRN3 DMR and 
GPR1/ZDBF2 DMR) (Table S4).  
 For the 68 ASM regions not adjacent to any known imprinted locus, we sought to 
identify genes subject to allele-specific expression in the nearby regions.  As shown in 
Table S3, of the 68 ASM regions, 20 were intergenic (> 5kb away from any annotated 
gene) while the other 48 regions could be associated with nearby genes.  For the 48 
genes, parental-allele-specific read counts for 24 genes could be obtained from our 
previous study (Chen et al., 2016).  We found that all of these genes exhibited biallelic 
gene expression and had no association with the nearby ASM regions (shown in in Fig. 
4D and E, and Fig. S8 are five examples).  The remaining 24 genes were either lowly 
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expressed in skeletal muscle or had no heterozygous SNPs available to ascertain the 
parental alleles.  It is possible that some of these ASM regions are associated with tissue-
specific or transcript-isoform-specific monoallelic gene expression.  
 Lack of direct associations between DMRs and DEGs in LOS   
 As for the DEG analysis, each LOS fetus was analyzed independently and 
compared to the average of all four controls to identify DMRs using the Bsseq R package 
(Hansen et al., 2012).  The hierarchical clustering of CpG methylation within DMRs 
showed that control fetuses clustered together and were separated from the LOS fetuses 
(Fig. 5A).  The numbers of DMRs identified were similar for the four LOS fetuses with 
most DMRs identified in LOS #1 (Fig. 5B).  Notably, we identified loss of DNA 
methylation of KvDMR1 in LOS#1 and #4 (Fig. 5C), indicating the validity of the 
statistical method used for DMR determination, as we have previously identified these 
specific epimutations by the bisulfite polymerase chain reaction (PCR), cloning, and 
sequencing (Chen et al., 2013).  However, our previous study only reported a DMR with 
a size of only 385bp (37 CpGs) while the WGBS analyses allowed us to identify 
methylation differences between control and LOS across the entire CpG island (1957bp, 
207 CpGs, UMD3.1 Chr29: 49,552,845-49,554,801).  Further characterization of the 
DMRs revealed that most of them contained less than 20 CpGs and were of methylation 
differences between 0.2-0.5 (Fig. 5D).  
 We then characterized the genomic distances between the identified DMRs and 
the DEGs, in order to determine whether any of the DMRs could be linked to aberrant 
gene expression in LOS.  We first queried the genomic regions within 5kb range of the  
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Figure 5. Identification and characterization of DMRs in fetal skeletal muscle 
between control and LOS  (A). Hierarchical clustering of CpG methylation within 
DMRs between control and LOS using 1-Pearson’s correlation distance.  Bodyweight 
for each fetus is also shown. (B). Number of DMRs identified by the Bsseq R package 
between each LOS fetus and all four controls.  (C). Smoothed methylation profiles of 
the F1 fetuses at KvDMR1 with the pink area representing the DMR identified 
(size=520bp; ΔM=mean methylation difference of the DMR between all four LOS and 
the controls; grey=controls; blue=LOS #1; black=LOS #2; green=LOS #3; red=LOS 
#4).  Ticks at bottom represent CpG sites. (D). Number of CpGs and the mean 
methylation difference of each DMR identified in each LOS fetus.  
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DEGs and found that on average only ~1.5% of DEGs in each LOS fetus could be 
associated with the identified DMRs (Fig. 6A).  Increasing the range queried from 5kb to 
20kb only added an additional ~0.5% of DEGs that associate with the identified DMRs 
(Fig. 6A).  To determine whether the numbers of DEGs that are associated with the 
DMRs were greater than expected by chance, the identified DMRs were shuffled within 
each chromosome (excluding genome assembly gaps) 1000 times.  For each dataset, 
DEGs were considered to be associated with altered DNA methylation if DMRs were 
within 5kb or 20kb range of the DEGs.  The expected counts of DEGs were calculated as 
the average of the 1000 randomized datasets.  As shown in Figure 6A, DEGs are 
associated with DMRs more often than expected by chance in LOS #1, #3, and #4 but not 
in LOS #2.  
We found that 1407 DEGs are common between LOS #3 and #4 (the two largest 
LOS fetuses) and we sought to determine if differential DNA methylation can explain 
misexpression of these genes (Fig. 2C).  Only 14 DMRs overlapped between LOS #3 and 
#4, and only one of these was located within 5kb of one common DEG (C5H12orf45) 
and another within 20Kb (RWDD1).  We also noted that not all LOS fetuses with aberrant 
DNA methylation at the same locus had differential gene expression of the associated 
gene (an example shown in Fig. 6B-C), suggesting that differential DNA methylation is 
not the sole cause of differential gene expression.  Lastly, minor methylation differences 
were detected in the TSS regions (-1.5kb to +500bp) of the DEGs between control and 
LOS (Fig. 6F and Fig. S9).  In summary, only a very small percent DEGs in fetal skeletal 
muscle could be directly associated with the DMRs between control and LOS.  
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Figure 6. Lack of associations between the DEGs and the DMRs in skeletal muscle of the 
LOS fetuses. (A). Percentage of DEGs that are associated with the DMRs in LOS fetuses.  A 
DMR is considered to be associated with a DEG if it is less than 5kb or 20kb away from the 
DEG.  To determine whether the number of DEGs associated with DMRs were greater than 
expected by chance, DMRs were shuffled within each chromosome 1000 times and the 
expected numbers of DEGs associated with the DMRs were calculated as the average of 1000 
datasets and were used in chi-square tests (*p < 0.01).  (B-C).  Examples of lack of association 
between DEGs and DMRs when the DMRs are within 5kb range of the DEGs.  For (B) ,the 
details may be found in Fig. 5.  Panel (C) shows the transcript abundance of MZF1 in all 
fetuses (asterisk: edgeR FDR < 0.05).  DEG: differentially expressed genes.  (D). Mean 
methylation level differences of the DEGs between control and LOS fetuses at the TSS region 
(-1.5kb to +500bp).  Only DEGs that had at least 2-fold change are shown here.  
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 Association of aberrant DNA methylation and differential gene expression at 
IGF2R/AIRN and MAGEL2 imprinted loci 
 Insulin-like growth factor 2 receptor  (IGF2R) is a scavenger receptor of the fetal 
growth factor IGF2, and is maternally expressed in cow (Bebbere et al., 2013; Chen et al., 
2015) (Fig. 7A) and mouse (Barlow et al., 1991), but exhibits polymorphic imprinting in 
human (Xu et al., 1993).  In this study, IGF2R exhibited decreased transcript abundance 
in three out of four LOS fetuses (Fig. 7C), and this differential gene expression was 
associated with the altered DNA methylation at DMR1 and DMR2 of the IGF2R locus 
(Fig. 7A-B, Fig. S9).  In all four LOS fetuses, we found loss of methylation of DMR2, 
which is located in the second intron of IGF2R with loss of methylation in all four LOS 
fetuses (Fig 7B).  Normally, DMR2 was methylated on the maternal allele and 
unmethylated on the paternal allele.  Hypomethylation of DMR2 has also been reported 
in sheep LOS (Young et al., 2001), suggesting the IGF2R locus is similarly misregulated 
in these two species.  DMR1, which is close to the promoter region of IGF2R, is 
normally partially methylated on the paternal allele and unmethylated on the maternal 
allele.   In our study, DMR1 was hypermethylated in LOS (Fig. 7A-B).   
 In mice, paternal silencing of IGF2R is mediated by the paternally expressed long 
non-coding RNA AIRN, which is transcribed in the antisense direction to IGF2R and is 
regulated by DMR2 of IGF2R (Wutz et al., 1997).  Thus, we reasoned that 
hypomethylation of DMR2 can lead to biallelic expression of AIRN, which represses the 
expression of IGF2R on both alleles and results in the decreased level of IGF2R in LOS 
fetuses.  However, contrary to our expectation, AIRN was biallelically expressed in both 
control and LOS fetal skeletal muscle (Fig. 7D), suggesting that down-regulation of  
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Figure 7. DNA methylation and differential gene expression at IGF2R/AIRN and MAGEL2 
imprinted loci.  A). Schematics of the IGF2R/AIRN locus.  Bent arrows represent the transcription 
start sites. White boxes represent the ASM regions (white lollipops = unmethylated; grey lollipop = 
partially methylated; black lollipops = methylated).  B). Smoothed methylation profiles for the two 
DMRs at IGF2R locus between control and LOS fetuses.  The pink areas represent the DMR 
identified (ΔM=mean methylation difference of the DMR between all four LOS and the controls; 
grey=controls; blue=LOS #1; black=LOS #2; green=LOS #3; red=LOS #4).  Ticks at bottom 
represent CpG sites.  C). Transcript abundance of IGF2R in control and LOS fetuses (asterisk: 
edgeR FDR < 0.05, LOS vs control).  D). Allelic expression analyses for AIRN by Sanger 
sequencing.  The SNP site is indicated by an arrow.  E) Smoothed methylation profile of MAGEL2 
locus.  The labels are as panel B. F). Transcript abundance of MAGEL2 in the F1 fetuses (asterisk: 
edgeR FDR < 0.05).    
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IGF2R is not mediated by biallelic expression of AIRN.  Nevertheless, decreased 
transcript abundance of IGF2R was associated with a hypomethylated DMR2 and 
hypermethylated DMR1 in LOS fetuses.   
 In addition to IGF2R, we detected an association between differential gene 
expression and differential DNA methylation at the MAGEL2 locus.  MAGEL2 is a 
paternally expressed gene (Chen et al., 2015) with its promoter methylated on the 
maternal allele but unmethylated on the paternal allele (Table S3).  As shown in Fig. 7E-
F, the increased transcript abundance of MAGEL2 in LOS #4 is associated with the loss 
of DNA methylation at its promoter region.   
 
3.4 Discussion 
 Since BWS was first described in the early 1960s (Weksberg et al., 2005) and the 
first cases of ART-induced LOS were reported in 1995 (Farin and Farin, 1995), the main 
focus in both fields has been to understand how loss-of-imprinting alone can contribute to 
the complex and variable phenotypic features of these overgrowth conditions.  In human, 
the epimutation and genetic alteration of the two imprinted loci (i.e., KCNQ1 and 
H19/IGF2 loci) affect nearly 70% of BWS patients with the hypomethylation at 
KvDMR1 accounting for ~50% of all BWS cases (Eggermann et al., 2016).  In addition, 
loss-of-imprinting at multiple loci was observed in ~25% of BWS cases with epimutation 
at the KCNQ1 locus (Eggermann et al., 2016).  Similarly in bovine, we have also shown 
that LOS exhibits loss-of-imprinting at multiple loci including the KCNQ1 locus (Chen et 
al., 2015; Chen et al., 2013).  However, to date, there has been no report of molecular 
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features that can consistently and reliably diagnose and predict these syndromes and the 
associated variable phenotypes.  Here we advance the field by describing the altered 
transcript abundance of genes beyond imprinted loci in LOS fetuses, showing that loss-
of-imprinting is not be the only molecular lesion of this condition.   
 In this study, WGCNA and KEGG pathway analyses identified that multiple 
pathways involved in myoblast proliferation and fusion of myoblasts into myotubes are 
misregulated in skeletal muscle of LOS fetuses.  This finding is consistent with the 
previous report that short-term culture of ovine embryos can affect myogenic 
programming and the altered myogenesis may contribute to the large muscles observed in 
the oversized fetuses (Maxfield et al., 1998).   In addition to skeletal muscle, altered 
transcript abundance of genes was also detected in liver, brain, and kidney of the LOS 
fetuses.  Interestingly, tissue specific alterations in transcript abundance varied between 
LOS fetuses.  For example, LOS #1 had the most DEGs in liver, LOS #3 in kidney and 
LOS #4 in muscle.  This observation is supported by findings in BWS in which different 
individuals have different susceptibility for Wilms tumor of the kidney or hepatoblastoma 
(Eggermann et al., 2016).  Future studies with in depth characterization of the histology 
and the transcriptome of the tissues at various developmental stages of LOS will better 
elucidate relationships between the altered gene pathways and the potential disturbed 
development of these organs.  
 An interesting finding of this study was that only a small percent of DEGs could 
be linked to the identified DMRs between control and LOS.   Recently, it has been shown 
that histone modifications such as H3K27me3 at distal regions in oocytes can escape 
epigenetic reprogramming and maintain inheritance during the pre-implantation 
	   117 
development (Zheng et al., 2016).  It is possible that molecular marks like H3K27me3 in 
bovine may act as an epigenetic memory of the use of ART procedures and mediate the 
differential gene expression and the aberrant development in later stages.  Alternatively, 
the DEGs identified in this study could represent the downstream effect of the aberrant 
expression of developmentally important genes affected by ART during pre-implantation 
development.  In summary, our study demonstrates that altered transcriptome in LOS 
skeletal muscle is largely uncoupled to DNA methylome epimutations and we submit that 
caution should be exercised in interpreting results from DNA methylation data alone 
when studying the etiology of these overgrowth syndromes. 
 In addition to providing novel insights on the etiology of LOS, our study 
characterized the cytosine methylation landscape at base resolution in bovine.  Consistent 
to what has been previously reported for other mammals, CpG islands in bovine are 
hypomethylated and a negative association between DNA methylation and gene 
expression levels are observed at HCP and ICP, but not LCP promoters (Messerschmidt 
et al., 2014).  Furthermore, we have identified and characterized novel ASM at both 
imprinted and non-imprinted loci in bovine.  For the imprinted loci, we have expanded 
the number of imprinted ASM in bovine by describing several novel DMRs such as 
DIRAS3 DMR, GTL2 DMR, and NAP1L5 DMR.  Moreover, we have shown that some 
known imprinted DMRs in human and/or mouse (e.g., the L3MBTL DMR in human and 
the primary DMRs RASGRF1 and IMPACT in mouse) are not subject to ASM in fetal 
bovine skeletal muscle, suggesting species-specific imprinting of these genes.  Lastly, we 
have identified ASM regions at non-imprinted loci which others (Tycko, 2010) have 
proposed may be the result of cis-acting regulatory polymorphisms.  It should be noted 
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that ASM regions identified in this study are not comprehensive because we could not 
assign all WGBS reads covering CpGs to either parental alleles due to the lack of 
informative SNPs.  In future studies, analyses of the F1 hybrids of different crosses may 
further improve the identification of ASM CpG sites. 
 In conclusion, we have shown that misregulation of non-imprinted genes in 
addition to loss-of-imprinting characterizes to the ART-induced overgrowth syndrome 
and have demonstrated that most of the aberrant gene expression in fetal skeletal muscle 
is not associated with aberrant DNA methylation.      
 
3.5  Materials and Methods 
 RNAseq data analyses 
  The production of the B. t. indicus × B. t. taurus F1 fetuses and collection of the 
fetal tissues were previously described by us (Chen et al., 2015).  All animal procedures 
were performed at TransOva Genetics by veterinarians, and all procedures were approved 
by their animal care and use committee.  RNAseq data of the control and LOS fetuses 
were obtained from one of our previous studies and were processed as previously 
described (Chen et al., 2015; Chen et al., 2016).  DEGs between each LOS fetus and the 
mean of all four controls were determined with the consideration of variance among the 
controls using the edgeR package (Anders et al., 2013; Robinson et al., 2010).  The 
WGCNA package (Langfelder and Horvath, 2008) was used to construct a weighted gene 
co-expression network for the skeletal muscle of the four control and four LOS fetuses.  
Further, the identified network modules were correlated with the bodyweight to identify 
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genes in modules most likely responsible for the altered bodyweight.  In addition, KEGG 
pathway analyses for the significant network modules and the DEGs in LOS fetuses were 
performed using the Database for Annotation, Visualization and Integrated Discovery 
(DAVID) (Huang da et al., 2009).    
  WGBS library preparation and sequencing 
 Genomic DNA isolated from skeletal muscle of four control and four LOS day 
~105 B. t. taurus × B. t. taurus F1 female fetuses (Chen et al., 2015) were subject to 
WGBS analyses.  The WGBS libraries were generated using the NEBNext Ultra DNA 
library Prep Kit for Illumina (NEB E7370) as per the manufacturer’s instructions.  Prior 
to sodium bisulfite mutagenesis, 0.5% unmethylated Lambda DNA was added to the 
bovine DNA to act as an internal control to monitor the bisulfite conversion rate.  Each 
WGBS library was sequenced using Illumina sequencing technology to generate 100bp 
paired-end reads. The raw FASTQ files are publically available at Gene Expression 
Omnibus (GEO accession no. GSE93775).   
 WGBS data analyses 
 Following adaptor removal and quality trimming, WGBS read pairs were aligned 
to the bovine reference genome assembly UMD3.1 using Bismark (version: 0.15.0) 
(Krueger and Andrews, 2011) with the default parameters.  Only uniquely aligned reads 
were used for subsequent analyses.  In order to distinguish the C>T SNPs from C>T 
substitutions that were caused by sodium bisulfite conversion in the F1 fetuses, Bis-SNP 
(version: 0.82.2) (Liu et al., 2012) was used to perform the SNP calling.  Only CpG sites 
that showed consensus CpG context for both parental alleles (i.e., do not overlap any 
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SNPs identified by Bis-SNP) were used for the subsequent analyses.  The methylation 
level was determined using the reads from both forward and reverse strands covering the 
same symmetric CpG site.  The methylation level was calculated as: (number of “C” 
reads)/(number of “C” reads + number of “T” reads).  
 In order to identify ASM regions, the WGBS read pairs overlapping SNPs were 
assigned to their parental origin based on the genotype of the B. t. indicus sire (Chen et 
al., 2016). Further, the allelic WGBS reads were pooled from four controls to determine 
the sequencing depth and only CpGs that had at least 4× coverage of each allele were 
used for Fisher’s exact test.  To estimate the FDR, WGBS read pairs overlapping SNPs 
were randomly assigned to be either B. t. indicus or B. t. taurus in origin in order to 
generate a randomized dataset of ASM sites (Xie et al., 2012).  ASM CpGs were 
identified using a p-value of 0.01, resulting in 109,794 ASM sites with a FDR of ~5% 
(compared to the 5507 CpGs identified as ASM sites in the permutated datasets).  Lastly, 
the identified ASM sites were clustered into regions as previously described (Xie et al., 
2012).  Methylkit R package (Akalin et al., 2012) was used to perform the hierarchical 
clustering of the methylation profiles. The DMRs between each LOS fetus and all four 
controls were identified using the Bsseq R package (Hansen et al., 2012).  
 To estimate the expected number of DEGs associated with DMRs, the identified 
DMRs were randomly shuffled within each chromosome using “shuffleBed” function 
from BedTools (Quinlan and Hall, 2010).  The UMD3.1 genome assembly gaps from 
UCSC genome Browser were excluded from the potential shuffled positions.  Shuffling 
was performed 1000 times and for each dataset, a DEG was considered to be associated 
with a DMR if the DMR falls into the DEG coordinates that had been extended by 5kb or 
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20kb.  The averaged DEG counts of the 1000 datasets were used as the expected count 
for chi-square test. 
 Statistical analyses and data visualization 
 Statistical analyses were implemented with R (http://www.r-project.org/).  Heat 
maps were generated with the R function “heatmap.2”.  The averaged methylation level 
of the annotated genes were generated using deepTools (Ramirez et al., 2014).  For ASM 
regions, bed files were converted to the bigwig format and visualized as custom tracks in 
the Integrative Genomics Viewer (IGV) (Robinson et al., 2011).   
 Allelic expression analyses of AIRN 
 Both DNA and cDNA of the F1 fetuses and DNA of the sire were amplified by 
PCR followed by Sanger sequencing to ascribe the parental origin of the transcript.  
Nucleic acid isolation, cDNA synthesis, and PCR amplifications were as previously 
reported (Chen et al., 2015).  
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3.7  Supplemental information for Chapter 3 
Supplemental materials and methods 
 WGBS library preparation and sequencing 
 Genomic DNA isolated from skeletal muscle of four control and four LOS ~d105 
B. t. taurus × B. t. taurus F1 fetuses were subject to WGBS analyses.  For library 
preparation, 1µg bovine DNA was subject to sodium bisulfite mutagenesis using NEB 
EpiMark Bisulfite Conversion Kit (NEB E3318) according to the manufacturer’s 
instructions.  Prior to the sodium bisulfite reaction, 5ng (0.5%) unmethylated cl857 Sam7 
Lambda DNA (48,502bp, Promega D1521) was combined with bovine DNA to act as an 
internal control to monitor the bisulfite conversion rate.  The bisulfite conversion rate was 
calculated as the percentage of thymines sequenced at the cytosine reference positions in 
the Lambda genome.  The WGBS libraries were generated using the NEBNext Ultra 
DNA library Prep Kit for Illumina (NEB E7370) as per the manufacturer’s instructions.  
Each WGBS library was sequenced in two lanes with 100bp paired-end reads on an 
Illumina HiSeq 2000 platform.  For Control #4 fetus, one lane of the WGBS library was 
sequenced on an Illumina HiSeq 2500 platform.    
 WGBS reads trimming and alignment 
 Raw WGBS read pairs were subject to quality trimming prior to alignment to the 
reference genome.  The Cutadapt program (version: 1.9.1) (Martin, 2011) was used to 
remove the adaptor sequences in the read pairs.  For base quality trimming, 
DynamicTrim (version 3.1) (Cox et al., 2010) was used to obtain the longest segment of 
the read in which each base has <1% error rate.  Following quality trimming, WGBS read 
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pairs were aligned to the bovine reference genome assembly UMD3.1 and the Lambda 
genome using Bismark (version: 0.15.0) (Krueger and Andrews, 2011)  with the default 
parameters.  Only uniquely aligned read pairs that had the expected read mate orientation 
and expected ranges of insert size were retained for further analyses.  
 Identification of SNPs using WGBS data 
 In order to distinguish the C>T SNPs in the F1 fetuses from the C>T substitutions 
that are caused by sodium bisulfite conversion, Bis-SNP (version: 0.82.2)(Liu et al., 
2012) was used to perform the SNP calling using the WGBS data.  In brief, the uniquely 
aligned WGBS read pairs were subject to several post-alignment processes prior to the 
SNP calling including PCR duplicates removal, insertions/deletions re-alignment, and 
base quality recalibration.  Known insertions/deletions (indel) and known SNPs 
downloaded from Ensembl and RefSeq FTP sites were supplied for the indel realignment 
and the base quality recalibration (ftp://ftp.ensembl.org/pub/release-
78/variation/vcf/bos_taurus/; ftp://ftp.ncbi.nlm.nih.gov/snp/organisms/cow_9913/VCF/; 
ftp://ftp.ncbi.nlm.nih.gov/snp/organisms/cow_30522/).  In addition, the SNPs identified 
from the DNA sequencing data (Chen et al., 2016) of the sire of the B. t. indicus X B. t. 
taurus F1 fetuses were also supplied for the base quality recalibration process.  After 
processing the uniquely aligned WGBS read pairs, Bis-SNP was used to identify SNPs 
with the exclusion of first 3bp and last 2bp of the both read mates using the option “-
trim5 3 –trim3 2” as these read positions were associated with strong methylation bias 
(Fig. S1). 
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 Determination of the methylation level of each CpG site 
  Only CpG site that show consensus CpG context for both parental alleles (i.e., do 
not overlap any SNPs identified by Bis-SNP) were used for the subsequent analyses.  As 
CpG methylation is symmetric, the methylation level was determined using the reads 
from both forward and reverse strands covering the same symmetric CpG site.  The 
methylation level was calculated as: (number of “C” reads)/(number of “C” reads + 
number of “T” reads).  For most analyses, only CpGs covered by at least by five reads 
were used for the calculation of the methylation level.  The exception is the allele-
specific methylation analyses, in which only CpGs covered at least by 8 reads (four reads 
per parental allele) were included for the statistical test.  For reads with PCR duplicates, 
only one of them was randomly choosed for the determination of the methylation level.   
 Identification of the ASM regions 
  Heterozygous SNPs of the fetuses were obtained from two sources for the 
determination of parental allele origin: 1) SNPs identified from the WGBS data using 
Bis-SNP (Liu et al., 2012); 2) SNPs identified from the RNA-seq data of the F1 hybrids 
(Chen et al., 2016).  The WGBS read pairs overlapping SNPs were assigned to their 
parental origins based on the genotype of the B. t. indicus sire (Chen et al., 2016).  If the 
SNP included a cytosine, its bisulfite converted form thymine was also considered.  
Further, the allelic WGBS reads were pooled from four controls to determine the 
sequencing depth and only CpGs that had at least 4× coverage of each allele were used 
for Fisher’s exact test.  To estimate the FDR, WGBS read pairs overlapping SNPs were 
permutated for their parental origin by randomly assigning them to either B. t. indicus or 
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B. t. taurus alleles.  The ASM for each CpG in the permutated dataset was assessed using 
Fisher’s exact test.  The permutation was performed five times and the numbers of 
identified ASM CpGs at different p-value cutoff were averaged.  ASM CpGs were 
identified using a p-value of 0.01, resulting 109,794 ASM sites with a FDR of ~5% as 
simply by chance 5507 ASM sites can be identified in the permutated datasets.  Lastly, 
the identified ASM sites were clustered into regions as previously described (Xie et al., 
2012).  In brief, significant ASM sites within 2kb were merged as DMR candidates.  For 
each candidate, at least five ASM sites were required and at least 75% CpGs should show 
consistent methylation bias toward the same allele.  The clustered DMRs were also 
manually inspected and annotated. 
 Association between DEGs and DMRs in LOS fetuses 
 Methylkit R package (Akalin et al., 2012) was used to perform the hierarchical 
clustering of the methylation profiles using 1-Pearson’s correlation distance. The DMRs 
between each LOS fetus and all four controls was identified using Bsseq R package 
(Hansen et al., 2012) with the default parameters except that only CpGs with at least 5 
reads coverage for each fetus were included for analyses.  For comparison, Bsseq was 
also used to identify DMRs between all four LOS fetuses and the controls.  
 RNA-seq data of the control and LOS fetuses were obtained from one of our 
previous studies and were processed as previously described (Chen et al., 2015; Chen et 
al., 2016).  DEGs between each LOS fetus and all four controls were determined using 
the edgeR package (McCarthy et al., 2012; Robinson et al., 2010).  In brief, for each LOS 
fetus, a DGElist was created with the gene read counts of the four controls and the LOS 
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fetus.  Following normalization (i.e., function “calcNormFactors”) and parameters 
estimation (functions “estimateGLMTrendedDisp” and “estimateGLMTagwiseDisp”), 
functions “glmFit” and “glmLRT” were used to identify genes with differential transcript 
abundance between the LOS and the mean of the four controls (FDR < 0.05).  To 
determine whether any DMRs are associated with DEGs, 5kb or 20kb regions 
surrounding the DEGs (including the gene body) were used to intersect with the DMRs 
using “intersectbed” from bedtools (Quinlan and Hall, 2010).  The methylation level of 
the TSS region (-1.5kb to +500bp) was calculated by averaging the methylation level of 
all CpGs with at least five reads coverage.  
 WGCNA and KEGG analyses 
 A weighted gene co-expression network was constructed for the skeletal muscle 
of the four control and four LOS fetuses using “blockwiseModule” function from the 
WGCNA package (Langfelder and Horvath, 2008).  Further, the identified network 
modules were linked to the external trait (i.e., bodyweight) to determine which module is 
significantly correlated to the bodyweight.  In addition, KEGG pathway analyses for the 
significant network modules were performed using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) (Huang et al., 2007).    
 Genomic annotations 
 The TSS and TES of the annotated genes were obtained from Bovine Genome 
Database (http://bovinegenome.org)(Elsik et al., 2015) and were curated with the RNA-
seq data of brain, kidney, liver, and skeletal muscle using cuffmerge (Trapnell et al., 
2010).  Annotation of CpG islands was obtained from UCSC genome browser 
	   127 
(Rosenbloom et al., 2015), in which the CpG islands are defined as genomic regions that 
fulfill the following criteria: 1) > 200bp, 2) GC content ≥ 50% and 3) the ratio of the 
observed CpGs to the expected CpGs (O/E) > 0.6.   
 Promoters are defined as -2kb to +500bp of the TSS (Liao et al., 2015).  High 
CpG Promoters (HCP) promoters contain a 500bp interval with: 1) GC content ≥ 55% 
and 2) the O/E ratio ≥ 0.6 (Mikkelsen et al., 2007).  Low CpG Promoters (LCP) 
promoters do not contain a 500bp interval with the O/E ratio ≥ 0.4 (Mikkelsen et al., 
2007).  The rest of the promoters are classified as Intermediate CpG Promoters (ICP) 
promoters (Mikkelsen et al., 2007).  The formula used for calculation of the O/E ratio of 
a sequence segment is as follows: number of CpGs * sequence length / (number of C * 
number of G) (Gardiner-Garden and Frommer, 1987). 
  Allelic expression analyses of AIRN 
 Both DNA and cDNA of the F1 fetuses and DNA of the sire were amplified by 
PCR followed by Sanger sequencing to ascribe the parental origin of the transcript.  
Nucleic acid isolation, cDNA synthesis, and PCR amplifications were as previously 
reported (Chen et al., 2015).  The primers used are as follows: forward (5’-
AGAAACGGGCACATTCA-3’) and reverse (5’-
GGCAATATTAGAACAGCTAAGAG-3’). 
 Statistical analyses and data visualization 
 Statistical analyses such as Fisher’s exact test were implemented with R 
(http://www.r-project.org/).  Fig. 2A and C and Fig. S2C-D were generated with R 
function “heatmap.2”.  Fig. 3C and 5B were generated using the “computeMatrix” and 
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“plotProfile” functions in deepTools (Ramirez et al., 2014).  For Fig. 4B-D, Fig. 5C, Fig. 
S5, Fig. S6A, C, and E, bed files were converted to the bigwig format using the 
“bedGraphToBigWig” from UCSC Genome Browser database and visualized as custom 
tracks in the Integrative Genomics Viewer (IGV) (Robinson et al., 2011).   
 
 
 
 
 
 
	   129 
 
Supplemental figures and tables for Chapter 3 
●
●
●
●
●
●
●
●
−1
0
1
−1 0 1
standardized PC1 (43.5% explained var.)
sta
nd
ar
diz
ed
 P
C2
 (2
1.
1%
 e
xp
lai
ne
d 
va
r.)
group
●
●
●
●
●
●
Control
Control2
LOS#1
LOS#2
LOS#3
LOS#4
●●
●
●
●
●
●
●−2
−1
0
1
0 1 2
standardized PC1 (58.7% explained var.)
sta
nd
ar
diz
ed
 P
C2
 (1
1.
1%
 e
xp
lai
ne
d 
va
r.)
group
●
●
●
●
●
Control
LOS#1
LOS#2
LOS#3
LOS#4
LOS#1 
LOS#2 
LOS#4 
LOS#3 
S
ta
nd
ar
di
ze
d 
P
C
2 
(1
1.
1%
 e
xp
la
in
ed
 v
ar
.) 
1 
0 
-1 
-2 
Standardized PC1 (58.7  explained var.) 
Controls 
Kidney 
   
S
ta
nd
ar
di
ze
d 
P
C
2 
(2
1.
1%
 e
xp
la
in
ed
 v
ar
.) 
 
 
-  
Standardized PC1 (43.5% explained var.) 
Controls 
-    
Skeletal muscle 
LOS#1 
LOS#2 
LOS#3 
LOS#4 
●
●
●
●
●
●
●
●
−1.0
−0.5
0.0
0.5
1.0
1.5
−1.0 −0.5 0.0 0.5 1.0 1.5
standardized PC1 (37.2% explained var.)
sta
nd
ar
diz
ed
 P
C2
 (2
7.
3%
 e
xp
lai
ne
d 
va
r.)
group
●
●
●
●
●
●
Control
Control2
LOS#1
LOS#2
LOS#3
LOS#4
●
●
●
●
●
●
●
●
−1
0
1
−1 0 1 2
standardized PC1 (45.1% explained var.)
sta
nd
ar
diz
ed
 P
C2
 (1
8.
6%
 e
xp
lai
ne
d 
va
r.)
group
●
●
●
●
●
●
Control
Control2
LOS#1
LOS#2
LOS#3
LOS#4
S
ta
nd
ar
di
ze
d 
P
C
2 
(1
8.
6%
 e
xp
la
in
ed
 v
ar
.) 
 
 
-  
Standardized PC1 (45.1% explained var.) 
-1 0 1 2 
Liver 
LOS#4 
LOS#3 
LOS#1 
LOS#2 
Controls 
S
ta
nd
ar
di
ze
d 
P
C
2 
(2
7.
3%
 e
xp
la
in
ed
 v
ar
.) 
 
0 
-1 
Standardized PC1 (37.2% explained var.) 
-1 0 1 
Controls  
LOS#1 
LOS#2 
LOS#3 
LOS#4 
Brain 
Figure S1.  Principle component analyses using all expressed genes in kidney, skeletal 
muscle, liver, and brain.  In skeletal muscle, liver, and brain, RNAseq library of Control #2 
(the grey dot circled with black) was sequenced with 50bp read length, while other fetuses were 
sequenced with 100bp read length. The read length differences may explain why Control #2 
fetus is not closely clustered with other control fetuses in these tissues.   
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   Panel B and C can be found in next page. 
Figure S2.  Identification and characterization of DEGs identified in the LOS fetuses.  A). 
Differentially expressed genes identified between each LOS fetus and the mean of the four controls.  B). 
KEGG pathways enriched for DEGs in kidney and brain (FDR < 0.05). C). KEGG pathways enriched 
for upregulated and downregulated genes in kidney and brain (FDR < 0.05).  
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Figure S2.  WGCNA and KEGG pathway analyses in skeletal muscle.  A).  WGCNA cluster dendrogram on all 
control and LOS fetuses groups genes into 33 modules, namely, 33 co-expressed gene networks.  B).  Correlation of 
WGCNA modules and the bodyweight of the fetuses. Arrows indicate the three modules that show significant correlation 
with the bodyweight.  C).  Heat map profiling of the genes of module green . Module green includes genes that are mostly 
misregulated in LOS #1 and #4.  D).  Heat map profiling of genes that belong to the “Spliceosome” pathway.  
Figure S3.  WGCNA and KEGG pathway analyses in skeletal muscle.  A).  WGCNA cluster 
dendrogram on all control and LOS fetuses groups genes into 33 modules, namely, 33 co-expressed 
g ne networks.  B).  Correlation of WGCNA modules and the bodyweight of the fetu es. Arrows 
indicate the three modules that show significant correlation with the bodyweight.  C).  Heat map 
profiling of the genes of module green. Module green includes genes that are mostly misregulated in 
LOS #1 and #4.  D).  Heat map profiling of genes that belong to the “Spliceosome” pathway.  
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Figure S3. Means CpG methylation level at each WGBS read position of the 
skeletal muscle from control and LOS fetuses. 
  
Figure S4. Mean CpG methylation level at each WGBS read position of the skeletal 
muscle from control and LOS fetuses. 
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Figure S4. Pipeline used for the identification of ASM regions in skeletal muscle of control fetuses. A). 
Schematics pipeline.  B).  The number of ASM sites identified with various p-value cutoffs is plotted.  The 
optimal cutoff choosed for identifying ASM sites is indicated. 
  
Figure S5. Pipeline used for the identification of ASM regions in skeletal muscle of control fetuses. 
A). S hematics pipeline.  B).  The number of ASM sites identified with various p-value cutoffs is 
plotted.  The optimal cutoff choosed for identifying ASM sites is indicated. 
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Figure S6. Characterization of the ASM regions identified in bovine fetal skeletal muscle.  
A) The size of the ASM regions. B) The number of CpGs in the ASM regions. Only CpGs 
identified with allele-specific DNA methylation were counted for each ASM region.  C) 
Localization of the ASM regions in CpG islands. D) Overall methylation level for the ASM 
regions. E) Methylation differences between parental alleles for the ASM regions.  CGI: CpG 
island. 
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Figure S7. Examples of imprinted ASM loci. Genome browser views of the imprinted ASM 
loci: H19/IGF2, DIRAS3, and GTL2/DLK1.  The –log
10
(p-value) for ASM significance (black) 
and the CpG methylation levels for total (green), B. t. indicus allele (blue, paternal), and B. t. 
taurus allele (red, maternal) are also shown.  Each bar represents a single CpG site. Mat: 
maternal allele; Pat: paternal allele. 
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Figure S8. Examples of ASM regions at non-imprinted loci.  A), C), and E). Genome 
browser views of the non-imprinted ASM loci: NRDE2, PLCL2, and SCARF1.  The –log
10
(p-
value) for ASM significance (black) and the CpG methylation levels for total (green), B. t. 
indicus allele (blue, paternal), and B. t. taurus allele (red, maternal) are also shown.  Each bar 
represents a single CpG site.  B), D), and F). Allelic expression percentage in skeletal muscle of 
the control fetuses. Mat: maternal allele; Pat: paternal allele. 
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Figure S9. A). Mean methylation level differences of the DEGs between controls and 
LOS #2 and #3 at the TSS region (-1.5kb to +500bp).  Only DEGs that have at least 2-fold 
change are shown here.  B). Number of CpGs and the mean methylation difference of 
each DMR identified when comparing all LOS fetuses to the controls. 
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Sample ≥1 read (%*) ≥3 reads (%*) ≥5 reads (%*) ≥8 reads (%*) ≥10 reads (%*) 
Control #1 25,422,282 (92.3) 24,523,876 (89.0) 22,835,084 (82.9) 18,144,557 (65.9) 13,953,964 (50.7) 
Control #2 25,380,860 (92.2) 24,233,110 (88.0) 22,007,331 (79.9) 16,221,532 (58.9) 11,560,309 (42.0) 
Control #3 25,420,791 (92.3) 24,414,185 (88.6) 22,484,754 (81.6) 17,326,183 (62.9) 12,984,193 (47.1) 
Control #4 25,260,324 (91.7) 23,354,088 (84.8) 19,582,672 (71.1) 11,582,224 (42.0) 6,717,916 (24.4) 
LOS #1 25,431,432 (92.3) 24,491,532 (88.9) 22,732,952 (82.5) 17,931,727 (65.1) 13,732,790 (49.9) 
LOS #2 25,427,128 (92.3) 24,505,589 (89.0) 22,772,178 (82.7) 18,057,629 (65.6) 13,958,856 (50.7) 
LOS #3 25,426,184 (92.3) 24,550,790 (89.1) 22,958,659 (83.4) 18,522,677 (67.3) 14,501,482 (52.7) 
LOS #4 25,416,233 (92.3) 24,368,611 (88.5) 22,334,119 (81.1) 16,895,545 (61.3) 12,340,998 (44.8) 
Table S2. Reads coverage at CpG sites  
*Percentage of CpGs in the reference assembly UMD3.1 covered by at least 1, 3, 5, 8, and 10 reads.  
Libraries Bodyweight Gestational day Raw reads Aligned reads 
Aligned 
reads (%) 
Uniquely 
aligned reads 
Uniquely 
aligned reads 
(%) 
Bisulfite 
conversion rate 
(%) 
Control #1 392g Day 104  396,328,924   333,030,504   84.0   267,417,844  67.5 99.73 
Control #2 406g Day 105  428,296,878   331,841,555   77.5   266,934,993  62.3 99.77 
Control #3 408g Day 106  418,901,079   336,561,860   80.3   268,410,454  64.1 99.75 
Control #4 416g Day 106  355,810,944   289,745,138   81.4   229,015,740  64.4 99.56 
LOS #1 514g Day 106  424,025,153   338,241,972  79.8  268,667,106  63.4 99.77 
LOS #2 518g Day 105  431,258,953   333,939,082  77.4  260,337,387  60.4 99.75 
LOS #3 620g Day 106  397,474,455   320,530,155  80.6  254,012,990  63.9 96.48 
LOS #4 714g Day 105  421,457,025   338,500,780  80.3  269,718,690  64.0 99.74 
Table S1. Summary of the reads alignment and bisulfite conversion rate for each WGBS library 
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Chapter 4 Global assessment of imprinted gene expression in the bovine 
conceptus by next generation sequencing 
4.1  Abstract 
 Genomic imprinting is an epigenetic mechanism that leads to parental-allele-
specific gene expression.  Approximately 150 imprinted genes have been identified in 
humans and mice but less than 30 have been described as imprinted in cattle.  For the 
purpose of de novo identification of imprinted genes in bovine, we determined global 
monoallelic gene expression in brain, skeletal muscle, liver, kidney and placenta of day 
~105 Bos taurus indicus × Bos taurus taurus F1 conceptuses using RNA sequencing.  To 
accomplish this, we developed a bioinformatics pipeline to identify parent-specific SNP 
alleles after filtering A-to-I RNA editing sites.  We identified 53 genes subject to 
monoallelic expression.  Twenty three are genes known to be imprinted in the cow and an 
additional 7 have previously been characterized as imprinted in human and/or mouse that 
have not been reported as imprinted in cattle.  Of the remaining 23 genes, we found that 
10 are uncharacterized or unannotated transcripts located in known imprinted clusters, 
whereas, the other 13 genes are distributed throughout the bovine genome and are not 
close to any known imprinted clusters.  To exclude potential cis-eQTL effects on allele 
expression, we corroborated the parental specificity of monoallelic expression in day 86 
Bos taurus taurus × Bos taurus taurus conceptuses and identified eight novel bovine 
imprinted genes.  Further, we identified 671 candidate A-to-I RNA editing sites and 
describe random X-inactivation in day 15 bovine extraembryonic membranes.  Our 
results expand the imprinted gene list in bovine and demonstrate that monoallelic gene 
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expression can be the result of cis-eQTL effects.  
 
4.2  Introduction 
 In mammals, approximately 150 genes have been shown to be expressed in a 
parental-allele-specific manner (Bartolomei and Ferguson-Smith, 2011).  These genes, 
collectively known as imprinted genes, are essential for normal embryonic growth, 
placental function, and postnatal behavior (Peters, 2014) and their misregulation has been 
linked to several developmental syndromes and types of cancers (Kalish et al., 2014; Lim 
and Maher, 2010).  Most imprinted genes are organized in clusters and are regulated by 
cluster-specific DNA elements termed imprinting control regions (ICR; Bartolomei and 
Ferguson-Smith, 2011).  ICRs are marked with DNA methylation and histone post-
translational modifications in a sex-specific manner during gametogenesis (Bartolomei 
and Ferguson-Smith, 2011).  These epigenetic signatures are maintained during 
development and serve to differentiate the parental alleles in somatic cells, when both 
genomes are found within the same nucleus (Bartolomei and Ferguson-Smith, 2011).  
Since the discovery of the first three imprinted genes in 1991 (Barlow et al., 1991; 
Bartolomei et al., 1991; DeChiara et al., 1991), more than 100 imprinted genes have been 
identified in humans and mice (http://igc.otago.ac.nz; 
http://www.har.mrc.ac.uk/research/genomic_imprinting/).  However, the list of imprinted 
genes is not yet comprehensive as their expression can vary by tissue and stage of 
development (Bartolomei and Ferguson-Smith, 2011; Peters, 2014).   
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Many fewer imprinted genes (n=34) have been reported in domestic farm animal 
species (Tian, 2014).  In addition, most imprinted genes in cow, pig, sheep, and rabbit 
have been characterized in studies designed to corroborate the allele-specific expression 
of genes previously described as imprinted in human and/or mouse (Bischoff et al., 2009; 
Chen et al., 2015; Chen et al., 2013; Okamura et al., 2005; Robbins et al., 2012; Young et 
al., 2003; Zaitoun and Khatib, 2006).  As in human and mouse, allele specificity in 
monoallelic expression of these genes is a requirement for proper embryonic and fetal 
growth; loss-of-imprinting (LOI) has been associated with abnormal development of the 
conceptus (Chen et al., 2013; Farin et al., 2006; Tian, 2014; Young et al., 2001).  One 
such example is large offspring syndrome (LOS) in bovine and ovine (Young et al., 
1998), a fetal overgrowth condition that is phenotypically and epigenetically similar to 
the loss-of-imprinting condition Beckwith-Wiedemann syndrome in human (Chen et al., 
2013).  In a previous study (Chen et al., 2015), we analyzed a group of genes known to 
have imprinted expression in human and/or mouse and showed loss of monoallelic 
expression and differential transcript abundance of multiple imprinted genes in LOS.  We 
also found that some of the genes (e.g., COPG2, IMPACT, HTR2A) do not express in the 
expected monoallelic fashion but rather are biallelically expressed in the bovine 
conceptus.  The species specificity of genomic imprinting suggests that certain genes may 
only be imprinted in cattle; therefore, de novo identification of imprinted genes using 
genome-wide scale approaches is required in order to achieve a more thorough 
understanding of this epigenetic mechanism and its role in fetal development of this 
economically important species. 
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 Advances in high throughput sequencing technology provide an unprecedented 
opportunity for the discovery of imprinted genes at the transcriptome level and has led to 
the discovery of additional imprinted genes in mice and humans (Wang and Clark, 2014).  
In mice, transcriptome wide identification of imprinted genes relies on RNA sequencing 
(from here on referred to as RNAseq) of F1 offspring resulting from reciprocal crosses of 
distantly related inbred mice to identify parental-allele-specific gene expression (Babak et 
al., 2008; Wang et al., 2008).  While this approach has been successful, bioinformatics 
analyses alone can suffer from a high false positive rate due to the potential technical 
artifacts of RNAseq (DeVeale et al., 2012).   Thus, the use of next generation sequencing 
to identify imprinted genes requires independent validation through traditional methods 
(i.e., Sanger sequencing).  In human, systemic characterization of genomic imprinting 
using RNAseq has recently been performed in 46 tissues from 178 adults (Baran et al., 
2015).   This study highlights the widespread tissue-specificity of genomic imprinting as 
well as the species-specificity of imprinting (some genes imprinted in human are not 
imprinted in the mouse) (Baran et al., 2015).   
  Beyond genomic imprinting, X chromosome inactivation (XCI) is another 
epigenetic phenomenon that can regulate gene dosage by silencing one of the parental 
alleles in females (Lee and Bartolomei, 2013).  Contrary to parental-origin-dependent 
silencing of imprinted genes, dosage compensation of X-linked genes in most organs is 
achieved by randomly silencing one of the X chromosomes (Lyon, 1961).  However, in 
extra-embryonic tissues of mouse and rat, XCI is imprinted and it is always the paternal 
X chromosome that is inactivated (Huynh and Lee, 2001; Wake et al., 1976).  It has not 
been resolved whether XCI is imprinted or random in the human placenta (Lee and 
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Bartolomei, 2013) and, in cattle, a study based on the allele-specific expression of the X-
linked gene MAOA indicates that XCI is imprinted in the placenta with preferential 
silencing of the paternal X chromosome (Xue et al., 2002).   
 In this study, we determined global allele-specific gene expression in day ~105 
Bos taurus indicus (B. t. indicus) × Bos taurus taurus (B. t. taurus) F1 conceptuses 
(gestation length ~280 days) using RNAseq.  We developed an analysis pipeline to 
identify monoallelically expressed genes by resolving several technical challenges such 
as correction of allelic mapping bias of RNAseq reads and filtering potential RNA editing 
sites in RNAseq data and then validated our findings by Sanger sequencing.  Further, we 
corroborated the parental specificity of monoallelic expression in day 86 B. t. taurus × B. 
t. taurus (Holstein breed) conceptuses to exclude potential cis-eQTL effects on allele 
expression.  Finally, we describe random X-inactivation in day 15 bovine extraembryonic 
membranes.   
 
4.3  Results 
 Pipeline for identification of monoallelically expressed genes in bovine using 
RNAseq  
The identification of imprinted gene expression requires the use of DNA 
polymorphisms to identify parental origin of the alleles in an F1 individual.  For bovids, it 
is not always possible to know the identity of the parental alleles, for example, if those 
individuals were conceived with oocytes obtained from abattoir ovaries.  This fact, 
together with the fact that cattle are not inbred, makes the global identification of genes 
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subject to allele-specific expression using RNAseq a challenging task.  Another challenge 
when working in bovine is encountered when aligning RNAseq reads to the publically 
available reference genome (i.e., UMD3.1) because only one B. t. taurus female (i.e., 
Hereford breed) is documented with only one of her alleles recorded.   In the present 
study, we developed a bioinformatics pipeline (Fig. 1) to identify candidate imprinted 
genes in cattle using RNAseq data from four gestation day ~105 female bovine 
conceptuses (fetus and placenta) generated from the breeding of one Nelore bull (ABS 
CSS MR N OB 425/1 677344 29NE0001 97155 [i.e., B. t. indicus]) to four Holstein 
breed (B. t. taurus) females of unknown genetics (Chen et al., 2013).  We utilized this 
breeding scheme, which involves fertile mating between subspecies of cattle that 
diverged ~620,000 years ago (MacHugh et al., 1997), to increase the likelihood of 
finding informative polymorphisms with which to ascribe parental origin of the nucleic 
acid being studied.    
First, the sire’s DNA was subjected to next generation sequencing (DNAseq) to 
identify all single nucleotide polymorphisms (SNPs) between his genome and the B. t. 
taurus reference genome UMD3.1 build.  In total, 347.3 million 2 × 100 bp paired-end 
reads (~20X coverage of the bovine reference genome) were obtained (Fig. S1A) and 
used to genotype the B. t. indicus sire.  We used Genome Analysis Toolkit (GATK; 
McKenna et al., 2010) and SAMtools (Li, 2011) pipelines for SNP calling and only SNPs 
identified by both pipelines (i.e., 93.11%; Fig. 1 and Fig. S1B and C) were used to edit 
the reference genome to generate a pseudo B. t. indicus genome.  Aligning RNAseq reads 
to a non-identical reference genome has been shown to introduce alignment bias (Degner 
et al., 2009; Stevenson et al., 2013) so we combined the reference genome and the pseudo  
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The B. t. indicus sire 
DNAseq 
SAMtools 
mpileup 
GATK 
HaplotypeCaller 
SNPs identified by both 
SAMtools and GATK pipelines 
 B. t. indicus × B. t. taurus 
 F1 hybrids RNAseq 
Generate a pseudo B. t. indicus genome 
Replace the reference allele 
with the B. t. indicus allele 
Build a custom 
diploid genome 
Call variants from RNAseq 
SNPs in RNAseq data 
Filter potential RNA editing sites 
Assign reads to parental alleles; 
binomial exact test for the allele-
specific read counts for each gene 
Combine with the  
B. t. taurus reference 
genome (UMD3.1) 
RNA variants common for both 
HISAT2 and BWA alignment 
HISAT2 BWA 
Alignment to the reference genome 
Alignment to the diploid genome 
Bioinformatics analyses 
Bench research 
Imprinted genes 
Validate allele-specific expression by Sanger 
sequencing (B. t. indicus × B. t. taurus F1) 
Corroborate the allele-specific expression in 
B. t. taurus × B. t. taurus conceptuses using 
Sanger sequencing  
Merge the diploid alignment to 
generate a new reference 
Figure 1.  Summary of the pipelines used in this study. Top left and right of figure show the 
bioinformatics methods used to identify monoallelically expressed genes in day ~105 Bos taurus 
indicus (B. t. indicus) × Bos taurus taurus (B. t. taurus) F1 conceptuses.   Bottom left shows the 
pipeline used to corroborate the findings of the bioinformatics analyses.  SNP = single nucleotide 
polymorphism.   
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B. t. indicus genome to create a custom diploid genome.  RNAseq reads from the B. t. 
indicus × B. t. taurus F1 conceptuses were mapped to the diploid genome using both the 
HISAT2 (Kim et al., 2015) and BWA (Li and Durbin, 2009) pipelines and only variants 
identified by both methods were retained for further analyses (Fig. 1) to minimize the 
potential effects of false positives.     
 Genotyping the day ~105 B. t. indicus × B. t. taurus F1 conceptuses using RNAseq 
RNAseq data were obtained from brain, kidney, liver, skeletal muscle and 
placenta of the four conceptuses (i.e., Control #1, #2, #3, and #4; Table S1) and were 
aligned to the custom B. t. indicus/B. t. taurus diploid genome.  We adapted the SNPiR 
pipeline (Piskol et al., 2013) to identify SNPs using all RNAseq reads from each 
conceptus.  To minimize false positive SNP calls, in addition to the default pipeline 
(BWA; Li and Durbin, 2009; Piskol et al., 2013), we also mapped the reads using 
HISAT2 (Kim et al., 2015) and only retained variants common to both alignment 
strategies (Fig. S2A, Table S1).  The identified RNA variants in the F1 conceptuses were 
compared to known bovine dbSNP entries (http://www.ncbi.nlm.nih.gov/SNP) and the 
identified B. t. indicus SNPs.  We found that ~98% of the RNA variants were matched to 
the bovine dbSNP entries and/or were supported by the B. t. indicus DNAseq reads and 
we refer to them as “genomic variants” (Fig. S2B).  The genomic variants exhibited a 
~2.5 transition/transversion ratio (see methods; Fig. S2C) while the remaining ~2% RNA 
variants (Fig. S2B), hereinafter referred to as “RNA-DNA differences (RDDs)”, 
exhibited 14-18 transition/transversion ratios and were enriched for A>G and T>C 
mismatches (Fig. S2D).    
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 Identification and validation of A-to-I RNA editing sites in B. t. indicus × B. t. 
taurus conceptuses 
 We reasoned that some of the RDDs with A>G and T>C mismatches resulted 
from adenosine-to-inosine (A-to-I) RNA editing, a tissue specific post-transcriptional 
mechanism in which adenosine is converted to inosine in RNA duplexes by adenosine 
deaminase acting on RNAs (ADARs; Nishikura, 2010).  A-to-I RNA editing is detected 
as A>G mismatches in cDNA (Nishikura, 2010).  To confirm the true identity of A-to-I 
RNA editing, we retrieved the variant information (i.e., read counts for both the reference 
and alternative alleles) in the RNAseq data of each tissue from each individual (Fig. 2A).  
Further, we required that each RDD have at least 10 reads coverage per tissue per 
conceptus to discriminate rare SNPs or sequencing errors from true RNA editing sites.  
For brain, liver, and skeletal muscle, only RDDs shared by Controls #1, #3, and #4 were 
used to identify RNA editing sites since the RNAseq reads for these tissues from Control 
#2 were sequenced at 50 bp length instead of 100 bp length for the other samples (Table 
S1).  We identified 404, 275, 266, 208, and 180 RNA variants in brain, kidney, liver, 
skeletal muscle, and placenta, respectively (Fig. 2A).  Of these, the majority (> 72%) 
were A>G mismatches (Fig. 2A and B) and we considered them to putatively represent 
A-to-I editing sites (Table S2; link to Table S2: 
http://www.tandfonline.com/doi/full/10.1080/15592294.2016.1184805).   
 We analyzed 7 predicated editing sites in four genes (i.e., COPA, SEC16A, 
GRIK2, and GABRA3) using Sanger sequencing to confirm that the editing site did not 
represent a heterozygous SNP in DNA and also to corroborate the editing of the RNA  
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Figure 2.  Identification of adenosine-to-inosine (A-to-I) RNA editing sites in day ~105 
B. t. indicus × B t. taurus F1 conceptuses.  A). Pipeline used to identify which RNA-DNA 
differences (RDDs) were potential A-to-I RNA editing sites. RDDs refer to RNA variants 
not found in the bovine dbSNP database nor in the B. t. indicus sire DNAseq reads.  RNA 
variants were identified using all the RNAseq reads of each conceptus.  Only RDDs with 
≥10 reads coverage per tissue per conceptus and had strand information of the transcript 
template were used to identify potential editing sites.  *Note: for brain, liver, and skeletal 
muscle only RDDs shared by Control #1, #3, and #4 were used to identify RNA editing sites 
since the RNAseq reads for those tissues in Control #2 were sequenced at 50 bp length 
instead of 100 bp length for all other samples.  B). Variant type distribution of the RDDs.  
“A>G” variants were considered candidate A-to-I RNA editing sites (detailed information of 
these sites may be found in Table S2).  C) and D). Validation of the identified A-to-I RNA 
editing sites by Sanger sequencing.  Red arrows indicate the editing sites.  Panel C shows an 
example of A-to-I editing in the coding sequence (CDS) of COPA, which can cause an 
amino acid change (IleèVal) while panel D shows two editing sites in the 3’ untranslated 
region (3’UTR) of SEC16A.  Further verification of A-to-I RNA editing sites may be found 
in Figure S3.    
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molecules (a second “G” peak in the sequencing chromatogram).  We were able to 
validate 6 of 7 to be true A-to-I editing sites (Fig. 2C and D, Fig. S3).   
 Characterization and species conservation of candidate A-to-I editing sites  
 Analysis of the putative A-to-I editing events indicated that ~96% (643/671) of 
these sites were within noncoding regions such as UTRs and introns and approximately 
two percent (15/671) were located in coding sequences (CDS; Fig. S4).  This observation 
is consistent with findings in human and mouse that the majority of A-to-I RNA editing 
events occur in non-coding regions (Ramaswami et al., 2013).  Of the sites located in 
CDS’, 14 could cause an amino acid change (Table S2). 
To determine whether the identified A-to-I RNA editing sites in bovine were 
conserved in human and/or mouse, we retrieved 80 bp of flanking sequences (40 bp 
upstream and 40 bp downstream; Pinto et al., 2014) and aligned the 81 nucleotides to the 
human and mouse genomes using BLAST .  A valid BLAST hit with  > 86% identity was 
required to ascribe a site as being conserved between species (Pinto et al., 2014).  With 
this criterion, 20 of the sites were predicted to be conserved between bovine and human 
and/or mouse.  Table 1 shows that 13 out of 20 editing sites are located in the CDS and 
12 of those editing events can cause an amino acid change.    
 Identification of genes with monoallelic expression in B. t. indicus × B. t. taurus 
conceptuses 
 As the RDDs were enriched with A-to-I editing sites, we used only genomic 
variants for the identification of monoallelically expressed genes.  We first assigned 
parental origin of each allele within the F1 RNAseq reads by determining which SNPs  
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Chromosome Tissue type Gene Gene section Outcome Conservation 
Chr3:9479773 Brain, kidney, liver,  skeletal muscle, placenta COPA CDS Nonsyn (Ile->Val) Human 
Chr4:114454773 Skeletal muscle, placenta FASTK Intron Unknown Human, mouse 
Chr5:76189492 Brain ELFN2 Intron Unknown Human 
Chr7:71024261 Brain CYFIP2 CDS Nonsyn (Lys->Glu) Human, mouse 
Chr9:48598875 Brain GRIK2 Intron Unknown Human, mouse 
Chr9:48598884 Brain GRIK2 Intron Unknown Human 
Chr9:48598902 Brain GRIK2 Intron Unknown Human, mouse 
Chr9:48600509 Brain GRIK2 Intron Unknown Human 
Chr9:48600848 Brain GRIK2 CDS Nonsyn (Gln->Arg) Human, mouse 
Chr9:48600865 Brain GRIK2 CDS Syn (Gly->Gly) Human  
Chr9:48634035 Brain GRIK2 CDS Nonsyn (Tyr->Cys) Human, mouse 
Chr9:48634048 Brain GRIK2 CDS Nonsyn (Ile->Val) Human, mouse 
Chr12:15671536 Brain, kidney, liver,  skeletal muscle, placenta COG3 CDS Nonsyn (Ile->Val) Human, mouse 
Chr13:67116409 Brain, skeletal muscle, placenta BLCAP CDS Nonsyn (Lys->Arg) Human 
Chr13:67116439 Brain, kidney, skeletal muscle, placenta BLCAP CDS Nonsyn (Gln->Arg) Human, mouse 
Chr13:67116448 Brain, kidney BLCAP CDS Nonsyn (Tyr->Cys) Human, mouse 
Chr17:42806463 Brain GRIA2 Intron Unknown Human, mouse 
Chr17:42806724 Brain GRIA2 CDS Nonsyn (Gln->Arg) Human, mouse 
Chr22:39005364 Brain CADPS CDS Nonsyn (Glu->Gly) Human, mouse 
ChrX:34866822 Brain GABRA3 CDS Nonsyn (Ile->Met) Human, mouse 
Table 1.  A-to-I RNA editing sites in bovine that are conserved in human and/or mouse  
Nonsyn: nonsynonymous editing; Syn: synonymous editing 
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were found in the sire’s DNAseq reads.  As illustrated in Figure S5, the only SNPs that 
were used to assign parental alleles were those that were homozygous in the B. t. indicus 
sire and that had at least one allele different from the allele found in the sire in the F1 
RNAseq data.  Following assignment of the parental alleles, allele-specific read counts 
covering each of the SNPs in the same gene were aggregated as previously described 
(DeVeale et al., 2012) and a binomial test was used to detect consistent allelic expression 
bias (false discovery rate (FDR) < 0.05; Table S3 and S4) .  As the annotation of the 
bovine genome is imperfect, we further manually annotated the candidate genes using the 
Integrative Genomic Viewer (IGV; Robinson et al., 2011).  We identified a total of 53 
genes subject to monoallelic expression in at least one of the analyzed tissues (i.e., 33 in 
brain, 36 in kidney, 38 in liver, 36 in muscle, and 35 in placenta; Table S3 and S4; link to 
Table S3-4: http://www.tandfonline.com/doi/full/10.1080/15592294.2016.1184805).  Of 
the identified 53 genes, 23 were known to be imprinted in the cow (also in human and/or 
mouse; http://igc.otago.ac.nz/; http://www.har.mrc.ac.uk/research/genomic_imprinting/) 
and 7 had previously been characterized as imprinted in human and/or mouse but had not 
been reported to be imprinted in cow (Table S5; link to Table S5: 
http://www.tandfonline.com/doi/full/10.1080/15592294.2016.1184805).  Of the 
remaining 23 genes, 10 were uncharacterized or unannotated transcripts located in known 
imprinted clusters, whereas the other 13 genes were distributed throughout the bovine 
genome and were not located close to any known imprinted clusters (Table S5).  
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 Validation of the imprinted genes previously identified in human and/or mouse   
 We used PCR followed by Sanger sequencing to validate the allele specific 
expression of GNASXL (GNAS/GNASXL domain), COPG2IT1 (MEST/COPG2 domain),  
MEG8 and MEG9 (GTL2/DLK1 domain), MIMT1, USP29, ZIM2 (PEG3/USP29 
domain), PON3 and PPP1R9A (PEG10/SGCE domain), and MKRN3 (SNRPN domain).  
The other 20 imprinted genes (Table S5) were not validated because we have previously 
described these genes to be imprinted (Chen et al., 2015).  In the GNAS domain, we 
identified GNASXL as a paternally expressed transcript isoform which has a unique first 
exon but shares identical sequences from exon 2 to the end of the transcript with the 
maternally expressed transcript GNAS (also known as NESP55 in cattle 
[NM_001271771.1], Fig. 3A).  By using the SNP located in the last exon of these 
transcripts (Fig. 3A) we validated the paternal expression of GNASXL and maternal 
expression of GNAS (Fig. 3B).  In addition, analyses of two other SNPs (one specific to 
the GNASXL first exon and the other specific to the GNAS first exon) confirmed this 
result (Fig S6A).  Further, DNA methylation of the GNASXL and GNAS promoter regions 
was confirmed using bisulfite mutagenesis followed by cloning and sequencing.  The 
GNASXL differentially methylated region (DMR; the locus’ putative ICR) showed 
hypomethylation of the paternal allele and hypermethylation of the maternal allele, which 
was associated with the paternal expression of this transcript (Fig. 3C and Fig. S6B).  To 
the contrary, the GNAS DMR was methylated on the paternal allele while unmethylated 
on the maternal allele, which was associated with the maternal expression of GNAS (Fig. 
3C and Fig. S6B).   In addition to GNASXL and GNAS, we verified the maternal 
expression of MEG8, MEG9, PPP1R9A, PON3 and ZIM2, and paternal expression of  
	   157 
  
Genomic DNA (B. t. indicus × B. t. taurus)  
 
Control #4 B. t. indicus sire  Control #1 
GNAS, skeletal muscle cDNA 
 
Control #1 Control #4 
GNASXL, skeletal muscle cDNA 
 
Control #1 Control #4 
A 
B 
C 
GNASXL DMR  GNAS DMR 
GNASXL DMR  
GNAS DMR  
D PEG3 
LOC100298176 LOC104974975 MGC157368 LOC508098 ZIM2 
MIMT1 USP29 
E MGC157368 (B. t. indicus × B. t. taurus)  
Control #4 B. t. indicus sire Control #1 
G
en
om
ic
 D
N
A 
B
ra
in
 c
D
N
A 
LOC100298176 (B. t. indicus × B. t. taurus)  
Control #3 B. t. indicus sire Control #1 
Last exon 
GNASXL 
GNAS 
* 
rs41255672 
* 
* 
Figure 3.  	  
	   158 
  
Figure 3. Validation of the allele-specific gene expression in GNAS/GNASXL and PEG3/USP29 
imprinted clusters in day ~105 B. t. indicus × B. t. taurus F1 conceptuses.  A). Schematics of the 
GNAS/GNASXL loci (not all exons are shown and are not drawn to scale).  Bent arrows represent the 
transcription start sites.  Patterned boxes above and below the gene structure (in black) represent the 
GNASXL and GNAS transcripts, respectively.  The red asterisk in the last exon represents the SNP 
used to discriminate the parental alleles for allele-specific expression analyses in panel B.  The black 
ovals represent the CpGs found within the amplicon used for DNA methylation analyses (i.e., panel 
C).  B). Validation of the maternal expression of GNAS and paternal expression of GNASXL by Sanger 
sequencing.  The SNP sites are indicated by red arrows.  Left: genotyping results obtained by Sanger 
sequencing of the B. t. indicus sire and the F1 individuals at the SNP site.  Middle and right: Sanger 
sequencing results of RT-PCR amplicons of GNAS and GNASXL.  Validation of the allelic expression 
of GNAS and GNASXL at other SNP sites may be found in Figure S6A.  C).  DNA methylation 
analyses of GNASXL (top) and GNAS (bottom) differentially methylated regions (DMRs).  DNA 
methylation was determined using bisulfite mutagenesis, cloning, and Sanger sequencing.  Parental-
origin of each clone was determined using heterozygous SNPs in the F1 individuals.  Methylation of 
CpG sites for each parental allele was summarized from at least 7 clones and is presented with pie 
charts with black representing the percent of methylated cytosines and white representing the percent 
of unmethylated cytosines at each site.  The complete bisulfite maps may be found in Figure S6B.  D). 
Schematics of the PEG3/USP29 imprinted cluster.  Bent arrows represent the transcription direction of 
each gene.  E). Validation of maternal expression of MGC157368 and LOC100298176.  Top panels 
for each gene are the genotyping results obtained by Sanger sequencing of the B. t. indicus sire and F1 
individuals.  Bottom panels are the Sanger sequencing results of the RT-PCR amplicons of 
MGC157368 and LOC100298176.  The validation of the allelic expression of other genes in the 
PEG3/USP29 imprinted cluster may be found in Figure S8.             = genes previously 
identified to be imprinted in human, mouse, and bovine.             = genes previously identified to 
be imprinted in human and/or mouse but not reported to be imprinted in bovine.           = 
uncharacterized transcripts in known imprinted clusters. 	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COPG2IT1, MIMT1, MKRN3, and USP29 in B. t. indicus × B. t. taurus F1 hybrids (Fig. 
S7-S9).   
 Validation of the monoallelic expression of the uncharacterized/unannotated 
transcripts in previously known imprinted clusters 
 We identified 10 uncharacterized/unannotated transcripts with monoallelic 
expression in previously known imprinted clusters, of which four transcripts were located 
in the PEG3/USP29 cluster and six transcripts were in the SNRPN domain.   In the 
PEG3/USP29 domain, the four uncharacterized transcripts (i.e., LOC508098, 
MGC157368, LOC104974975, and LOC100298176) were located downstream of the 
paternally expressed gene PEG3 and upstream of the maternally expressed gene ZIM2 
(Fig. 3D).  We verified the maternal expression of LOC508098, MGC157368, 
LOC104974975, and LOC100298176 (Fig. 3E, Fig. S8, Table S3 and S5).  According to 
RefSeq gene annotation (Pruitt et al., 2014), LOC508098, MGC157368, and 
LOC104974975 are protein-coding genes.  In addition, LOC100298176 has high protein-
coding potential (0.78 coding probability) based on the Coding Potential Assessment 
Tool (CPAT; Wang et al., 2013).  We considered a transcript with CPAT coding 
probability > 0.348 to possess protein-coding potential as previously reported for bovine 
(Billerey et al., 2014).  
 In the SNPRN domain, LOC100848941 and LOC101907203 were identified as 
two paternally expressed noncoding RNAs (ncRNAs) located downstream of the 
maternally expressed gene UBE3A (Fig. S9).    In addition, two paternally expressed 
ncRNAs (LOC100849023 and LOC101907679; Fig. 4A left panel) located upstream of 
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UBE3A were identified (Fig. S9). Finally, we verified paternal expression of an 
unannotated ncRNA (CPAT coding probability 0.06; Wang et al., 2013) with cuffmerge 
gene ID XLOC_045114 (Chr21:350,550-552,040 bp, UMD3.1) which was located 
~300kb upstream of the paternally expressed gene SNRPN (Fig. S9).  To determine 
whether XLOC_045114 has any human/mouse counterpart, we aligned its cDNA 
sequence to the human and mouse genomes using BLAST but were unable to confidently 
identify any matches.   
 Validation of monoallelically expressed genes not found in known imprinted 
clusters 
 We identified 13 genes with monoallelic expression that were located >15Mb 
distance from any known imprinted clusters.  For these genes, nine (i.e., AOX1, APCS, 
AS3MT, C1R, C1S, CDA, KRT7, OOEP, and RDH16) were annotated protein-coding 
genes, of which APCS, AS3MT, C1R, C1S, CDA, OOEP, and RDH16 were 
monoallelically expressed from the B. t. taurus allele (maternal), while AOX1 and KRT7 
were expressed from the B. t. indicus allele (paternal) (Fig. 4C and Fig. S10 left panels 
and Table S3).  The remaining four genes were either uncharacterized ncRNA (i.e., 
LOC101905472) or unannotated transcripts:  XLOC_009410 (Chr4:59,913,253-
59,913,967, UMD3.1, CPAT coding probability: 0.38), XLOC_012439 
(Chr5:115,431,044-115,432,886, UMD3.1, CPAT coding probability: 0.36), and 
XLOC_052524 (ChrX:113,053,268-113,055,164, UMD3.1, CPAT coding probability: 
0.02).  Consistent with RNAseq analysis, Sanger sequencing confirmed the maternal 
expression of XLOC_052524, and paternal expression of LOC101905472,  
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Figure 4.  Corroboration of the allele specificity in gene expression identified by RNAseq.   
A-C). left panels show results obtained from the day ~105 B. t. indicus × B. t. taurus F1 
conceptuses.   A-C). right panels show results obtained from the day 86 B. t. taurus × B. t. taurus 
individuals.  For each gene, the top lines are the genotyping results of the F1s and their sire while 
the bottom lines are the Sanger sequencing results of the RT-PCR amplicons of the F1 
conceptuses.  A). An example of a gene that had parental-origin-dependent monoallelic 
expression.  LOC101907679, an uncharacterized transcript in the SNRPN imprinted cluster was 
paternally expressed in both B. t. indicus × B. t. taurus and B. t. taurus × B. t. taurus individuals.  
B).  An example of a gene that had sequence-dependent monoallelic expression.  For 
LOC101905472, the “C” allele was always predominantly expressed, regardless of its parental-
origin.  C).  An example of a gene (i.e., CDA) that was monoallelically expressed in B. t. indicus × 
B. t. taurus F1 hybrids but biallelically expressed in B. t. taurus × B. t. taurus individuals.  Further 
validations of allele-specific expression in B. t. indicus × B. t. taurus F1s and B. t. taurus 
conceptuses may be found in Figure S10-11.  
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XLOC_012439, and XLOC_009410 in the B. t. indicus × B. t. taurus F1 hybrids (Fig. 4B 
and Fig S10 left panels and Table S3).    
 Corroboration of the allele-specificity of gene expression in day 86 B. t. taurus × 
B. t. taurus conceptuses 
 Beyond genomic imprinting, cis-eQTL (cis-regulating expression quantitative 
trait loci) can also induce biased allelic gene expression (Wang and Clark, 2014).  As we 
lack the ability to produce the reciprocal B. t. taurus × B. t. indicus F1 conceptuses, we 
used tissues from nine day 86 B. t. taurus × B. t. taurus female conceptuses (Holstein 
breed all sired by bull: 507HO10723 DE-SU 527 SPUR-ET) to corroborate allelic 
specificity of transcription of genes not previously reported to be imprinted in bovine 
(n=33; Table S5).  We used PCR followed by Sanger sequencing to identify informative 
SNPs in the B. t. taurus × B. t. taurus conceptuses.  Of the analyzed 33 genes we found 
20 genes with heterozygous SNPs in at least one conceptus (Fig 4, Fig S10 and S11 right 
panels).  Of these, nine genes (i.e., COPG2IT1, GNAS, GNASXL, MEG8, 
LOC101907679, LOC100298176, LOC104974975, LOC1009849023, MEG8, and 
XLOC_052524) showed consistent parental-allele-specific gene expression between the 
B. t. indicus × B. t. taurus and B. t. taurus × B. t. taurus conceptuses while RDH16 and 
CDA were found to be biallelically expressed and C1R, C1S, LOC101905472, and 
XLOC_012439 were monoallelically expressed but not imprinted (Fig 4, Fig S10 and 
S11).  We were not able to assign parental origin to the monoallelically expressed APCS, 
ZIM2, USP29, LOC508908, and XLOC_009410 alleles as the sire was heterozygous at 
these loci (Fig. 5, Fig. S10 and S11).   Using this scheme, eight novel imprinted genes 
were identified (Fig. 5B) and imprinted expression of another 23 genes  
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Figure 5.  Summary of the imprinted and monoallelically expressed genes identified in the current 
study.  For A-C), different colors denote the type of expression of listed genes for each analyzed tissue.  
A). Genes previously reported to be imprinted in bovine. B). Genes not previously reported to be 
imprinted in bovine.  C). Genes with monoallelic expression in the B. t. indicus × B. t. taurus F1s but 
which parental origin of the transcript could not be corroborated due to lack of informative SNPs in the 
B. t. taurus × B. t. taurus conceptuses or as a result of the heterozygosity of their sire.  # = genes with 
inter-individual variations in allele-specific gene expression.   LOC100848941^ is an isoform of 
LOC100848941 (SNPRN imprinted cluster) only identified in brain.  Allele-specific read counts and 
allelic expression ratios of each gene may be found in Tables S3. 
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in cattle was corroborated (Fig. 5A).  RNAseq results indicated that 16 of these genes 
showed allele-specific expression in all analyzed tissues, seven had biallelic expression in 
at least one tissue, and eight were lowly expressed in some tissues (Fig. 5A and 5B).  We 
also identified a paternal transcript in the SNRPN domain (referred here as 
“LOC100848941 brain isoform”) which connected the two paternal transcripts 
LOC100848941 and LOC101907203 (Fig. S9 top panel).   
 Allele-specific expression analyses of X-linked genes in bovine placenta  
 To determine whether X-chromosome inactivation (XCI) in bovine placenta is 
random or imprinted (Dindot et al., 2004; Xue et al., 2002), allele expression ratios for 
the annotated X-linked genes were analyzed in placenta of the four B. t. indicus × B. t. 
taurus F1 female conceptuses.  If the XCI is imprinted, we expect that most of the X-
linked genes would be expressed from the maternal allele, except for those genes that 
escape XCI (Wang et al., 2012).  However, if XCI is random, we expect that both 
parental alleles of the X-linked genes would be expressed and that allele expression ratios 
would be variable among individuals due to the sampling effects (Wang et al., 2012). We 
plotted the distribution of the allele expression ratios for both autosomal genes and X-
linked genes in placenta of the four B. t. indicus × B. t. taurus F1 conceptuses (Fig. 6A).  
For autosomal genes, the distribution of the allele expression ratios of all four individuals 
had an approximate 50:50 ratio.  However, the X-linked genes showed biallelic 
expression but with inter-individual variation of the allele expression ratios (mean ranges 
from 29.0 to 66.7%; Fig. 6A), which is consistent with the distribution of the allele 
expression ratios for the X-linked genes in the mule and horse placenta (Wang et al., 
2012).   We further analyzed the allele expression ratios of 14 X-linked genes that have  
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Figure 6.  Allele-specific expression analyses for autosomal and X-linked genes in placental 
membranes from day ~105 B. t. indicus × B. t. taurus F1 hybrids.  The placental membranes used for 
this study were the intercotyledonary region of the chorioallantois.  A). Histograms of the allelic 
expression ratios for the autosomal genes (top) and X-linked genes (bottom) in placenta from each 
conceptus.  The Y-axis represents the percent of genes with varied levels of expression from the B. t. 
taurus (maternal) allele (X axis).  N = number of annotated genes with informative SNPs.  Mean = the 
mean of the percent allelic expression.  B). Plot of allelic expression ratios of XIST (filled circles), two 
pseudo-autosomal genes (gray diamonds), and 14 X-linked genes (open circles) from the placenta 
RNAseq data.  The X-linked genes have previously been described as being subjected to imprinted X 
chromosome inactivation in mouse.  The detailed allele-specific read counts of these genes may be 
found in Table S6.  C). Sanger sequencing results of XIST allelic expression in the B. t. indicus × B. t. 
taurus F1 placenta, in in vivo- (AI) and in vitro- (IVF)-produced day 15 (D15) bovine extraembryonic 
membranes (EEM), and CT1 trophectoderm cell line.  Top row is the genotyping results while the two 
bottom rows are sequencing results for the RT-PCR amplicons.  Both random primers and oligo(dT) 
were used for cDNA synthesis.  
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previously been described as imprinted in mouse placenta (McGraw et al., 2013) and/or 
extra-embryonic cell lines (Merzouk et al., 2014), two genes (CD99 and ZBED1) found 
in the pseudoautosomal region (PAR; Das et al., 2009), and the ncRNA XIST which is 
expressed from the inactive X (Lee and Bartolomei, 2013).  We observed that similar to 
the X-linked genes, XIST was expressed from both parental alleles (Fig 6B and C, Table 
S6).  Further, we found an anti-association between the allelic expression ratio of XIST 
and the X-linked genes in two of the samples (Fig 6B and Table S6).  Conversely to XIST 
and the X-linked genes, the allele expression ratios of the PAR genes CD99 and ZBED1 
centered toward 50:50 with no apparent association with X-linked genes or XIST 
expression (Fig. 6B).  For this study the placental samples were taken from the 
intercotyledonary chorioallantois for which predecessor cells come from the 
trophectoderm and the epiblast (Bianchi et al., 1993; Luckett, 1978), therefore, the 
possibility exists that the randomness of X-linked gene allele expression observed here 
was simply the result of the expression observed in tissues derived from the inner cell 
mass (Lee and Bartolomei, 2013).  To refine our findings, we turned to day 15 bovine 
extraembryonic membranes (EEM)(Dobbs et al., 2014) and CT1 cells (Talbot et al., 
2000), a trophectoderm cell line derived from a single bovine female blastocyst.  The 
EEM were dissected from the female conceptuses by removing the embryonic disk and 
should contain no epiblast derivatives(van Leeuwen et al., 2015).  Sanger sequencing 
results showed that XIST was expressed from both parental alleles in EEM of the four day 
15 conceptuses analyzed (Fig. 6C and Fig. S12), indicating random XCI in bovine 
extraembryonic membranes.  However, in CT1 cells only one allele of XIST was 
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expressed.  It is possible that this “monoallelic” XIST expression resulted from the clonal 
expansion of the cells that randomly inactivate one of the X chromosomes.   
 
4.4   Discussion 
 To date, approximately 150 imprinted genes have been identified in humans and 
mice (http://igc.otago.ac.nz; http://www.har.mrc.ac.uk/research/genomic_imprinting/), 
but less than 30 genes have been described as imprinted in cattle (Tian, 2014).  In this 
study, we advance the genomic imprinting field by the de novo identification of imprinted 
genes in bovine using RNAseq.  To do so, we identified parent-specific SNP alleles in 
RNAseq data after filtering A-to-I RNA editing sites and determined global allele-
specific gene expression in B. t. indicus × B. t. taurus F1 conceptuses.  We also 
corroborated the allele specificity of the identified monoallelically expressed genes using 
B. t. taurus × B. t. taurus progenies to exclude potential cis-eQTL effects on allelic 
expression.  These analyses confirmed the allelic origin of 23 transcripts previously 
reported to be imprinted in bovine and identified eight novel imprinted genes in the 
bovine conceptuses.  Of note, we were not able to corroborate the allele-specific 
expression of 16 genes in the B. t. taurus × B. t. taurus conceptuses because of a lack of 
informative SNPs.  However, of these 16 genes, PPP1R9A, PON3, MKRN3, and ZIM2 
have previously been reported to be imprinted in human and/or mouse and showed 
consistent allele-specific expression in the B. t. indicus × B. t. taurus F1s, which together 
suggest that these four genes are also imprinted in bovine.  
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 Most imprinted genes are organized in megabase-sized clusters.  Within the 
cluster is a differentially methylated imprinting control region that regulates the proper 
allelic expression of the imprinted genes across the entire domain (Edwards and 
Ferguson-Smith, 2007; Wan and Bartolomei, 2008).   Of the 53 monoallelically 
expressed genes identified in this study, 30 genes have previously been reported to be 
imprinted in humans and/or mice and 24 are distributed in eight imprinted clusters 
namely; GNAS/GNASXL domain, PEG3/USP29 domain, GTL2/DLK1 domain, 
PEG10/SGCE domain, MEST/COPG2 domain, SNRPN domain, H19/IGF2 domain, and 
KCNQ1 domain.  Further, ten previously uncharacterized/unannotated transcripts were 
identified to be subject to allele-specific expression in two known imprinted clusters (i.e., 
four transcripts in PEG3/USP29 domain and six in the SNRPN domain) in the B. t. 
indicus × B. t. taurus conceptuses.  Of these 10 transcripts, LOC100298176 and 
LOC1014974975 (within the PEG3/USP29 domain) and LOC101907679 and 
LOC100849023 (within the SNRPN domain) were demonstrated to be imprinted in the 
bovine conceptuses.  For the remaining six transcripts, parental-specificity could not be 
ascertained due to a lack of informative SNPs in the B. t. taurus × B. t. taurus 
conceptuses.  However, we suggest that these genes are also imprinted in bovine because 
of the proximity of these uncharacterized/unannotated transcripts to known imprinted 
genes is less than 100 kb and they are within known and well characterized clusters.  In 
addition, in the SNRPN domain, the last exon of the antisense LOC100848941 brain 
isoform extends to the UBE3A gene.  It is tempting to speculate that the paternal 
expression of this transcript may be involved in the repression of the paternal copy of 
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UBE3A as is observed for UBE3A-ATS in human (Rougeulle et al., 1998) and mouse 
(Meng et al., 2012).   
 Gene expression can be affected by genetic variants.  cis-eQTL refers to the class 
of genetic variants that affect gene expression on the same DNA molecule thus leading to 
allele-specific or allele-biased gene expression (Rockman and Kruglyak, 2006).  To 
determine whether monoallelic gene expression identified in the B. t. indicus × B. t. 
taurus F1s was due to cis-eQTL effects or genomic imprinting, we corroborated the 
parent-specificity of the transcripts in B. t. taurus × B. t. taurus progenies as we lack the 
ability to produce reciprocal B. t. taurus × B. t. indicus crosses.  Our findings confirmed 
that monoallelic gene expression is not necessarily the result of genomic imprinting 
(Wang and Clark, 2014).  For the example of LOC101905472, it is always the “C” allele 
that is predominantly expressed regardless of its parental-origin in both B. t. indicus × B. 
t. taurus and B. t. taurus × B. t. taurus conceptuses.  Further, CDA and RDH16 showed 
monoallelic expression in B. t. indicus × B. t. taurus conceptuses but biallelic expression 
in B. t. taurus × B. t. taurus progenies.  Our results demonstrate that strong cis-eQTL 
could lead to monoallelic gene expression and highlight the importance of the 
determination of allele-specific gene expression using different mating structures crosses 
prior to claiming that any monoallelically expressed genes are imprinted.   
 Genome-wide assessment of imprinted gene expression in non-inbred organisms 
such as cattle and humans can be challenging, as heterozygous SNPs are not always 
informative of parental-origin of an allele.  We were unable to assign the allele-origin of 
a heterozygous SNP in the B. t. indicus × B. t. taurus F1s if the B. t. indicus sire was 
heterozygous at the same site.  Discovery of imprinted genes using RNAseq relies on 
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aligning reads to a reference genome, however, some bovine sequences have recently 
been shown to be absent or misassembled in the current bovine reference genome 
UMD3.1 (Whitacre et al., 2015) and perfection of the reference assembly will help 
improve the RNAseq-based identification of imprinted genes in cattle.  Further, technical 
limitations of standard RNAseq may also preclude the comprehensive discovery of 
imprinted genes.  For example, the identification of antisense imprinted transcripts such 
as APEG3, a paternally expressed antisense transcript in the PEG3 locus (Choo et al., 
2008),  is not possible as our samples were not sequenced using a strand-specific 
RNAseq protocol (Levin et al., 2010).  In addition, the procedures performed for RNA 
isolation for this study prevent us from identifying small imprinted RNAs as well as non-
polyadenylated molecules (e.g., some long ncRNAs).  In future studies, the single-cell 
RNAseq technology will allow allele-specific gene expression analyses at exquisite 
resolution (Deng et al., 2014) and help identify genes that are only imprinted in specific 
cell types such as Ube3a in neurons (Yamasaki et al., 2003).   
 Advances in next generation sequencing technology have allowed the discovery 
of more than a million A-to-I RNA editing sites in human (Ramaswami et al., 2012; 
Ramaswami et al., 2013) and thousands of sites in mouse (Danecek et al., 2012; Neeman 
et al., 2006).  Conversely to human and mouse, only 23 A-to-I RNA editing sites have 
been reported in cattle and these editing sites were identified as a result of searching 
evolutionarily conserved human/mouse A-to-I RNA editing sites in bovine brain RNAseq 
data (Pinto et al., 2014).  In this study, we greatly expand the list by identifying 
671potential A-to-I RNA editing sites in the bovine conceptuses using RNAseq.  
Consistent with the observation that most A-to-I editing sites in human and mouse are not 
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located in coding regions (Li and Church, 2013; Ramaswami et al., 2013), ~96% of the 
identified editing sites in this study were in UTRs and introns.  These editing events 
could either regulate RNA splicing processes (Rueter et al., 1999) or prevent the 
formation of double stranded RNA that may be recognized as non-self by the immune 
system (Liddicoat et al., 2015).  We also found that ~3% (20/671) of the editing sites 
identified in bovine are conserved in human and/or mouse and 11 of these sites are within 
neurotransmitter receptor genes such as GRIK2, GRIA2, and GABRA3.   One of the 
notable conserved A-to-I RNA editing sites is in GRIA2 CDS region (Chr17:42,806,724; 
UMD3.1), which has ~99% edited transcripts in brain and can result in the replacement 
of a glutamine residue by arginine in the GRIA2 protein.  This editing site has been 
demonstrated to be the physiologically most important editing substrate of Adar2 because 
the seizure and lethality phenotype of Adar2 null mice can be reverted when the unedited 
Gria2 transcripts are replaced with the edited allele (Higuchi et al., 2000). 
 Imprinted X-chromosome inactivation in extraembryonic membranes has been 
described in mouse (Huynh and Lee, 2001) and rat (Wake et al., 1976).  In bovine, a 
report showed that the X-linked gene MAOA is preferentially expressed from the 
maternal X-chromosome in term placenta suggesting imprinted X-inactivation in this 
species (Xue et al., 2002).   Here we show that XIST is expressed from both parental 
chromosomes in epiblast-free (van Leeuwen et al., 2015)extraembryonic membranes 
from day 15 bovine conceptuses(Dobbs et al., 2014).  From our results, we favor the 
hypothesis that XCI is random in bovine extraembryonic membranes and not imprinted 
as previously suggested.  
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 In summary, with this work we advance the field of genomic imprinting by 
expanding the list of imprinted genes in bovine and demonstrate that monoallelic gene 
expression can be due to cis-eQTL effects.  In addition, our results greatly increase the 
number of identified A-to-I RNA editing sites in bovine conceptuses.  We also show that 
XCI is random in bovine extraembryonic membranes.  These findings will facilitate 
future studies to further dissect the molecular mechanisms and physiological roles of 
genomic imprinting and A-to-I RNA editing during fetal development of this 
economically important species.  
 
4.5   Materials and methods 
 Whole genome sequencing of the B. t. indicus sire 
 Genomic DNA isolated from the semen of the B. t. indicus sire (Nelore breed; 
ABS CSS MR N OB 425/1 677344 29NE0001 97155) used to generate the B. t. indicus × 
B. t. taurus F1 hybrids was subject to DNAseq.  In brief, two DNAseq libraries (one with 
350 bp target insert size, the other with 550 bp target insert size) were prepared using 
Illumina TruSeq DNA PCR-Free Sample Preparation Kit according to the manufacturer’s 
instructions (Illumina).  Each DNAseq library was sequenced in a single lane with 2 ×100 
bp paired-end reads on an Illumina HiSeq 2000 platform.  One percent PhiX DNA was 
spiked into the bovine genomic DNA sample prior to library preparation to act as an 
internal control and allow the HiSeq optical system optimal base calling.   A total of 
347.3 million raw read pairs were obtained for genotyping the B. t. indicus sire after 
removing the DNAseq reads derived from PhiX DNA (Fig. S1).  The raw FASTQ files 
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are publically available at Gene Expression Omnibus (GEO accession no. GSE77389). 
 Identification of the SNPs of B. t. indicus sire using DNAseq 
 Raw DNAseq read pairs were subject to quality trimming prior to alignment to 
the reference genome (Fig. S1).  The FastqMcf program (version: 1.04.636; 
https://code.google.com/p/ea-utils/wiki/FastqMcf) was used to remove the adaptor 
sequences in the reads.  Further, DynamicTrim (version: 3.3.1; Cox et al., 2010) was used 
to obtain the longest segment of the read in which each base has <1% error rate.  After 
quality trimming, DNAseq read pairs were aligned to the bovine reference genome 
assembly UMD3.1 using Bowtie2 (version: 2.2.3; Langmead et al., 2009).  Only read 
pairs that had the expected read mate orientation and expected ranges of insert size were 
retained for further analyses.   
 Following Bowtie2 alignment, Genome Analysis Tool Kit (GATK; version: 3.3-
0; DePristo et al., 2011; McKenna et al., 2010) was used to further process the aligned 
read pairs for SNP calling.  Known insertions/deletions (indel) and known SNPs 
downloaded from Ensembl and RefSeq FTP sites were supplied for insertions/deletions 
re-alignment and base quality recalibration (ftp://ftp.ensembl.org/pub/release-
78/variation/vcf/bos_taurus/; ftp://ftp.ncbi.nlm.nih.gov/snp/organisms/cow_9913/VCF/; 
ftp://ftp.ncbi.nlm.nih.gov/snp/organisms/cow_30522/).  After processing the aligned read 
pairs, GATK HaplotypeCaller was used to identify SNPs using the default parameters.  
Aligned read pairs subjected to indel realignment were also used for SNP calling by 
GATK HaplotypeCaller and SAMtools mpileup (version: 0.1.19; Li, 2011; Li et al., 
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2009) without the base quality recalibration step in order to improve the identification of 
true SNPs. 
 Generation of the pseudo B. t. indicus genome and construction of a B. t. 
indicus/B. t. taurus diploid genome 
A pseudo B. t. indicus genome was generated by editing the reference allele 
(UMD3.1; i.e., B. t. taurus) with the SNPs found in our B. t. indicus sire identified by the 
three SNP calling pipelines mentioned above (Fig. S1B, C, and D).  The diploid genome 
was generated by combining the B. t. taurus and the pseudo B. t. indicus FASTA files.    
 RNAseq of the day ~105 B. t. indicus × B. t. taurus F1 conceptuses 
 The four day ~105 B. t. indicus × B. t. taurus F1 conceptuses used in this study 
(i.e., Control #1, #2, #3, and #4) were previously described (Chen et al., 2013).  These 
conceptuses shared the same B. t. indicus sire (ABS CSS MR N OB 425/1 677344 
29NE0001 97155).  RNAseq data of brain, kidney, liver, and skeletal muscle of the F1 
individuals were previously described (GEO accession number: GSE63509; Chen et al., 
2015).   In addition, for the current study, we generated RNAseq data from the placenta 
(intercotyledon regions) of these conceptuses following the RNA isolation, library 
preparation and sequencing procedures described previously (Chen et al., 2015).  The raw 
FASTQ files are publically available at GEO database (accession no. GSE77389).  
 Alignment of RNAseq reads to the custom diploid genome 
 Prior to alignment, single-end RNAseq reads were processed as previously 
described (Chen et al., 2015).  In brief, FastqMcf  (version: 1.04.636; 
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https://code.google.com/p/ea-utils/wiki/FastqMcf) and DynamicTrim (version: 3.3.1; Cox 
et al., 2010) programs were used to remove adaptor sequences and low quality bases in 
the reads, respectively. Only reads with a length greater than 30 bp were used for 
alignment.  The RNAseq reads were aligned to the custom diploid genome to minimize 
single reference genome alignment bias (Degner et al., 2009; Munger et al., 2014; 
Stevenson et al., 2013; Yuan et al., 2015).  
 HISAT2 (version: 2.0.0; Kim et al., 2015) was used to align RNAseq reads to the 
diploid genome using the following parameters: --score-min L, 0, -0.2 –mp 6, 6 –known-
splicesite-infile known-splicesite-RefSeq-Ensembl.txt.  These parameters require at least 
96% sequence identity for the RNAseq reads to be aligned.  The known splicing 
junctions in Ensembl and RefSeq databases were downloaded from the Bovine Genome 
Database (http://www.bovinegenome.org; Elsik et al., 2015).  The alignment of the 
RNAseq reads to the diploid genome was then merged to identify: i) reads that were 
aligned to the same single genomic position in both the B. t. taurus reference genome and 
the pseudo B. t. indicus genome, and ii) reads that were uniquely aligned to either 
genome but not aligned to the other.   
 Transcript assembly and determination of transcript abundance 
 Cufflinks (version: 2.2.1; Trapnell et al., 2010) was used for transcript assembly 
of each RNAseq library.  Cuffmerge (version: 2.2.1; Trapnell et al., 2010) was used to 
generate a unified gene annotation for all libraries.  Gene models generated by Cuffmerge 
were then compared to Ensembl and RefSeq gene models using Cuffcompare (version: 
2.2.1; Trapnell et al., 2010).  If a Cuffmerge gene model matched one Ensembl/RefSeq 
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gene model (i.e., shared the same intron chain; class_code “=”), this Cuffmerge gene 
model was considered annotated.  If a cuffmerge gene model did not match any 
Ensembl/RefSeq gene model (e.g., class_code “u” or “x”), it was considered 
unannotated.  In addition, if a single Cuffmerge gene model matched more than one 
Ensembl/RefSeq gene model, the Cuffmerge gene model was replaced by the 
corresponding Ensembl/RefSeq gene models.   
 RNAseq read counts for each gene model were generated using HTSeq-count 
(version: 0.5.4; Anders et al., 2013) with mode: intersection-nonempty. Read counts were 
then normalized to the library size using Bioconductor package edgeR (version: 3.8.6; 
McCarthy et al., 2012; Robinson et al., 2010).  For each tissue type, genes with ≥ 4 
counts/million (CPM) between all conceptuses were considered to be expressed and were 
retained for allele-specific expression analyses.  
 Identification of SNPs in the B. t. indicus × B. t. taurus F1 conceptuses 
transcriptomes using RNAseq 
 The SNPiR pipeline (Piskol et al., 2013) was adapted to identify SNPs from the 
RNAseq data.  The adapted SNPiR pipeline included 3 major steps: i) align RNAseq 
reads to the diploid UMD3.1/B. t. indicus genome using BWA mem (Li and Durbin, 
2009), ii) call variants using GATK UnifiedGenotyper (McKenna et al., 2010), and iii) 
filter potential false positive variants (as described below).  For read mapping, BWA 
mem (version: 0.7.7; Li and Durbin, 2009) was used to align the reads to the diploid 
genome using default parameters.  As BWA does not align reads that span splice 
junctions, we next aligned the unmapped reads to the known splice junctions 
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(http://www.bovinegenome.org; Elsik et al., 2015).  The RNAseq reads that were 
successfully aligned to the diploid genome were then merged with the splice junction 
alignments.   The uniquely aligned RNAseq reads were subjected to PCR duplicates 
removal (only for the purpose of SNP identification), insertions/deletions re-alignment, 
and base quality recalibration.  All RNAseq read alignments from each conceptus were 
then pooled for SNP calling.  GATK UnifiedGenotyper was used to call variants using 
the following loose criteria: -stand_call_conf 0 –stand_emit_conf 0 –mbq 20 –
output_mode EMIT_ALL_CONFIDENT_SITES –U ALLOW_N_CIGAR_READS.  The 
last step of these analyses was to apply a series of stringent filtering steps to remove 
potential false positive variants.  Specifically, variants were required to have quality Q > 
20 and all variants that were only found at the end (< 6 bp to read ends) of aligned reads 
were discarded.  Further, RNA variants in repetitive regions annotated by UCSC 
(http://hgdownload.cse.ucsc.edu/goldenPath/bosTau6/database/) were discarded and 
variants that were in a homopolymer runs ≥ 5 bp were also removed.  In addition, intronic 
variants that were within 4 bp of splice junctions were discarded.  Finally, to ensure that 
the reads supporting the variants were uniquely aligned, BLAT (version: 34; Kent, 2002) 
was used to re-align these reads to the reference genome.  A read alignment was required 
to meet two criteria to be considered as a unique mapping: i) the best alignment hit 
overlapped the variant site, and ii) the second best hit resulted in a <95% sequence 
identity to the reference genome.  Only the variants for which at least half of the 
alignments were unique to the reference genome were retained for further analyses. 
To minimize potential false positives, only the RNA variants identified by both 
the HISAT2 and BWA alignment strategies were used for further analyses.  Further, the 
	   179 
RNA variants that were supported by the B. t. indicus DNAseq reads and/or were present 
in RefSeq and Ensembl dbSNP (downloaded from RefSeq and Ensembl FTP sites) were 
defined as genomic variants, while others were defined as RDDs.  It should be noted that 
if a SNP in dbSNP was submitted with molecular type as “cDNA”, this SNP was 
considered to be an RDD (i.e., a potential RNA editing site).  The genomic variants were 
considered to be the result of SNPs and were used to assign RNAseq reads to parental 
alleles for allele-specific gene expression analyses, while the RDDs were used to identify 
A-to-I RNA editing sites.  Finally, the transition/transversion (Ts/Tv) is the number of 
transition variants (purine-to-purine, pyrimidine-to-pyrimidine) to the number of 
transversion variants (purine-to-pyrimidine, pyrimidine-to-purine). 
 Identification of A-to-I RNA editing sites using the RNAseq data of B. t. indicus × 
B. t. taurus F1 conceptuses 
 The RDDs were subjected to further filtering to identify A-to-I RNA editing sites.  
Only the RDDs that were detected in the same tissue for all four conceptuses (≥ 10 reads 
coverage/conceptus) were retained for further analyses.  The rationale for this was that 
true A-to-I RNA editing sites should be present in all animals while low frequency SNPs 
should not (Ramaswami et al., 2013).  It should be noted that the RNAseq reads for brain, 
liver, and skeletal muscle of Control #2 were of 50 bp in length and for these samples, the 
RDDs were kept for further analyses if they were present in Control #1, #3, and #4 
conceptuses (all 100 bp reads).  Finally, the RDDs were manually annotated to determine 
the variant type (e.g., A>G or T>C) according to the DNA strand of the transcript 
template.  For example, if a “T>C” variant was in a transcript that was transcribed from 
the antisense DNA strand then the variant type was converted from “T>C” to “A>G”.  
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Only the RDDs that had the “A>G” variant type were considered candidate A-to-I RNA 
editing sites. 
 To determine whether any of the A-to-I RNA editing sites identified in bovine 
day~105 conceptuses were conserved in human and/or mouse, 40 bp upstream and 
downstream sequences (Pinto et al., 2014) of the bovine A-to-I RNA editing site were 
BLAST  against the human (hg19) and mouse builds (mm9).  Both human and mouse 
genomes were downloaded from the UCSC database 
(http://hgdownload.soe.ucsc.edu/goldenPath/hg19/bigZips/; 
http://hgdownload.soe.ucsc.edu/goldenPath/mm9/bigZips/, respectively).  For a site to be 
considered to be conserved between bovine, mouse, and/or human, 70 of the 81 
nucleotides had to provide a perfect match (Pinto et al., 2014) and the site had to have 
previously been reported to be an A-to-I RNA editing site.  The previously identified 
editing sites in human and mouse were downloaded from the RADAR database 
(http://rnaedit.com; Ramaswami and Li, 2014). 
 Allele-specific gene expression analyses using the RNAseq data of B. t. indicus × 
B. t. taurus F1 conceptuses 
 The DNA variants of the B. t. indicus sire were used to determine the allele-origin 
of the RNAseq reads in the B. t. indicus × B. t. taurus F1 hybrids.  As illustrated in Fig. 
S5, only SNP sites that were homozygous in the B. t. indicus sire and for which the SNP 
was heterozygous or an alternate homozygote in the conceptuses were used to determine 
the allele-origin of the RNAseq reads.  Following the allele-origin assignment, allele-
specific read counts for SNPs in the same gene were aggregated for allele-specific gene 
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expression analyses, as this strategy has been shown to improve the sensitivity of 
prediction of imprinted genes using RNAseq (DeVeale et al., 2012).  To identify genes 
with monoallelic expression in each tissue type, allele-specific read counts of the same 
gene were pooled for all four individuals and the significance of allelic expression bias 
was determined using the binomial test (see statistical analyses section). To further filter 
potential false positives, these candidate genes were manually inspected using the 
Integrative Genomic Viewer (IGV; Robinson et al., 2011) and genes with spurious 
alignment of the RNAseq reads or discordant allelic bias of the SNPs within the same 
exon were discarded.    
 Validation of the A-to-I RNA editing sites in B. t. indicus × B. t. taurus F1 hybrids  
 DNA and cDNA of the B. t. indicus × B. t. taurus F1 conceptuses were amplified 
by PCR and were subjected to Sanger sequencing to validate the A-to-I RNA editing sites 
identified by RNAseq.  Nucleic acid isolation, cDNA synthesis, and PCR amplification 
were as previously reported (Chen et al., 2015; Chen et al., 2013). Primer information 
may be found in Table S7 (link to Table S7: 
http://www.tandfonline.com/doi/full/10.1080/15592294.2016.1184805).   
 Validation of the allele-specific gene expression in B. t. indicus × B. t. taurus F1 
hybrids 
 To validate the allele specificity of the monoallelically expressed genes, both 
DNA and cDNA of the F1 hybrids and DNA of the sire were amplified by PCR and 
sequenced over the SNP sites used to ascribe parental origin of the transcripts.  Nucleic 
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acid isolation, cDNA synthesis, and PCR amplifications were as previously reported 
(Chen et al., 2015; Chen et al., 2013). Primer information may be found in Table S7.  
 Corroboration of the allele-specific gene expression in day 86 B. t. taurus × B. t. 
taurus conceptuses 
 B. t. taurus females (i.e., Holstein breed) were subjected to estrous 
synchronization and artificial insemination with sex-sorted semen from a single B. t. 
taurus bull (i.e., Holstein breed; 507HO10723 DE-SU 527 SPUR-ET).  Nine B. t. taurus 
× B. t. taurus female conceptuses were collected at day 86 of gestation.  At collection, 1 × 
1 mm2 samples of internal organs including brain, kidney, liver, skeletal muscle and fetal 
placenta (intercotyledon area) were snap frozen in liquid nitrogen and stored at -80 °C.  
Both DNA and cDNA of the B. t. taurus × B. t. taurus conceptuses and DNA of the B. t. 
taurus sire were amplified by PCR to corroborate the parental-specific gene expression 
(i.e., imprinted status) of the identified monoallelically expressed genes detected in the B. 
t. indicus × B. t. taurus F1 hybrids.  Nucleic acid isolation, cDNA synthesis, and PCR 
amplification were as previously reported (Chen et al., 2015; Chen et al., 2013). Primer 
information may be found in Table S7. 
 DNA methylation analysis at GNAS/GNASXL domain 
 Bisulfite mutagenesis of genomic DNA was performed following the One-Step 
Modification Procedure of the Imprint DNA Modification Kit (Sigma).  Methyl Primer 
Express Software (version 1.0, Applied Biosystems) was used to design primers that 
amplify regions proximal to the GNAS and GNASXL promoters.  Both amplicons spanned 
SNPs identified by the whole genome sequencing of the B. t. indicus sire.  Bisulfite PCR 
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reactions were as previously reported (Chen et al., 2015; Chen et al., 2013).  The cycling 
programs were as follows: initial denaturation at 94°C for 2 minutes and 15 seconds, 45 
cycles of 94°C for 30 seconds, 56.1/58.7°C for 45 seconds (ramping rate: 1°C/second), 
and 72°C for 45 seconds, and final extension at 72°C for 5 minutes.  The PCR products 
were resolved by agarose gel electrophoresis and isolated as previously described (Chen 
et al., 2013).  The PCR amplicons were cloned using pGEM-T Easy Vector System 
(Promega) according to the manufacturer’s instructions.  Bacteria used were NEB 5-alpha 
F'Iq Competent E. coli (NEB). Bacteria colonies were screened by blue-white screen 
method and positive colonies were subject to Sanger sequencing as described above. 
 Statistical analyses 
 All RNAseq libraries were normalized by the trimmed mean of M-values method 
(Robinson and Oshlack, 2010).  For each gene, a binomial exact test was applied to 
examine if the B. t. indicus or B. t. taurus allele represented more than 85% of all reads 
(Chen et al., 2015). Genes were then ranked by their p-values and adjusted to compute 
false discovery rates (FDRs) using the Storey method (Storey, 2002). Genes for which 
the FDR was less than 0.05 were considered to be monoallelically expressed.  
 Data access 
 The DNAseq reads from the B. t. indicus sire and the RNAseq reads from the B. t. 
indicus × B. t. taurus F1 conceptuses are available in the NCBI Gene Expression 
Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/) under accession numbers 
GSE77389 (DNAseq reads of the sire and RNAseq reads of the placenta) and GSE63509 
(RNAseq reads of the brain, kidney, liver, and skeletal muscle).  The sequences of the 
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unannotated transcripts identified in this study have been submitted to GenBank 
(http://www.ncbi.nlm.nih.gov/genbank/) under accession numbers KU530101-
KU530107. 
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Figure S1.  Genotyping the B. t. indicus sire using whole genome sequencing.  A). Summary of the B. t. 
indicus sire DNAseq results.  B). Pipelines used for SNP identification.  C). Venn diagram showing the 
overlapping of the SNPs identified using different pipelines.  D). Number of heterozygous and homozygous 
SNPs identified in the B. t. indicus sire using different pipelines. 
4.7 Supplemental information for Chapter 4 
 
Supplemental figures and tables for Chapter 4 
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Figure S2.  Genotyping the B. t. indicus × B. t. taurus F1 hybrids using RNAseq.  A). Venn 
diagrams showing the overlapping of the RNA variants identified using the HISAT2 or BWA as reads 
aligner.  B). Comparison of the identified RNA variants with bovine dbSNP entries and the B. t. 
indicus sire SNPs.  C). Variant type distribution of the genomic variants (i.e., variants matched to 
bovine dbSNP entries and/or supported by the B. t. indicus sire DNAseq reads).  D). Variant type 
distribution of the RNA-DNA differences (RDDs). Ts = transition (purine-to-purine, pyrimidine-to-
pyrimidine); Tv = transversion (purine-to-pyrimidine, pyrimidine-to-purine). 
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Figure S3.  Validation of the identified A-to-I RNA editing sites in the B. t. indicus × B. t. 
taurus F1 hybrids by Sanger sequencing.  The red arrows indicate the editing sites.  A). An 
example of A-to-I editing in coding sequences (CDS) of COPA.  B). Two RNA editing sites in 
CDS of GRIK2.  C). Two RNA editing sites in the CDS of GABRA3, one of which was not 
validated by Sanger sequencing (i.e., ChrX:34,866,869). 
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Figure S4.  Pie charts for the A-to-I RNA editing sites at different gene sections in each tissue 
of the B. t. indicus × B. t. taurus F
1
 hybrids.  CDS:  coding sequence; UTR: untranslated region; 
ncRNA: noncoding RNA. 
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Figure S5.  Illustration of the strategy used to assign parental alleles of RNAseq reads in the 
B. t. indicus × B. t. taurus F1 hybrids. 
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Figure S6.  Allele-specific gene expression and DNA methylation analyses at 
GNAS/GNASXL imprinted domain in the B. t. indicus × B. t. taurus F1 hybrids.  A). 
Schematics of GNAS/GNAXL loci and Sanger sequencing validation of the allele-specific 
gene expression of GNAS and GNASXL.  Details are as Figure 3.  Primers used for RT-PCR 
are shown as arrows facing each other.  B). Full bisulfite maps of GNAS and GANSXL 
DMR.  Each row = one strand of DNA; open circles, unmethylated CpG sites; filled circle, 
methylated CpG sites; missing circles are due to SNPs or undetermined bases because of 
sequencing issues. 
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Figure S7.  Validation of the allele-specific expression of the genes that are previously described as 
imprinted in human and/or mouse in the B. t. indicus × B. t. taurus F1 hybrids.  A). GTL2/DLK1 
domain.  B). PEG10/SGCE domain.  C). MEST/COPG2 domain.  Details are as Figure 3. 
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Figure S8. Validation of the allele-specific gene expression in PEG3/USP29 imprinted 
domain in the B. t. indicus × B. t. taurus F1 hybrids.  Details are as Figure 3.  
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Figure S9.  Validation of the allele-specific gene expression in SNRPN imprinted domain 
in the B. t. indicus × B. t. taurus F1 hybrids.  For LOC100848941 and LOC101907203, SNPs 
used for allelic expression analyses are indicated by asterisks.  RT-PCR primers amplifying 
each transcript are indicated by arrows facing each other.  Other details are as Figure 3. 
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Figure S10.  	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Figure S10.  Corroboration of the allele-specific expression of the singleton genes identified 
in the B. t. indicus × B. t. taurus F1 hybrids and the B. t. taurus × B. t. taurus conceptuses.  For 
each gene, the left panel is the Sanger sequencing validation of the monoallelic expression in the 
B. t. indicus × B. t. taurus F1 hybrids while the right panel is the corroboration of the allelic 
expression in the B. t. taurus × B. t. taurus conceptuses.  Other details are as in Figure. 4.  
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Figure S11.  	  
	   199 
  
LOC100298176 (B. t. taurus × B. t. taurus) 
5720 B. t. taurus sire 7682 
G
en
om
ic
 D
N
A 
B
ra
in
 c
D
N
A 
LOC100298176 (B. t. indicus × B. t. taurus)  
Control #3 B. t. indicus sire Control #1 
LOC104974975 (B. t. taurus × B. t. taurus) 
5720 B. t. taurus sire 7682 
G
en
om
ic
 D
N
A 
B
ra
in
 c
D
N
A 
LOC104974975 (B. t. indicus × B. t. taurus)  
Control #4 B. t. indicus sire Control #1 
G
en
om
ic
 D
N
A 
B
ra
in
 c
D
N
A 
MEG8 (B. t. indicus × B. t. taurus) 
Control #4 B. t. indicus sire Control #1 
G
en
om
ic
 D
N
A 
S
ke
le
ta
l 
m
us
cl
e 
cD
N
A 
MEG8 (B. t. taurus × B. t. taurus) 
5720 B. t. taurus sire 7682 
G
en
om
ic
 D
N
A 
S
ke
le
ta
l 
m
us
cl
e 
cD
N
A 
Figure S11.  	  
	   200 
  
S
ke
le
ta
l m
us
cl
e 
cD
N
A 
USP29 (B. t. taurus × B. t. taurus)  
5720 B. t. taurus sire 7682 
G
en
om
ic
 D
N
A 
B
ra
in
 c
D
N
A 
K
id
ne
y 
cD
N
A 
Li
ve
r c
D
N
A 
P
la
ce
nt
a 
cD
N
A 
USP29 (B. t. indicus × B. t. taurus) 
Control #4 B. t. indicus sire Control #1 
G
en
om
ic
 D
N
A 
B
ra
in
 c
D
N
A 
K
id
ne
y 
cD
N
A 
Li
ve
r c
D
N
A 
S
ke
le
ta
l m
us
cl
e 
 
cD
N
A 
P
la
ce
nt
a 
cD
N
A 
Figure S11.  	  
	   201 
  
S
ke
le
ta
l m
us
cl
e 
cD
N
A 
ZIM2 (B. t. taurus × B. t. taurus) 
8342 B. t. taurus sire 7879 
G
en
om
ic
 D
N
A 
K
id
ne
y 
cD
N
A 
Li
ve
r c
D
N
A 
P
la
ce
nt
a 
cD
N
A 
S
ke
le
ta
l m
us
cl
e 
cD
N
A 
ZIM2 (B. t. indicus × B. t. taurus)  
Control #3 B. t. indicus sire Control #1 
G
en
om
ic
 D
N
A 
K
id
ne
y 
cD
N
A 
Li
ve
r c
D
N
A 
P
la
ce
nt
a 
cD
N
A 
Figure S11.  	  
Figures S11.  Corroboration of the allele-specific expression of the genes in the B. t. taurus × 
B. t. taurus conceptuses that are either known imprinted genes in human/mouse or are 
located in known imprinting clusters.  Details are as Figure. 4. 
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Chapter 5 General discussion 
 In the 1960s, Drs. Beckwith and Wiedemann first described BWS as a somatic 
overgrowth disorder with predisposition of childhood cancer (Beckwith, 1969; 
Wiedmann, 1964).  In the 1980s, genetic linkage studies indicated that BWS is related to 
chromosome 11p15.5 (Koufos et al., 1989; Ping et al., 1989), a region that turned out to 
harbor two imprinted clusters, namely, the KCNQ1 locus and the H19/IGF2 locus.  Since 
then, with the help of several mouse models of BWS, the main focus of the field has been 
to address how loss-of-imprinting at 11p15.5 leads to the complex and variable 
phenotypic features of BWS.  However, to date, there has been no report of molecular 
features that can consistently and reliably diagnose and predict BWS and the associated 
variable phenotypes.   
 The first cases of ART-induced LOS were reported in 1995 (Farin and Farin, 
1995) and several reasons have prompted us to use LOS as an animal model to study the 
molecular etiology of human BWS.  First, LOS recapitulates most BWS phenotypic 
features including the cardinal symptoms such as somatic overgrowth, enlarged tongue, 
ear malformation, and abdominal wall defects (Chen et al., 2013; Mussa et al., 2016; 
Young et al., 1998).  Second, LOS fetuses exhibit the most common epimutation 
observed in BWS, namely, hypomethylation at the KCNQ1 locus (Chen et al., 2013; Hori 
et al., 2010).  Third, both BWS and LOS have a higher risk in the offspring born with the 
use of ART and both syndromes can also occur naturally (reviewed in Choufani et al., 
2010; Personal communication with RMR; Young et al., 1998).  Fourth, the development 
of LOS in bovine is more similar to BWS compared to the mouse models, which rely on 
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genetic manipulations of the imprinted genes and exhibit more severe phenotypes that are 
not observed in BWS (e.g., embryonic/neonatal lethality).    
 We have advanced the field by providing the following insights. 1) LOS is a 
multi-locus loss-of-imprinting syndrome and the number of genes exhibiting loss-of-
imprinting is positively correlated with bodyweight. 2) Loss of allele-specific expression 
of imprinted genes in LOS is associated with aberrant DNA methylation at the associated 
imprinted DMRs in a tissue-specific manner. 3) LOS fetuses not only exhibit loss of 
allele-specific expression of imprinted genes, but also display differential transcript 
amount of these genes compared to controls. 4) Different tissues within LOS fetuses have 
perturbations of distinct gene pathways and in particular, multiple pathways involved in 
myoblast proliferation and fusion into myotubes are mis-regulated in skeletal muscle of 
LOS fetuses. 5) Numerous local methylation differences exist between control and LOS. 
6) Most of identified DEGs between control and LOS could not be directly associated 
with altered DNA methylation, suggesting that caution should be exercised when making 
conclusions about the etiology of such syndromes by interpreting time-point-specific 
DNA methylation data.  
  In addition to characterizing the transcriptome and methylome in LOS at day 
~105 pregnancy (gestation = 280 days), we also identified eight novel bovine imprinted 
genes and showed that monoallelic gene expression can be the result of cis-eQTL effects.  
Further, during the de novo identification of novel imprinted genes, it was imperative to 
differentiate DNA polymorphisms from RNA editing sites in order to accurately assign 
the parental-origin of RNAseq read.  By doing this, we identified 671 A-to-I RNA editing 
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candidate sites, thus increasing the list in bovine by 651 potential sites. It should be noted 
that no differences in A-to-I RNA editing were observed between LOS and control.  
Despite the progress accomplished by my dissertation research, the molecular 
etiology of BWS/LOS is still not understood and several key points remain to be 
addressed in future studies. The following sections will present and address some of these 
points. 
 
5.1 How does the use of ART lead to epigenetic instability?   
5.1.1 Superovulation and loss-of-imprinting 
  Superovulation is commonly used to increase oocyte number for assisted 
reproduction and numerous studies have reported that superovulation results in loss-of-
imprinting (reviewed in Denomme and Mann, 2012).  For instance, superovulation can 
induce gain of methylation of the paternally methylated H19/IGF2 DMR and loss of 
methylation of the maternally methylated Snrpn DMR in mouse blastocysts (Market-
Velker et al., 2010).  However, no DNA methylation defects at imprinted gDMRs (i.e., 
Snrpn DMR, KvDMR1, Peg3 DMR, and H19 DMR) are detected so far in ovulated 
oocytes following hyperstimulation, which suggests that superovulation leads to loss-of-
imprinting by affecting imprint maintenance in early embryos rather than imprint 
establishment in oocytes (Denomme et al., 2011).   
 Several maternal factors have been identified to maintain the epigenetic stability 
in early embryos such as the oocyte-specific DNA methyltransferase Dnmt1o and 
Kruppel-associated box zinc finger proteins Zfp57 and Trim28 (Howell et al., 2001; Li et 
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al., 2008; Messerschmidt et al., 2012).  Absence of these maternal factors in oocytes 
leads to embryonic or neonatal lethality largely due to the defects in genomic imprints 
maintenance in early embryos (Howell et al., 2001; Li et al., 2008; Messerschmidt et al., 
2012).  It is possible that superovulation induces ovulation of oocytes that do not reach 
full maturity and do not have sufficient maternal factors such as Dnmt1o, Zfp57, and 
Trim28 to maintain DNA methylation at imprinted gDMRs in early embryos.  In 
addition, superovulated oocytes may represent a rather heterogeneous population of cells 
with some oocytes reaching full maturity while some others with insufficient maternal 
epigenetic factors, which may explain the stochastic feature of superovulation-induced 
loss-of-imprinting (i.e., only some embryos showing loss-of-imprinting while others are 
normal).  In future studies, determination of the transcriptome of individual naturally- and 
superovulated oocytes will ascertain the molecular machinery that is responsible for the 
developmental incompetence of oocytes caused by hyperstimulation.  
5.1.2 Embryo culture and loss-of-imprinting  
 Following fertilization, embryos are usually cultured in vitro to eight-cell or 
blastocyst stage before being transferred to a recipient.  It is well established that embryo 
culture can result in loss-of-imprinting in the absence of superovulation (reviewed in 
Denomme and Mann, 2012).  Notably, mouse embryos cultured in what is considered an 
optimal medium (i.e., KSOM) are less susceptible to loss-of-imprinting and gene 
expression changes compared to a suboptimal medium like Whitten’s (Mann et al., 2004; 
Rinaudo and Schultz, 2004).  It may be speculated that embryos cultured in vitro undergo 
a stress response that consumes more energy otherwise would be used for imprint 
maintenance.  In agreement with this, the glucose transporter gene Slc2a1 that shuttles 
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glucose from the blastocoel cavity to ICM cells is downregulated in cultured embryos 
compared to in vivo embryos (Leppens-Luisier et al., 2001; Uechi et al., 1997).  Thus, the 
decreased availability of glucose may lead to inadequate ATP generation, which could 
negatively affect the regulation of genomic imprinting as ATP powers a number of 
epigenetic factors such as chromatin remodelers (reviewed in Hargreaves and Crabtree, 
2011).  However, it remains unclear why every cultured embryo does not exhibit loss-of-
imprinting and every imprinted gene is not equally affected.    
5.1.3 Loss-of-imprinting in placenta induced by ART  
 The placenta is more susceptible to loss-of-imprinting when the conceptus is 
conceived with the use of ART (de Waal et al., 2014; de Waal et al., 2015; Mann et al., 
2004; Rivera et al., 2008).  Currently, a couple of hypotheses have been put forward to 
explain why epimutations are more frequent in the extra-embryonic lineages when ART 
procedures are applied.  In the first hypothesis, it is thought that extraembryonic cells are 
in direct contact with the culture media and are more severely affected by in vitro culture 
(Mann et al., 2004).  However, this hypothesis does not explain why yolk sac, which is 
derived from primitive endoderm that resides in the inner space of the blastocyst, also 
exhibits similar severity of loss-of-imprinting (Rivera et al., 2008).  Further, 
administration of hyperstimulation hormones without embryo culture and embryo 
transfer can induce more severe loss-of-imprinting in placenta compared to the embryo 
proper (Fortier et al., 2008).  Collectively, this evidence suggests that the direct contact of 
trophectoderm to the culture medium is not the main reason for the differential frequency 
of epimutation between the embryo and the placenta.  Another hypothesis is based on the 
fact that genomic imprinting is differentially regulated in embryo and placenta.  For 
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instance, repression of the maternal flanking genes by the long ncRNA Kcnq1ot1 at the 
Kcnq1 locus depends on DNA methylation in the embryo but relies on histone 
modifications in the placenta (Lewis et al., 2004; Umlauf et al., 2004).  It is possible that 
histone modifications are more dynamic and reversible compared to DNA methylation.  
Thus, the imprinted genes in placenta are more prone to epigenetic errors.  
 In addition to loss-of-imprinting, ART can also induce aberrant gene expression 
and DNA methylation at non-imprinted loci in placenta (de Waal et al., 2015).  For 
example, the use of IVF results in decreased transcript abundance of glucose transporter 
Glut3, which is correlated with the increased DNA methylation level at a CpG island that 
is 1000 bp upstream of the transcription start site (de Waal et al., 2015).  Currently, the 
connections between loss-of-imprinting and misregulation of non-imprinted genes remain 
unclear.  
 
5.2 Molecular etiology of LOS 
5.2.1 Loss-of-imprinting in LOS 
 LOS was first found to be associated with the epigenetic change in IGF2R in 
sheep (Young et al., 2001).  This finding generated questions about the epigenetic 
likeliness of LOS and BWS as Igf2r is not often imprinted in human (Monk et al., 2006).  
Later, we observed biallelic expression of the long ncRNA KCNQ1OT1 and loss of 
methylation of KvDMR1 on the maternal allele in bovine LOS fetuses (Chen et al., 
2013), which epimutations account over 50% of BWS individuals (reviewed in Choufani 
et al., 2010).  More recently, we demonstrated that bovine LOS is a multi-locus loss-of-
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imprinting syndrome (Chen et al., 2015), which is in parallel with the fact that a subset of 
BWS individuals with hypomethylation at the KCNQ1 locus also exhibits imprinting 
errors at other loci (Azzi et al., 2009; Bliek et al., 2009; Eggermann et al., 2016).  Of 
particular interest, the number of imprinted genes showing biallelic gene expression is 
correlated with the bodyweight of LOS fetuses, suggesting that severity of loss-of-
imprinting could be an indicator for LOS overgrowth phenotype (Chen et al., 2015).  
Although some imprinted genes showing loss-of-imprinting in LOS fetuses are known 
fetal growth regulators such as IGF2R and CDKN1C (Barlow et al., 1991; Tunster et al., 
2011), how misregulation of other imprinted genes contributes to variable phenotypes of 
LOS is still not understood.  In future studies, detailed examination morphology, 
histology, and metabolic status of LOS fetuses will help establish the relationship 
between individual imprinted gene/domain and specific phenotypes of LOS. 
 It should be noted that biallelic expression of imprinted genes in LOS fetuses are 
not always associated with aberrant DNA methylation at the adjacent DMRs (Chen et al., 
2015), which is consistent with the observations reported by several other groups (de 
Waal et al., 2014; de Waal et al., 2012a; Susiarjo et al., 2013).  One possibility is that 
only specific cell types in a particular tissue express the imprinted gene and are 
responsible for the monoallelic or biallelic expression pattern detected in the tissue.  
Thus, abnormal DNA methylation in the specific cell types could be masked by the 
normal DNA methylation profiles of other cell types that do not express the imprinted 
gene. Alternatively, aberrant expression of imprinted genes can be due to either 
misregulation of other epigenetic modifications besides DNA methylation or 
misregulation of DNA methylation at other DMRs.  Another interesting observation is 
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that biallelic expression of imprinted genes does not always lead to increased transcript 
abundance.  For example, IGF2R is biallelically expressed in kidney, skeletal muscle and 
liver in all LOS fetuses but exhibits decreased transcript abundance in these tissues 
compared to controls (Chen et al., 2015).  This observation is consistent with previous 
reports that misregulation of imprinted genes can be independent of allele-specific gene 
expression or allele-specific DNA methylation (Boucher et al., 2014; Dalgaard et al., 
2016).  It is likely that additional layer of regulatory factors exist to ensure the fine-
turning expression of imprinted genes.  
 It is unclear why the BWS and LOS individuals exhibit variable loss-of-
imprinting and variable phenotype.  Genetic variation between individuals may not 
completely explain the variability as the LOS fetuses in our studies shared the same sire 
and the dams are from the same population of B. t. taurus animals (Chen et al., 2015; 
Chen et al., 2013).  Instead, stochastic epimutation originating from the in vitro oocyte 
maturation and embryo culture are more plausible causes for the variable loss-of-
imprinting observed in LOS fetuses.  To understand the mechanisms of imprinting errors 
induced by these ART procedures, it would be necessary to determine how early these 
epimutations can be detected in in vitro-derived bovine embryos.  As not all embryos 
exhibit loss-of-imprinting following the use of ART procedures, individual embryos 
should be used for assessment of allele-specific expression and allele-specific DNA 
methylation of imprinted genes.        
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5.2.2 Aberrant gene expression at non-imprinted loci in LOS 
 Using high throughput RNA sequencing, we found that LOS fetuses exhibited 
different numbers of DEGs and that each tissue within LOS fetuses had perturbations of 
distinct gene pathways.  These findings indicate that the molecular lesion of LOS is not 
limited to loss-of-imprinting and the variable phenotypes observed in LOS could be 
contributed by misregulation of both imprinted and non-imprinted genes.  In agreement 
with this, we found that multiple pathways involved in myoblast proliferation and fusions 
into myotubes are misregulated in skeletal muscle of LOS fetuses.  As proposed by a 
previous study in sheep LOS (Maxfield et al., 1998), these altered myogenesis pathways 
may contribute to the large muscles in the oversized LOS fetuses. 
 It is unclear how the use of ART procedures leads to aberrant gene expression at 
the non-imprinted loci.  It is possible that the misregulation of non-imprinted genes is 
either an upstream or downstream effect of the ART-induced loss-of-imprinting.  In 
support of this, it has been shown that imprinted genes regulate fetal development 
through an imprinted gene network in which many non-imprinted genes are also co-
regulated (Varrault et al., 2006).  However, it is also likely that abnormal expression of 
non-imprinted genes and loss-of-imprinting are independent events.  For example, mouse 
conceptuses generated with the use of embryo transfer can exhibit placentomegaly and 
junctional zone overgrowth, but the DNA methylation appears normal at several 
imprinted genes that are associated with the similar phenotypes (de Waal et al., 2015).  In 
future studies, transcriptome analyses of control and LOS fetuses at various 
developmental stages will help decipher these possibilities.  
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5.2.3 Lack of association between DMRs and DEGs in LOS 
 For the purpose of identifying the mechanistic causes of abnormal gene 
expression in LOS fetuses, we profiled the genome wide DNA methylation at single base 
resolution of control and LOS skeletal muscle using whole genome bisulfite sequencing.  
We found numerous local methylation differences between control and LOS fetuses.  
Surprisingly, only a small percent of DEGs could be directly associated with the 
identified DMRs between control and LOS, while altered DNA methylation may not be 
the direct cause of the large number of DEGs identified in LOS.  One potential epigenetic 
modification that mediates the misregulation of the non-imprinted genes is the repressive 
histone modification H3K27me3.  H3K27me3 is mostly enriched at the CpG island 
promoters of a number of developmentally important genes that are not regulated by 
DNA methylation (Boulard et al., 2015).  It has been shown that Ezh2, the 
methyltransferase responsible for H3K27me3, regulates muscle gene expression and 
skeletal muscle differentiation (Caretti et al., 2004).  Further, impaired reprogramming of 
H3K27me3 in early embryos compromises the blastocyst development in bovine 
(Canovas et al., 2012).  Collectively, it is possible that H3K27me3 in bovine acts as an 
epigenetic memory for the use of ART and mediates the abnormal gene expression in 
later stages.  
5.2.4 Challenges for studying LOS 
 Several challenges impede the complete understanding of the etiology of LOS.  
The most prominent one is that we are still not able to predict which in vitro cultured 
embryos will develop LOS.  A current strategy is to supplement estrus serum in the 
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culture media to increase the frequency of LOS fetuses.  However, generation of LOS 
fetuses using this method is not reproducible.  For example, production of in vitro 
embryos at different occasions may yield different number of LOS fetuses or LOS fetuses 
at each time may show different abnormalities (reviewed in Young et al., 1998).  If the 
molecular signature of LOS can be defined in early embryos, a pre-implantation screen 
for LOS prior to embryo transfer will increase the efficiency for production of LOS.   In 
addition, it has been recognized that LOS fetuses exhibit a number of misregulated genes 
and a wide range of abnormalities.  Thus, it is also challenging to establish the connection 
between the altered gene expression and the observed phenotypes in LOS.  In future 
studies, experiments involving genetic manipulation may be necessary to ascertain the 
causal relationship between the aberrant gene expression and the phenotypic defects in 
LOS individuals. 
 
5.3 Conclusions 
 The work in this dissertation demonstrates that bovine LOS is a multi-locus loss-
of-imprinting syndrome, as in a subset of BWS patients. Further, we show that loss-of-
imprinting is not the only molecular lesion for LOS and misregulation of both imprinted 
and non-imprinted genes may contribute to the abnormal phenotypes observed in LOS. 
Importantly, most aberrant gene expression in LOS is not directly associated with the 
altered DNA methylation.  In addition to providing insights for the etiology of LOS, we 
also identify novel imprinted genes in bovine and expand the A-to-I RNA editing sites 
(from ~20 to 671) in bovine fetal tissues. In future studies, continued investigation of 
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LOS at various development stages will lay the foundation to predict the occurrence of 
LOS and help understand the molecular mechanisms of these congenital overgrowth 
conditions. 
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